<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">90683</article-id><article-id pub-id-type="doi">10.7554/eLife.90683</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.90683.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-213498"><name><surname>Howard</surname><given-names>Gregory Caleb</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8373-4573</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194076"><name><surname>Wang</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237492"><name><surname>Rose</surname><given-names>Kristie L</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-352153"><name><surname>Jones</surname><given-names>Camden</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325924"><name><surname>Patel</surname><given-names>Purvi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325925"><name><surname>Tsui</surname><given-names>Tina</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325926"><name><surname>Florian</surname><given-names>Andrea C</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-352154"><name><surname>Vlach</surname><given-names>Logan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-194082"><name><surname>Lorey</surname><given-names>Shelly L</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325927"><name><surname>Grieb</surname><given-names>Brian C</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325928"><name><surname>Smith</surname><given-names>Brianna N</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325929"><name><surname>Slota</surname><given-names>Macey J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325930"><name><surname>Reynolds</surname><given-names>Elizabeth M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325931"><name><surname>Goswami</surname><given-names>Soumita</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325932"><name><surname>Savona</surname><given-names>Michael R</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-352155"><name><surname>Mason</surname><given-names>Frank M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1338-494X</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325933"><name><surname>Lee</surname><given-names>Taekyu</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-29801"><name><surname>Fesik</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-121871"><name><surname>Liu</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-159709"><name><surname>Tansey</surname><given-names>William P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3900-0978</contrib-id><email>william.p.tansey@vanderbilt.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Cell and Developmental Biology, Vanderbilt University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Biostatistics, Vanderbilt University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Center for Quantitative Sciences, Vanderbilt University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Mass Spectrometry Research Center, Vanderbilt University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Biochemistry, Vanderbilt University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Medicine, Vanderbilt University Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Pharmacology, Vanderbilt University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vm5rt34</institution-id><institution>Department of Chemistry, Vanderbilt University</institution></institution-wrap><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Eilers</surname><given-names>Martin</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00fbnyb24</institution-id><institution>University of Würzburg</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Department of Biology, Belmont University, Nashville, United States</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Department of Urology, University of California San Francisco, San Francisco, United States</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>29</day><month>04</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP90683</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-07-12"><day>12</day><month>07</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-07-29"><day>29</day><month>07</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.07.26.550648"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-10-17"><day>17</day><month>10</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90683.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-10"><day>10</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.90683.2"/></event></pub-history><permissions><copyright-statement>© 2023, Howard et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Howard et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-90683-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-90683-figures-v1.pdf"/><abstract><p>The chromatin-associated protein WD Repeat Domain 5 (WDR5) is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the ‘WIN’ site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the most notable of which are those derived from MLL-rearranged (MLLr) leukemias. Peptidomimetic WINi were originally proposed to inhibit MLLr cells via dysregulation of genes connected to hematopoietic stem cell expansion. Our discovery and interrogation of small-molecule WINi, however, revealed that they act in MLLr cell lines to suppress ribosome protein gene (RPG) transcription, induce nucleolar stress, and activate p53. Because there is no precedent for an anticancer strategy that specifically targets RPG expression, we took an integrated multi-omics approach to further interrogate the mechanism of action of WINi in human MLLr cancer cells. We show that WINi induce depletion of the stock of ribosomes, accompanied by a broad yet modest translational choke and changes in alternative mRNA splicing that inactivate the p53 antagonist MDM4. We also show that WINi are synergistic with agents including venetoclax and BET-bromodomain inhibitors. Together, these studies reinforce the concept that WINi are a novel type of ribosome-directed anticancer therapy and provide a resource to support their clinical implementation in MLLr leukemias and other malignancies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>WDR5</kwd><kwd>cancer therapy</kwd><kwd>ribosomes</kwd><kwd>p53</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HHSN261200800001E</award-id><principal-award-recipient><name><surname>Fesik</surname><given-names>Stephen</given-names></name><name><surname>Tansey</surname><given-names>William P</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA200709</award-id><principal-award-recipient><name><surname>Tansey</surname><given-names>William P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012394</institution-id><institution>Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Fesik</surname><given-names>Stephen</given-names></name><name><surname>Tansey</surname><given-names>William P</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA217834</award-id><principal-award-recipient><name><surname>Grieb</surname><given-names>Brian C</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA268703</award-id><principal-award-recipient><name><surname>Grieb</surname><given-names>Brian C</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>American Society for Clinical Oncology</institution></institution-wrap></funding-source><award-id>Young Investigator Award</award-id><principal-award-recipient><name><surname>Grieb</surname><given-names>Brian C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Analysis of the action of WDR5 inhibitors in leukemia cells reveals decreased ribosome inventory, impaired protein synthesis, induction of nucleolar stress, and activation of p53 via alternative splicing of MDM4.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>WDR5 is a highly conserved protein that moonlights in a variety of functions in the nucleus. It rose to prominence as a component of epigenetic writer complexes that deposit histone H3 lysine 4 (H3K4) methylation (<xref ref-type="bibr" rid="bib48">Guarnaccia and Tansey, 2018</xref>), but was subsequently found to act outside these complexes to facilitate the integrity of the mitotic spindle (<xref ref-type="bibr" rid="bib5">Ali et al., 2017</xref>), bookmark genes for reactivation after mitosis (<xref ref-type="bibr" rid="bib83">Oh et al., 2020</xref>), and promote transcription of a subset of ribosomal protein genes [RPGs]; (<xref ref-type="bibr" rid="bib15">Bryan et al., 2020</xref>) via recruitment of the oncoprotein transcription factor MYC to chromatin (<xref ref-type="bibr" rid="bib115">Thomas et al., 2019</xref>). WDR5 is also frequently overexpressed in cancer, where its overexpression correlates with aggressive disease and poor clinical outcomes (<xref ref-type="bibr" rid="bib48">Guarnaccia and Tansey, 2018</xref>). Accordingly, WDR5 is an auspicious target for inhibition in a range of malignancies including MLL-rearranged (MLLr) leukemias (<xref ref-type="bibr" rid="bib17">Cao et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>), MYC-driven cancers (<xref ref-type="bibr" rid="bib4">Aho et al., 2019b</xref>), C/EBPα-mutant leukemias (<xref ref-type="bibr" rid="bib47">Grebien et al., 2015</xref>), p53 gain-of-function cancers (<xref ref-type="bibr" rid="bib130">Zhu et al., 2015</xref>), neuroblastomas (<xref ref-type="bibr" rid="bib15">Bryan et al., 2020</xref>), rhabdoid tumors (<xref ref-type="bibr" rid="bib42">Florian et al., 2022</xref>), and metastatic breast cancers (<xref ref-type="bibr" rid="bib16">Cai et al., 2022</xref>).</p><p>Although WDR5 PROTACs have been described (<xref ref-type="bibr" rid="bib126">Yu et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Li et al., 2022</xref>; <xref ref-type="bibr" rid="bib127">Yu et al., 2023</xref>), safety concerns over destroying a pan-essential protein such as WDR5 (<xref ref-type="bibr" rid="bib107">Siladi et al., 2022</xref>) means that most drug discovery efforts have focused on small-molecule inhibition of key binding sites on the protein. Some initiatives target a hydrophobic cleft on WDR5 known as the ‘WDR5-binding motif’ (WBM) site (<xref ref-type="bibr" rid="bib79">Macdonald et al., 2019</xref>; <xref ref-type="bibr" rid="bib20">Chacón Simon et al., 2020</xref>) that contacts MYC (<xref ref-type="bibr" rid="bib114">Thomas et al., 2015</xref>). But the majority of efforts target the ‘WDR5-interaction’ (WIN) site of WDR5 (<xref ref-type="bibr" rid="bib48">Guarnaccia and Tansey, 2018</xref>)—an arginine binding cavity that tethers WDR5 to chromatin (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>) and makes contact with partner proteins carrying an arginine-containing ‘WIN’ motif (<xref ref-type="bibr" rid="bib49">Guarnaccia et al., 2021</xref>). Multiple WIN site inhibitors (WINi) have been described (<xref ref-type="bibr" rid="bib13">Bolshan et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Karatas et al., 2013</xref>; <xref ref-type="bibr" rid="bib101">Senisterra et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Cao et al., 2014</xref>; <xref ref-type="bibr" rid="bib47">Grebien et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Karatas et al., 2017</xref>; <xref ref-type="bibr" rid="bib119">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>; <xref ref-type="bibr" rid="bib116">Tian et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Chen et al., 2021a</xref>; <xref ref-type="bibr" rid="bib27">Chen et al., 2021b</xref>), including those that are orally bioavailable and have antitumor activity in vivo (<xref ref-type="bibr" rid="bib27">Chen et al., 2021b</xref>; <xref ref-type="bibr" rid="bib112">Teuscher et al., 2023</xref>). Given the intense interest in developing WINi for cancer therapy, and the rapid pace of improvement in these molecules, it is likely that WINi will be ready for clinical vetting in the near future.</p><p>That said, controversy remains regarding the mechanism of action of WINi, even in the context of MLLr leukemias, where there is strong empirical support for their utility (<xref ref-type="bibr" rid="bib121">Weissmiller et al., 2024</xref>). MLL-rearranged leukemias are defined by translocation of one copy of <italic>MLL1</italic>—a gene that encodes one of six MLL/SET proteins that are the catalytic subunits of the histone methyltransferase (HMT) complexes responsible for H3K4 methylation (<xref ref-type="bibr" rid="bib48">Guarnaccia and Tansey, 2018</xref>). The near universal retention of a pristine copy of <italic>MLL1</italic> in these cancers led to the idea that MLLr leukemias depend on wild-type MLL1 to support the activity of oncogenic MLL1-fusion oncoproteins (<xref ref-type="bibr" rid="bib113">Thiel et al., 2010</xref>)—a function in turn that depends on insertion of a low-affinity WIN motif within MLL1 into the WIN site of WDR5 (<xref ref-type="bibr" rid="bib6">Alicea-Velázquez et al., 2016</xref>). Consistent with this notion, early peptidomimetic WINi are active against MLLr leukemia cells in vitro and are reported to suppress levels of H3K4 methylation at canonical MLL1-fusion target genes such as the <italic>HOXA</italic> loci, causing cellular inhibition through a combination of differentiation and apoptosis (<xref ref-type="bibr" rid="bib17">Cao et al., 2014</xref>). Subsequently, however, wild-type MLL1 was shown to be dispensable for transformation by MLL-fusion oncoproteins (<xref ref-type="bibr" rid="bib25">Chen et al., 2017</xref>), and our analysis of picomolar small-molecule WINi revealed that they act in MLLr cells without inducing significant changes in the expression of <italic>HOXA</italic> genes or levels of H3K4 methylation (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). Instead, WINi displace WDR5 from chromatin and directly suppress the transcription of ~50 genes, the majority of which are connected to protein synthesis, including half the cohort of RPGs. We also found that WINi provoke nucleolar stress and induce p53-dependent cell death. Based on our findings, we proposed that WINi kill MLLr cells via depletion of part of the ribosome inventory that induces apoptosis via a ribosome biogenesis stress response.</p><p>The concept of ribosome-directed cancer therapies is not new (<xref ref-type="bibr" rid="bib61">Laham-Karam et al., 2020</xref>; <xref ref-type="bibr" rid="bib111">Temaj et al., 2022</xref>). Besides mTOR and translational inhibitors, one of the most prevalent strategies in this realm is inhibition of ribosomal RNA (rRNA) production or processing, which is a feature of both existing chemotherapies such as platinum-containing compounds (<xref ref-type="bibr" rid="bib14">Bruno et al., 2017</xref>), as well as newer targeted RNA polymerase I inhibitors (<xref ref-type="bibr" rid="bib38">Drygin et al., 2011</xref>; <xref ref-type="bibr" rid="bib85">Peltonen et al., 2014</xref>). Although these agents exert their anticancer effects through multiple mechanisms (<xref ref-type="bibr" rid="bib61">Laham-Karam et al., 2020</xref>), they are generally thought to disrupt the stoichiometry of RNA and protein components of the ribosome, leading to an excess of ribosomal proteins that inactivate MDM2 to induce p53-dependent cancer cell death. The paradigm we developed for WINi is modeled after that of rRNA inhibitors, although it is important to note that a significant point of divergence from rRNA poisons is that in this model WINi induce p53 not by promoting excess ribosomal protein accumulation, but by causing a selective imbalance in the ribosome subunit inventory. How such an imbalance could lead to p53 induction, as well as other consequences it may have on cellular processes, remains unknown.</p><p>Fortifying understanding of the mechanism of action of WINi in MLLr cancer cells is key to their clinical implementation. At present, there is no precedent for the mechanism we propose, no understanding of the impact of selective ribosome subunit depletion on translation or other tumor-relevant processes, and no expectations for how resistance to WINi could emerge or how their antitumor actions could be made more effective. To ameliorate these deficiencies, we took an integrated multi-omics approach, combining transcriptional and translational profiling with genome-wide CRISPR screening to probe WINi action in MLLr cells. Our studies show that although the transcriptional effects of WINi on ribosome subunit expression are confined to those RPGs directly regulated by WDR5, effects at the protein level are not, and WIN site inhibition leads to diminution of the entire stock of cytosolic ribosomes. Ribosome subunit attrition is accompanied by a broad translational choke, induction of nucleolar stress, and activation of p53—driven in large part via RPL22-dependent alternative splicing of the p53 antagonist MDM4. We also show that WINi are synergistic with approved and targeted agents including venetoclax and BET-bromodomain inhibitors. Collectively, these findings solidify a novel mechanism of action for WINi in MLLr cells and highlight a path for their optimal clinical implementation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Impact of WINi on the transcriptome of MLLr cancer cells</title><p>Our model for the action of WINi in MLLr leukemia cells is based on analysis of two early-generation compounds (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>): C3 (<italic>K<sub>d</sub></italic> = 1.3 nM) and C6 (<italic>K<sub>d</sub></italic> = 100 pM). Subsequently (<xref ref-type="bibr" rid="bib116">Tian et al., 2020</xref>), we discovered more potent molecules such as C16 (<italic>K<sub>d</sub></italic> &lt; 20 pM) that have not been extensively profiled. To determine if improvements in the potency of WINi have resulted in divergent activities, we first compared C6 with C16 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Both molecules bind the WIN site of WDR5 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), but differ in affinity due to a bicyclic dihydroisoquinolinone core that locks C16 into a favorable binding conformation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Consistent with its higher affinity, C16 is ~20 times more potent than C6 in inhibiting MV4;11 (MLL–AF4) and MOLM13 (MLL–AF9) leukemia lines (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B and C</xref>): in MV4;11 cells, for example, the GI<sub>50</sub> for C6 is 1 μM compared to 46 nM for C16. These differences in potency are reflected at the level of RPG suppression. Using a target engagement assay (<xref ref-type="bibr" rid="bib42">Florian et al., 2022</xref>) that measures transcript levels from seven RPGs—five (<italic>RPS14</italic>, <italic>RPS24</italic>, <italic>RPL26</italic>, <italic>RPL32</italic>, and <italic>RPL35</italic>) that are always bound by WDR5 and two (<italic>RPS11</italic> and <italic>RPS14</italic>) that are never bound—we observe that maximal suppression of RPG transcripts occurs at ~2 μM for C6 and ~100 nM for C16 in MV4;11 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) and MOLM13 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>) cells. To functionally compare these two inhibitors of different potencies, we used these RPG-normalized doses in all our subsequent studies.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Impact of WIN site inhibitors (WINi) on the transcriptome of MLLr cancer cells.</title><p>(<bold>A</bold>) Chemical structures of C6 and C16. (<bold>B</bold>) Crystal structures of C6 or C16 bound to the WIN site of WDR5 with electrostatic surfaces mapped (PDB IDs: 6E23 [<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>]; 6UCS [<xref ref-type="bibr" rid="bib116">Tian et al., 2020</xref>]). The image shows a close-up view of the WIN site. (<bold>C</bold>) Superimposed WIN site-binding conformations of C6 (green) and C16 (blue). (<bold>D</bold>) Transcript levels as determined by QuantiGene analysis of representative WDR5-bound (color) or non-bound (grayscale) ribosomal protein genes in MV4;11 cells treated with a serial dilution range of either C6 (left) or C16 (right) and relative to DMSO-treated cells (n = 2–3; mean ± SEM). Vertical dashed line indicates either 2 µM C6 (left) or 100 nM C16 (right). (<bold>E</bold>) Number of genes with significantly (false discovery rate [FDR] &lt; 0.05) altered transcript levels following treatment of MV4;11 cells with C6 (2 µM) or C16 (100 nM) for 48 hr, as determined by RNA-Seq (n = 3). See <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref> for complete output of RNA-seq analysis. (<bold>F</bold>) Comparison of gene expression changes elicited by C6 (x-axis) and C16 (y-axis), represented as Log2 fold change (FC) compared to DMSO. WDR5-bound genes are colored red. Locations of <italic>RPL22L1</italic> and <italic>ZMAT3</italic> are indicated. (<bold>G</bold>) Overlap of genes with decreased (left) or increased (right) transcript levels in MV4;11 cells treated with C6 or C16. (<bold>H</bold>) Gene set enrichment analysis (GSEA) showing the distribution of genes suppressed in MV4;11 cells in response to C6 (left) or C16 (right) against the list of all genes bound by WDR5 in those cells (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). NES, normalized enrichment score. (<bold>I</bold>) Enrichment analysis of genes suppressed (left) or induced (right) by C6 or C16 in MV4;11 cells. KEGG and Hallmark.MSigDB pathways are shown. Fold enrichment of indicated pathways is presented on the x-axis, the number of genes is shown in italics in each bar, and colors represent -Log10 FDR. See <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref> for additional GSEA (Hallmark) and over-representation analysis (ORA) (Hallmark) analyses of differentially expressed genes. (<bold>J</bold>) Transcript level changes in WDR5-bound (left) and non-bound (right) RPGs elicited by C6 (top) or C16 (bottom).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Output of RNA-seq analysis of MV4;11 cells treated with C6/C16.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>GSEA Hallmark and over-representation analysis (ORA) Hallmark enrichment analysis of differentially expressed genes in RNA-seq.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Transcript changes elicited by WIN site inhibitors (WINi) in MLLr cancer cells.</title><p>(<bold>A</bold>) Crystal structures of C6 or C16 bound to the WIN Site of WDR5 with electrostatic surfaces mapped (PDB IDs: 6E23 [<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>]; 6UCS [<xref ref-type="bibr" rid="bib116">Tian et al., 2020</xref>]). (<bold>B</bold>) Viabilities of MV4;11 cells treated with a serial dilution range of either C6 (left) or C16 (right) for 72 hr, relative to viability of DMSO-treated cells (n = 3; mean ± SEM). (<bold>C</bold>) As in (<bold>B</bold>) but for MOLM13 cells. (<bold>D</bold>) Transcript levels as determined by QuantiGene analysis of representative WDR5-bound (color) or non-bound (grayscale) ribosomal protein genes in MOLM13 cells treated with a serial dilution range of either C6 (left) or C16 (right) and relative to DMSO-treated cells (n = 3; mean ± SEM). Vertical dashed line indicates either 2 µM C6 (left) or 100 nM C16 (right). (<bold>E</bold>) Transformed z-scores of genes with significantly altered transcript levels (RNA-seq) in MV4;11 cells treated with either C6 (2 µM) or C16 (100 nM) for 48 hr, compared to DMSO treatment. (<bold>F</bold>) Volcano plots, showing transcript level alterations in MV4;11 cells treated 48 hr with 2 µM C6 (left) or 100 nM C16 (right) compared to DMSO (n = 3; red indicates false discovery rate [FDR] &lt; 0.05). (<bold>G</bold>) Dispersion plot describing the variance in gene expression for the RNA-seq data in a previous study (left) and this study (right).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Impact of WIN site inhibitors (WINi) on <italic>RPL22L1</italic> and p53 target gene expression.</title><p>(<bold>A</bold>) Venn diagram, showing the overlap of consensus p53 target genes (<xref ref-type="bibr" rid="bib41">Fischer, 2017</xref>) with genes significantly induced by C6 or C16 in MV4;11 cells. (<bold>B</bold>) Graph showing the changes in expression of the 91 common genes in (<bold>A</bold>) elicited by WINi C6 (red) or C16 (blue) in MV4;11 cells, compared to DMSO. (<bold>C</bold>) Changes in expression (and false discovery rate [FDR]) of <italic>RPL22L1</italic> elicited in response to C6 (red) or C16 (blue) treatment of K562 leukemia cells (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>) or five rhabdoid tumor cell lines (TTC642, KYM-1, G401, TM87-16, and TTC549; <xref ref-type="bibr" rid="bib42">Florian et al., 2022</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig1-figsupp2-v1.tif"/></fig></fig-group><p>We performed RNA-sequencing (RNA-seq) on MV4;11 cells treated for 48 hr with DMSO, C6, or C16 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Spike-in controls were not included. Both compounds elicit thousands of gene expression changes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), a majority of which are less than twofold in magnitude (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). We had previously performed RNA-seq on MV4;11 cells treated with 2 μM C6 and observed just ~75 induced and ~460 reduced transcripts (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). In this earlier work, however, increased variance among replicates made it difficult for as many small gene expression changes to reach statistical significance as in the current study (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). Comparing the new RNA-seq datasets, we observe similar effects of C6 and C16 on the MV4;11 cell transcriptome (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), with more than 80% of the transcripts altered by C16 altered in the same direction by C6 (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). In both cases, suppressed genes are enriched in those bound by WDR5 in MV4;11 cells (<xref ref-type="fig" rid="fig1">Figure 1H</xref>), although a majority of transcriptional changes occur at loci bereft of detectable WDR5 binding (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). For both compounds, expression of genes connected to protein synthesis, the cell cycle, DNA replication, mTORC signaling, and MYC are reduced, while expression of those connected to chemokine signaling, apoptosis, and p53 is induced (<xref ref-type="fig" rid="fig1">Figure 1I</xref>, <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). Indeed, ~90 ‘consensus’ p53 target genes (<xref ref-type="bibr" rid="bib41">Fischer, 2017</xref>) are induced by C6/C16 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>), including the tumor suppressor <italic>ZMAT3</italic> (<xref ref-type="fig" rid="fig1">Figure 1F</xref>; <xref ref-type="bibr" rid="bib10">Bieging-Rolett et al., 2020</xref>). Finally, we note that for both compounds the transcriptional effects on RPG expression are almost entirely confined to those RPGs bound by WDR5 (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). The conspicuous exception to this trend is <italic>RPL22L1</italic>—a paralog of <italic>RPL22</italic>—mRNA levels which are strongly reduced by C6/C16 (<xref ref-type="fig" rid="fig1">Figure 1F and J</xref>). This feature of the response is not confined to MLLr cells as <italic>RPL22L1</italic> expression is also decreased by WINi in sensitive rhabdoid tumor cell lines (<xref ref-type="bibr" rid="bib42">Florian et al., 2022</xref>), but not in the insensitive K562 leukemia line (<xref ref-type="bibr" rid="bib15">Bryan et al., 2020</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). Despite not being a direct WDR5 target gene, therefore, <italic>RPL22L1</italic> expression is recurringly suppressed by WINi in responsive cancer cell lines.</p><p>Together, these data reveal that improvements in the potency of WINi have not resulted in substantive changes in their impact on the transcriptome of MLLr cells and reinforce the concept that inhibition of select RPG expression—and induction of a p53-related transcriptional program—defines the response of the transcriptome to WIN site blockade in this setting.</p></sec><sec id="s2-2"><title>Impact of WINi on the translatome of MLLr cancer cells</title><p>We previously showed that treatment of MV4;11 cells with C6 results in a time-dependent decrease in translation as measured by bulk labeling of nascent polypeptide chains with <italic>O</italic>-propargyl-puromycin (OPP) (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). We confirmed this finding with C6 and extended it to C16, showing that while there is no significant effect on protein synthesis capacity after 24 hr of WINi treatment, a progressive decline begins at 48 hr, reaching an ~40% reduction at the 96 hr treatment point (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>). To determine more precisely the effects of WIN site inhibition on translational processes, we performed ribosome profiling (Ribo-seq; <xref ref-type="bibr" rid="bib81">McGlincy and Ingolia, 2017</xref>) in parallel with the RNA-seq analyses described above. Spike-in controls were not included. By sequencing ribosome-protected fragments (RPFs) in 48-hr-treated and control cells, and normalizing to transcript levels from RNA-seq, we calculated the translation efficiency (TE) of each transcript and used this to determine how C6/C16 influence translation, independent of effects on mRNA abundance.</p><p>In these experiments, RPFs have the characteristic length of ribosome-protected mRNA fragments (28–32 nucleotides; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>), are enriched in coding sequences (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>), and map to the expected reading frame (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>), all of which indicate successful profiling. In contrast to RNA-seq, where we see equal numbers of transcript increases and decreases in response to C6/C16, the overwhelming effect of these compounds on translation efficiency is inhibitory (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Of the ~10,000 transcripts profiled, between ~4,500 (C16) and ~5,900 (C6) transcripts show decreased TE compared to less than 10 transcripts with increased translation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). As we observed in the RNA-seq, changes in TE are generally less than twofold (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and there is extensive overlap between the two inhibitors, with ~90% of the transcripts decreased in TE by C16 also decreased by C6 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In general, C6/C16 reduce translation of mRNAs in a manner independent of basal translation efficiencies (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), although if we bin transcripts according to basal TE we observe that the number of highly translated transcripts (fourth quartile) impacted by C6/C16 is greater than for those transcripts with lower basal TE (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Within these quartiles, however, the magnitude of reduction in TE is equivalent (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). Interestingly, mRNAs carrying better matches to the 5'TOP motif—which links translation to mTORC1 signaling (<xref ref-type="bibr" rid="bib88">Philippe et al., 2020</xref>)—show less decrease in TE compared to those with poorer matches (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>), suggesting that mTORC1-regulated mRNAs may be spared from the full translational effects of WIN site inhibition.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Impact of WIN site inhibitors (WINi) on the translatome of MLLr cancer cells.</title><p>(<bold>A</bold>) Volcano plots depicting alterations in translation efficiency (TE) induced by 48 hr treatment of MV4;11 cells with either 2 µM C6 (left) or 100 nM C16 (right) compared to DMSO (n = 2; red indicates false discovery rate [FDR] &lt; 0.05 and Log2 FC &gt; 0.25), as determined by Ribo-seq. (<bold>B</bold>) Number of mRNAs with significantly (FDR &lt; 0.05 and Log2 FC &gt; 0.25) altered TE levels following treatment of MV4;11 cells with C6 (2 µM) or C16 (100 nM) for 48 hr. See <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref> for complete output of Ribo-seq analysis. (<bold>C</bold>) Overlap of mRNAs with significantly decreased TE in response to C6 or C16 treatment. (<bold>D</bold>) TE of mRNAs in DMSO-treated MV4;11 cells plotted against translation efficiencies of mRNAs in cells treated with either C6 (left) or C16 (right). Red indicates mRNAs with significantly altered translation efficiencies following inhibitor treatment (FDR &lt; 0.05 and Log2 FC &gt; 0.25). (<bold>E</bold>) Numbers of differentially translated mRNAs (∆TE) in each quartile of genes (stratified by TE in DMSO) in cells treated with C6 (left) or C16 (right). (<bold>F</bold>) Enrichment analysis of common mRNAs suppressed by C6/C16 at the mRNA (blue) and translational (red; TE) level in MV4;11 cells. Hallmark.MSigDB pathways are shown. The x-axis indicates the number of suppressed genes in each category; the italic numbers are the corresponding FDR. See <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref> for the full Hallmark.MSigDB analysis, as well as for Reactome and KEGG pathways. (<bold>G</bold>) Enrichment analysis of mRNAs suppressed translationally by C6/C16 but with no significant changes in mRNA levels. Gene Ontology (GO) Biological Process (BP) and Molecular Function (MF) categories are shown, as well as KEGG pathways. The x-axis displays -Log10 FDR; the number of mRNAs is shown in italics in each bar. See <xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref> for extended enrichment analyses, broken down by TE and mRNA direction changes. (<bold>H</bold>) TE changes in WDR5-bound (left) and non-bound (right) RPGs elicited by C6 (top) or C16 (bottom).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Output of Ribo-seq analysis of MV4;11 cells treated with C6/C16.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Hallmark, Reactome, and KEGG enrichment analysis of differentially translated genes in Ribo-seq.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig2-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2—source data 3.</label><caption><title>Enrichment analysis of differentially translated genes, broken down by mRNA level change direction.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig2-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>WIN site inhibitors (WINi) suppress bulk protein synthesis.</title><p>(<bold>A</bold>) Representative histograms from protein synthesis assays in MV4;11 cells treated 24, 48, or 96 hr with either 0.1% DMSO (blue), 2 µM C6 (red), or 100 nM C16 (orange). Cells were pulsed with <italic>O</italic>-propargyl-puromycin (OPP) to label nascent proteins, Alexa Fluor 647 linked to incorporated OPP in Click chemistry reactions, and fluorescence measured by flow cytometry analysis. MV4;11 cells treated 30 min with 100 µg/mL cycloheximide (‘CHX’; green) serve as a positive control for inhibited protein synthesis. MV4;11 cells pulsed with DMSO (‘No OPP’; black) serve as a control for background fluorescence. (<bold>B</bold>) Quantification of protein synthesis assays. Fluorescence from CHX-treated cells was set as the baseline, and fluorescence presented relative to DMSO-treated (DM) cells at each time point (n = 3; normalized geometric mean ± SEM). p-Values calculated by Student’s <italic>t</italic>-tests are represented by asterisks: *&lt;0.05, **&lt;0.01, ***&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>WIN site inhibitors (WINi) suppress translation.</title><p>(<bold>A</bold>) Distribution of ribosome-protected fragment (RPF) lengths in each Ribo-seq sample/replicate. The length distribution of RPFs in mammalian Ribo-seq experiments typically peaks at 30–31 nucleotides. (<bold>B</bold>) Proportion of RPFs mapping to the coding sequence (CDS) or 5′ or 3′ untranslated regions (UTR) of transcripts. Color of dots is the same as in (<bold>A</bold>). (<bold>C</bold>) Proportion of RPFs mapping to each reading frame in the 5′ UTR (left), the CDS (middle), and the 3′ UTR (right). Color of dots is the same as in (<bold>A</bold>). (<bold>D</bold>) Magnitudes of significant translation efficiency (TE) alterations of mRNAs in each quartile (stratified by TE in DMSO) in cells treated with C6 (left) or C16 (right). Color dots represent individual genes. Bottom, middle, and top horizontal lines of each box represent first, second, and third quartiles, respectively. Vertical lines extend to data points within 1.5-fold of the interquartile range. Black dots represent values beyond 1.5-fold of the interquartile range. (<bold>E</bold>) Changes in TE induced by C6 (left) or C16 (right) in MV4;11 cells, binned according to mRNA TOPscores (<xref ref-type="bibr" rid="bib88">Philippe et al., 2020</xref>). Dashed lines represent the median; dotted lines indicate quartiles. Significance by <italic>t</italic>-test is indicated compared to group with TOPscore 0–1 (*≤0.05, **≤0.0001). (<bold>F</bold>) UpSet plot, showing the breakdown of genes encoding PRMT5 substrates <xref ref-type="bibr" rid="bib91">Radzisheuskaya et al., 2019</xref> whose transcript levels and/or translation efficiencies decrease following WIN site inhibition (p<italic>-</italic>value calculated by hypergeometric test for over-representation of genes encoding PRMT5 substrates in genes with decreased translation efficiencies). (<bold>G</bold>) Overlap of C6/C16 common mRNAs with decreased abundance (RNA; blue) and those with decreased TE (salmon), grouped according to the indicated Hallmark.MSigDB categories. (<bold>H</bold>) Overlap of all C6/C16 common mRNAs with altered abundance and decreased TE. (<bold>I</bold>) The top row of the heatmap displays the codon stability coefficient (CSC) for each codon (<xref ref-type="bibr" rid="bib122">Wu et al., 2019</xref>) ranked from lowest ('non-optimal') to highest ('optimal'). The middle row displays enrichment of each codon in mRNAs that are decreased at both the TE and mRNA levels (RNA + TE) versus those that show a decrease in TE without an accompanying decrease in mRNA abundance (TE only). Bottom row is -Log10 false discovery rate (FDR).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>WIN site inhibitors (WINi) impair translation of mitochondrial ribosomal proteins.</title><p>(<bold>A</bold>) Top: transcript level changes in mitochondrial ribosomal protein genes elicited by C6 or C16, as indicated. Bottom: translational efficiency (TE) changes in mitochondrial ribosomal protein genes elicited by C6 or C16. All of the mitochondrial RPGs are nuclear-encoded; none have detectable binding of WDR5.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig2-figsupp3-v1.tif"/></fig></fig-group><p>Interrogating specific changes in TE induced by C6/C16, we see that the biological categories of transcripts with decreased TE echo many of those observed with decreased mRNA levels, but include more genes in each category. For example, manually curating each list for transcripts encoding the ~60 validated substrates of the protein arginine methyltransferase PRMT5 (<xref ref-type="bibr" rid="bib91">Radzisheuskaya et al., 2019</xref>) reveals that 42 are translationally suppressed by C6/C16 compared to just 10 that are suppressed at the mRNA level (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F</xref>). Probing for Hallmark categories in the Human Molecular Signatures Database (MSigDB; <xref ref-type="bibr" rid="bib74">Liberzon et al., 2015</xref>) uncovers the extent of this phenomenon (<xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>), with categories linked to MYC, E2F, mTORC1 signaling, and the G2M checkpoint (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) all represented by more genes in the ribosome profiling than in the RNA-seq experiments. Within these categories, a majority of genes suppressed by C6/C16 at the mRNA level are also further suppressed translationally (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2G</xref>). This is not a general trend in the response, however, as fewer than half of the total transcripts with reduced mRNA abundance experience this additional translational inhibition (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2H</xref>). The finding that TE changes induced by C6/C16 extend the biological characteristics of changes in mRNA abundance may indicate a role for impaired translation in contributing to at least some of the mRNA level differences triggered by WINi. Indeed, comparing transcripts with decreased TE but no mRNA decrease with transcripts with decreased TE and mRNA levels reveals the latter are enriched in so-called ‘optimal codons’ (<xref ref-type="bibr" rid="bib122">Wu et al., 2019</xref>) that normally promote mRNA stability but are linked to mRNA instability when translation is inhibited (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2I</xref>).</p><p>Implicit in the previous discussion, a majority of the translational decreases triggered by C6/C16 occur at transcripts for which there are no significant changes in mRNA abundance (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2H</xref>). Expectedly, genes with decreased TE but no mRNA level changes are enriched in several of the major Hallmark categories described above (<xref ref-type="supplementary-material" rid="fig2sdata3">Figure 2—source data 3</xref>). But we also observe enrichment in genes connected to the proteasome, spliceosome, mRNA surveillance, and translation (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). The latter category includes subunits of the mitochondrial ribosome (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>), translation and ribosome biogenesis factors, and an expanded cohort of transcripts from RPGs (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). Indeed, compared to mRNA levels, where C6/C16-induced changes are confined (with the exception of <italic>RPL22L1</italic>) to a decrease in expression of WDR5-bound RPGs, translational effects are not, and some of the most pronounced TE changes occur at non-WDR5 ribosomal protein target genes. Thus, beyond what we have been able to infer from previous studies, WINi causes a widespread reduction in the ability of MLLr cells to efficiently translate mRNAs connected to almost every aspect of protein synthesis and homeostasis.</p></sec><sec id="s2-3"><title>Impact of WINi on the ribosome inventory of MLLr cancer cells</title><p>Based on the finding that WDR5 controls expression of half the RPGs, we speculated that WINi induce a ribosome subunit imbalance that leads to induction of p53 (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). It is also possible, however, that quality control mechanisms deplete the entire inventory of ribosomal proteins (RP) during prolonged WIN site blockade. To distinguish between these possibilities, we tracked changes in ribosomal protein levels at two timepoints: 24 hr, when there is no overt cellular response to WIN site inhibition, and 72 hr, when cell proliferation begins to be inhibited (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). The abundance of ribosomal proteins allows for the use of label-free quantitative mass spectrometry (LFQMS; <xref ref-type="bibr" rid="bib32">Cox et al., 2014</xref>) in whole-cell lysates to feasibly track ribosome protein levels, while also providing insight into other changes in protein levels promoted by WINi. Spike-in controls were not included.</p><p>In this analysis, we tracked ~3,200 proteins at each timepoint (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>), ~850 of which are significantly altered by C16 treatment. Consistent with the subtle effects of WINi on mRNA abundance and TE, most differences in protein levels triggered by C16 are less than twofold in magnitude (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). At 24 hr, ~90% of the proteins that change in response to C16 score as increased, whereas by 72 hr this number drops to ~60% (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Although the induction of proteins in response to C16 is unexpected for agents that decrease translational capacity, we note that protein synthesis is largely unaffected after 24 hr of C16 treatment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), and that this phenomenon is unlikely to be an artifact of normalization. Indeed, the distribution of peptide intensities in the LFQMS data is unaffected by normalization (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), and we see almost as many highly abundant proteins increasing as decreasing with C16 treatment (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B–D</xref>), arguing against the idea that large decreases in highly expressed proteins (such as the RPs; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>) are creating the appearance of less abundant proteins being induced. Instead, we suggest that this may be a transient compensatory mechanism, or an early part of the response to WINi. Regardless, most instances of increased protein levels are transient—fewer than one-third of these proteins are still induced at day 3 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>)—whereas a majority of the proteins decreased at day 1 are also decreased at day 3. Enrichment analysis (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A</xref>, <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>) reveals that proteins induced at 24 hr are modestly enriched in those connected to exocytosis and leukocyte activation, as well as mTORC1 signaling and MYC. By 72 hr, we see induction of proteins linked to glycolysis and fatty acid metabolism, as well as apoptosis. Additionally, manual curation reveals that the number of induced p53 target proteins increases over time: 13 are induced at 24 hr compared to 24 at the 3-day point (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Commensurate with the onset of a functional response to WINi, therefore, is a modest expansion in the apparent impact of p53 on the proteome, as well as the emergence of apoptotic response indicators.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Impact of WIN site inhibitors (WINi) on the ribosome inventory of MLLr cancer cells.</title><p>(<bold>A</bold>) Lysates from MV4;11 cells treated 24 or 72 hr with either 0.1% DMSO or 250 nM C16 were subjected to liquid chromatography coupled with tandem mass spectrometry and analyzed by label-free quantification (LFQMS). The table shows the number of proteins detected in DMSO and C16 samples and those with significantly altered levels at each time point (n = 4; adj. p-value&lt;0.05). See <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref> for complete output of LFQMS analysis. (<bold>B</bold>) Volcano plot, showing protein level alterations in cells treated with C16 for 24 hr (red indicates adj. p-value&lt;0.05). The location of RPL22L1 is indicated. (<bold>C</bold>) As in (<bold>B</bold>) but for 72 hr treatment with C16. (<bold>D</bold>) Overlap of proteins significantly increased (top) or decreased (bottom) following 24 or 72 hr C16 treatment. (<bold>E</bold>) Protein level alterations induced by C16 in consensus p53 target proteins (<xref ref-type="bibr" rid="bib41">Fischer, 2017</xref>) at the 24 and 72 hr treatment timepoints. Those proteins only altered in abundance at 24 hr are represented as blue dots; proteins only altered at 72 hr are red; proteins altered at both timepoints are gray. (<bold>F</bold>) As in (<bold>E</bold>) but for ribosomal proteins. (<bold>G</bold>) Changes in expression of proteins encoded by WDR5-bound (left) and non-bound (right) RPGs elicited by 24 (top) or 72 (bottom) hr treatment with C16. Note that, due to the magnitude of change, Log2(FC) for RPL22L1 is presented on a separate scale.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Output of label-free quantitative mass spectrometry (LFQMS) analysis of MV4;11 cells treated with C16.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Enrichment analysis of proteins altered in abundance by 24 or 72 hr of C16 treatment.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig3-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Distribution of peptide/protein intensities in label-free quantitative mass spectrometry (LFQMS) analysis.</title><p>(<bold>A</bold>) Peptide intensities of all proteins detected in each mass spectrometry run before (left) and after normalization (right). (<bold>B</bold>) Magnitudes of significant protein level alterations within each decile (stratified by protein intensity in DMSO samples) in MV4;11 cells treated 24 hr with 250 nM C16. Red points represent ribosome proteins. (<bold>C</bold>) Box plot representation of data presented in (<bold>B</bold>). Bottom, middle, and top horizontal line of each box represents first, second, and third quartiles, respectively. Vertical lines extend to data points within 1.5-fold of the interquartile range. Black dots represent values beyond 1.5-fold of the interquartile range. (<bold>D</bold>) Number of proteins increased or decreased within each decile.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Enrichment analysis of proteins with altered expression in response to C16 treatment.</title><p>(<bold>A</bold>) Graphs showing enrichment of proteins in GO BP (top) and Hallmark.MSigDB (bottom) pathways that are induced by C16 treatment at 24 (blue) or 72 (green) hr. The x-axis displays -Log10 (FDR); the number of proteins in each category is given in italics. (<bold>B</bold>) Graphs showing enrichment of proteins in Gene Ontology (GO) Biological Process (BP) (top) and Hallmark.MSigDB (bottom) pathways that are suppressed by C16 treatment at 24 (red) or 72 (brown) hr. The x-axis displays -Log10 (FDR); the number of proteins in each category is given in italics. See <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref> for output of the full enrichment analyses.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>WIN site inhibitors suppress rRNA levels.</title><p>(<bold>A</bold>) In-gel fluorescence assay detecting metabolically labeled rRNA (top) isolated from MV4;11 cells treated 24, 48, or 96 hr with either DMSO (0.1%), C6 (2 µM), or C16 (100 nM), and pulsed with 2′-azido-2′-cytidine (AzCyd). As a positive control for inhibited rRNA synthesis, MV4;11 cells were treated 1 hr with 5 nM actinomycin D (‘ActD’). As a control for background labeling, MV4;11 cells were pulsed with DMSO (‘No AzCyd’). Fluorescent probes were covalently linked to incorporated AzCyd in Click chemistry reactions. Total RNA (bottom) was detected by SYBR stain. (<bold>B</bold>) Quantification of metabolic rRNA labeling (n = 3; mean ± SEM). p-Values calculated by Student’s <italic>t</italic>-tests are indicated. Raw unprocessed gel images are presented in <xref ref-type="supplementary-material" rid="fig3s3sdata1">Figure 3—figure supplement 3—source data 1</xref>.</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Raw unprocessed gel images corresponding to <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-90683-fig3-figsupp3-data1-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>C16 induces redistribution of nucleophosmin from the nucleolus to the nucleoplasm.</title><p>(<bold>A</bold>) Representative immunofluorescent images of MV4;11 cells treated with vehicle (DMSO control), C16 (100 nM), or ActD (5 nM) for the times indicated and stained for nucleophosmin (NPM1, green), gH2A.X pSer139 (double-stranded break marker, magenta) and Hoechst (blue). DNA damage arises upon cell death following drug treatment. Scale bars are 5 μm. (<bold>B</bold>) Quantification of the ratio of nucleolar to total NPM1 in the cells described in (<bold>A</bold>). C6, C16, and ActD treatment disrupted NPM1 localization. p-Values calculated by Student’s <italic>t</italic>-tests are represented by asterisks: **0.0012, ****&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig3-figsupp4-v1.tif"/></fig></fig-group><p>Not surprisingly, proteins that are reduced in abundance at 24 hr are significantly enriched in those linked to the ribosome (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B</xref>). This enrichment becomes stronger at 72 hr. We also observe, at 72 hr, suppression of proteins linked to MYC and E2F targets, as well as mTORC1 signaling. In terms of ribosome components, this analysis reveals a progressive decline in the ribosomal protein inventory. Going from 24 to 72 hr, there is an increase in the number of impacted ribosomal subunits as well as in the magnitude of their suppression (<xref ref-type="fig" rid="fig3">Figure 3F</xref>), and eventually almost all ribosomal subunits are in deficit, regardless of whether or not they are encoded by a WDR5-bound gene (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). RPL22L1 is the most strongly suppressed protein at 72 hr (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), with its levels reduced by an order of magnitude after 3 d of C16 treatment. Consistent with the highly coordinated nature of ribosome biogenesis (<xref ref-type="bibr" rid="bib37">Dörner et al., 2023</xref>), decreases in the abundance of RP are accompanied by a progressive decline in rRNA expression—as revealed by metabolic labeling of RNAs with 2'-azido-2'-cytidine (AzCyd) (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>, <xref ref-type="supplementary-material" rid="fig3s3sdata1">Figure 3—figure supplement 3—source data 1</xref>). Together, these experiments reveal that changes in ribosomal protein levels predicted from our transcriptomic studies manifest in reduced expression of ribosome components. Contrary to our earlier idea that WINi promote ribosome subunit imbalance, however, these data support a simpler model in which these inhibitors ultimately induce attrition of the majority of ribosomal proteins—as well as mature rRNAs.</p><p>Finally, we asked if the decline in ribosome inventory triggered by C16 is associated with nucleolar stress, as we have shown with C6 (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). We used immunofluorescence to measure the redistribution of nucleophosmin (NPM1) from the nucleolus to the nucleoplasm; a characteristic of this phenomenon (<xref ref-type="bibr" rid="bib97">Russo and Russo, 2017</xref>). Because inhibition of ribosome biogenesis via some rRNA inhibitors can induce a DNA damage response (<xref ref-type="bibr" rid="bib98">Sanij et al., 2020</xref>), we also probed for the DNA damage marker ɣ-H2AX. We observed no obvious change in nucleolar morphology with up to 72 hr of C16 treatment (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A</xref>). We did, however, see a significant decrease in the nucleolar enrichment of NPM1 at the 72 hr treatment timepoint (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4B</xref>), indicative of a nucleolar stress response. Notably, we did not observe induction of ɣ-H2AX foci in either the nucleolus or nucleoplasm, detecting it only in cells that were morphologically apoptotic (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A</xref>), consistent with studies showing that ɣ-H2AX is induced via the DNA fragmentation that occurs during apoptosis (<xref ref-type="bibr" rid="bib96">Rogakou et al., 2000</xref>). Based on this analysis, we conclude that activation of nucleolar stress occurs in response to prolonged exposure to C16 and that, compared to some rRNA inhibitors, widespread induction of DNA damage is not a specific consequence of the action of WINi.</p></sec><sec id="s2-4"><title>A loss-of-function screen for modulators of the response to WINi</title><p>Next, we conducted a two-tier loss-of-function screen to identify genes that modulate the response of MLLr cells to WINi (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Our objective was to compare C6 and C16, and to identify high-confidence hits that are disconnected from cell viability. In tier 1, we carried out a screen using the GeCKOv.2 sgRNA library (<xref ref-type="bibr" rid="bib53">Joung et al., 2017</xref>), which targets ~19,000 genes with six sgRNAs each, as well as ~1,200 miRNAs (four sgRNAs each). After transducing the library into MV4;11 cells expressing Cas9, we treated for 2 wk with 2 μM C6, during which time rapidly growing cells emerged within the transduced population (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). We harvested genomic DNA, performed next-generation sequencing, and compared sgRNA representation before and after C6 treatment. We then inventoried genes with significant enrichment/depletion in corresponding sgRNAs in the treated population, removed pan-essential genes (<xref ref-type="bibr" rid="bib117">Tsherniak et al., 2017</xref>), and created a custom library in which non-essential protein-coding ‘hits’ are targeted by four different sgRNAs (<xref ref-type="bibr" rid="bib36">Doench et al., 2016</xref>). The smaller tier 2 library was then screened against C6 or C16, this time against a parallel DMSO-treated control population. This two-tiered approach allowed us to efficiently screen two different WINi and identify hits that are validated (for C6 at least) with up to 10 unique sgRNAs.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>A two-tier loss-of-function screen for modulators of the response to WIN site inhibitors (WINi).</title><p>(<bold>A</bold>) Two-tier screen design. In the first tier, Cas9-expressing MV4;11 cells were transduced with a genome-wide sgRNA library and treated with 2 µM C6 until a resistant cell population emerged. sgRNA representation in the pretreatment population was compared to the post-treatment population (n = 2). In the second tier, cells were transduced with a custom library of distinct sgRNAs targeting non-pan-essential ‘hits’ from the first tier, cultured in the presence of DMSO, C6, or C16, and sgRNA representation in C6/C16-treated cultures compared to that from DMSO-treated cultures (n = 2). (<bold>B</bold>) Volcano plot, showing gene-level changes in sgRNA representation from the first tier (orange indicates false discovery rate [FDR] &lt; 0.05). Datapoints corresponding to <italic>TP53</italic>, <italic>RPL22</italic>, and <italic>CDKN2A</italic> are indicated. See <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref> for full output of the tier 1 screen. (<bold>C</bold>) Comparison of gene-level changes in sgRNA representation in C6- and C16-treated populations in the second tier screen, each compared to DMSO-treated populations (red indicates FDR &lt; 0.05; black indicates non-targeting control sgRNAs). See <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref> for full output of the tier 2 screen. (<bold>D</bold>) Top: overlap of genes from the tier 2 screen with enriched (left) or depleted (right) sgRNAs in C6- and C16-treated MV4;11 populations, compared to the DMSO control. Bottom: overlap of genes with enriched (left) or depleted (right) sgRNAs in the first versus second tiers of the screen. ‘Tier 1’ contains only those genes targeted in the tier 2 screen. ‘Tier 2’ contains the intersection of genes with altered sgRNAs in both the C6 and C16 treatments. (<bold>E</bold>) Ranked heatmap, representing the mean gene-level Log2 fold change (FC) of sgRNAs from the C6 and C16 treatments in the tier 2 screen, as well as gene enrichment analysis outputs. Note that ‘Signal transduction by p53 class mediator’ is a GO:BP term (orange); ‘p53’ assignments (yellow) were added by manual curation.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Output of the tier 1 screen.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Output of the tier 2 screen.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig4-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig4-v1.tif"/><permissions><copyright-statement>© 2024, BioRender Inc</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>BioRender Inc</copyright-holder><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Figure 4A was created using <ext-link ext-link-type="uri" xlink:href="https://www.biorender.com/">BioRender</ext-link>, and is published under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND</ext-link> license. Further reproductions must adhere to the terms of this license.</license-p></license></permissions></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Genome-wide CRISPR screen identifies genes that influence response to C6/C16.</title><p>(<bold>A</bold>) Tier 1 screen: daily cell counts of MV4;11 Cas9 and MV4;11 Cas9+GeCKOv2 (Library) populations treated with either DMSO or 2 µM C6. The two replicates of this screen are shown separately. (<bold>B</bold>) Normalized counts of each sgRNA (x-axis) in the GeCKOv.2 library targeting <italic>TP53</italic> in the initial transduced cells (red; not visible on this scale) and the C6-treated population (blue). Data represents means of replicates; * indicates false discovery rate (FDR) &lt; 0.05. (<bold>C</bold>) As in (<bold>B</bold>) but for sgRNAs targeting <italic>CDKN2A</italic>. (<bold>D</bold>) Schematic of the <italic>CDKN2A</italic> gene locus with indicated sites complementary to tier 1 and tier 2 screen sgRNAs. Red sgRNAs increase in representation in CRISPR screens. (<bold>E</bold>) miRNet 2.0 (<xref ref-type="bibr" rid="bib21">Chang and Xia, 2023</xref>) analysis of the 27 miRNAs enriched in the tier 1 screen produced a single significant hit corresponding to the KEGG p53 signaling pathway. The miRNAs are represented as blue boxes and target genes as red circles; the connections between them are indicated. (<bold>F</bold>) As in (<bold>B</bold>) but for sgRNAs targeting <italic>RPL22</italic>. (<bold>G</bold>) Volcano plots, showing gene-level changes from the tier 2 screen in sgRNA representation in C6- (left) and C16- (right) treated populations compared to DMSO control cultures (orange indicates FDR &lt; 0.05). (<bold>H</bold>) Graph depicting gene-level Log2 FC and FDR values for genes that were flagged as C6- (squares) or C16- (circles) specific in the tier 2 screen. (<bold>I</bold>) GO enrichment analysis of the 57 C6/C16 common genes emerging from tier 2 of the screen. Italics represent the number of genes in each category.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Although the first tier did not discriminate between genes that modulate fitness and those that modulate WINi response, several interesting observations emerged. Guide RNAs corresponding to ~70 genes were enriched and ~675 were depleted (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), most of the latter of which are pan-essential (<xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). Satisfyingly, <italic>TP53</italic> is the most highly enriched gene in the screen (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). <italic>CDKN2A</italic> also scored as highly enriched in the initial screen (<xref ref-type="fig" rid="fig4">Figure 4B</xref>)—specifically those sgRNAs targeting p14<sup>ARF</sup>(<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C and D</xref>), an inhibitor of the p53 ubiquitin ligase MDM2 (<xref ref-type="bibr" rid="bib103">Sherr, 2001</xref>). Further support for the importance of p53 is evidenced by network analysis (<xref ref-type="bibr" rid="bib21">Chang and Xia, 2023</xref>) of the 27 miRNAs flagged as enriched (<xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>), which display connections to p53 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). Finally, we note that the second most highly enriched gene in the first tier encodes a ribosomal protein: RPL22 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>). Because of the strong enrichment of sgRNAs against <italic>RPL22</italic> and <italic>TP53</italic>, we removed both genes from the second tier screen.</p><p>The second tier screen (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>, <xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>) revealed that the response of MV4;11 cells to C6 and C16 is very similar, both in terms of the enriched/depleted genes and their rankings (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). A majority of genes that modulate the response to C6 similarly modulate the response to C16 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). For most of the depleted genes that appear specific to one WINi, similar depletion is observed with the other WINi, but is generally just over the FDR cutoff (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H</xref>). But for C6-specific enriched genes we see that most have high FDR values in the C16 samples, arguing that the earlier generation compound has expanded, off-target, activities. Gene Ontology (GO) enrichment analysis of the 57 common genes emerging from the screen revealed enrichment in four overlapping categories connected to p53 signaling, apoptosis, the DNA damage response (DDR), and histone modifications (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1I</xref>). The representation of genes connected to p53 and apoptosis reinforces the importance of p53-mediated cell death to the response of MLLr cells to WINi. We observe, for example, that loss of function of the p53 antagonist and ubiquitin ligase MUL1 (<xref ref-type="bibr" rid="bib54">Jung et al., 2011</xref>), increases sensitivity to C6/C16, whereas loss of canonical p53 effectors NOXA, BAX, and ZMAT3 is associated with a decrease in response. The DNA damage response category overlaps with that of p53 but is nonetheless distinct and includes genes encoding the ATM and CHK2 kinases (<xref ref-type="bibr" rid="bib11">Blackford and Jackson, 2017</xref>) and the FOXM1 transcription factor that activates DDR gene expression networks (<xref ref-type="bibr" rid="bib131">Zona et al., 2014</xref>). This category also includes two depleted genes, encoding FBXL5—which antagonizes ATM signaling (<xref ref-type="bibr" rid="bib24">Chen et al., 2014</xref>)—and DYRK1A—a kinase involved in the DDR (<xref ref-type="bibr" rid="bib60">Laham et al., 2021</xref>), DREAM complex activation (<xref ref-type="bibr" rid="bib76">Litovchick et al., 2011</xref>), and RPG transcription (<xref ref-type="bibr" rid="bib34">Di Vona et al., 2015</xref>). The involvement of this category of enriched genes is intriguing, given the lack of ɣ-H2AX accumulation in non-apoptotic cells (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>), and warrants further investigation in the future.</p><p>A majority of genes in the histone modification category, when disrupted, blunt the response to both WINi (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). These genes include those encoding the H3K27 demethylase KDM6A (<xref ref-type="bibr" rid="bib63">Lan et al., 2007</xref>), the MLL/SET protein KMT2D (MLL2; <xref ref-type="bibr" rid="bib104">Shinsky et al., 2015</xref>), and ARID4A—a component of the mSin3/HDAC1 co-repressor complex (<xref ref-type="bibr" rid="bib62">Lai et al., 2001</xref>). The most conspicuous sensitizing gene in this group is BRD3, a member of the BET family of proteins that includes BRD2 and BRD4 (<xref ref-type="bibr" rid="bib39">Eischer et al., 2023</xref>). Interestingly, although BRD4 was not included in the second screen tier as it is pan essential, BRD2 was not included because it was not significantly enriched/depleted in the first tier (<xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>), revealing that the actions of BRD3 in modulating response to WINi are not shared with all family members. Further supporting the importance of BRD3 to the response, we note that SPOP, which targets BET family proteins for proteasomal destruction (<xref ref-type="bibr" rid="bib50">Janouskova et al., 2017</xref>), is one of the most significantly enriched hits from the screen (<xref ref-type="fig" rid="fig4">Figure 4E</xref>).</p><p>Collectively, these findings demonstrate functional involvement of the ribosomal protein RPL22 in the response to WINi and confirm the importance of the p53 network to robust inhibition of MLLr cell growth by these agents. These findings also identify a number of candidate predictive biomarkers of response that can be further interrogated for their value as patient selection criteria.</p></sec><sec id="s2-5"><title>Identification of agents that synergize with WINi in MLLr cells</title><p>Given the ways in which resistance to WINi can arise (<xref ref-type="fig" rid="fig4">Figure 4</xref>), the most efficacious application of these agents will likely be in combination with other therapies. We therefore asked whether C16 synergizes with 11 approved or targeted agents. Several of the agents were chosen based on the results of our screen. Harmine—an inhibitor of the DYRK1A kinase (<xref ref-type="bibr" rid="bib45">Göckler et al., 2009</xref>)—and the BET family inhibitor mivebresib (<xref ref-type="bibr" rid="bib75">Lin et al., 2017</xref>) each target the product of sensitizing genes, whereas venetoclax inhibits BCL-2 (<xref ref-type="bibr" rid="bib109">Souers et al., 2013</xref>)—an inhibitor of BAX, which scored as a resistance gene. We also tested agents connected to the DDR (etoposide, olaparib, and the ATR inhibitor VE821; <xref ref-type="bibr" rid="bib23">Charrier et al., 2011</xref>), protein synthesis and homeostasis (alvespimycin and rapamycin), and p53 (nutlin-3a). Due to the enrichment of PRMT5 substrates in our translational profiling (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F</xref>), we queried the PRMT5 inhibitor pemrametostat (<xref ref-type="bibr" rid="bib22">Chan Penebre et al., 2015</xref>). Because DOT1L inhibitors suppress not only classic MLL fusion target genes (<xref ref-type="bibr" rid="bib9">Bernt and Armstrong, 2011</xref>; <xref ref-type="bibr" rid="bib33">Daigle et al., 2011</xref>) but also RPGs (<xref ref-type="bibr" rid="bib67">Lenard et al., 2020</xref>), we tested for synergy with the DOT1L inhibitor pinometostat (<xref ref-type="bibr" rid="bib33">Daigle et al., 2011</xref>). We treated MV4;11 cells with a dose matrix spanning 49 unique dose combinations and quantified synergy δ-scores using the zero interaction potency (ZIP) model (<xref ref-type="bibr" rid="bib125">Yadav et al., 2015</xref>; <xref ref-type="fig" rid="fig5">Figure 5A and B</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>, and <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Identification of agents that synergize with WIN site inhibitors (WINi) in MLLr cells.</title><p>(<bold>A</bold>) Peak synergy (&gt;0) and antagonism (&lt;0) zero interaction potency (ZIP) delta (δ) scores from synergy assays in which MV4;11 cells were treated for 3 d with 49 unique dose combinations of C16 and the indicated compound of interest (n = 4). See <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> for numerical ZIP delta analysis output. (<bold>B</bold>) Heatmaps of MV4;11 cell growth inhibition at each dose of C16 and the indicated six compounds. The remaining five combinations tested are shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>. (<bold>C</bold>) As in (<bold>A</bold>) but for MOLM13 cells. See <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> for numerical ZIP delta analysis output. (<bold>D</bold>) As in (<bold>B</bold>) but for MOLM13 cells. The remaining five combinations tested are shown in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>. (<bold>E</bold>) Number of genes with significantly (false discovery rate [FDR] &lt; 0.05) altered transcript levels following treatment of MV4;11 cells with C16 (100 nM), mivebresib (Mibv; 2.5 nM), or the combination for 48 hr, as determined by RNA-seq (n = 3). See <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref> for complete output of RNA-seq analysis. (<bold>F</bold>) UpSet plot, showing the overlap of genes suppressed (left) or induced (right) in response to C16, mivebresib, or the combination. (<bold>G</bold>) UpSet plot, showing the breakdown of Reactome ‘Translation’ pathway genes suppressed in response to C16, mivebresib, or the combination. (<bold>H</bold>) Enrichment of Reactome Pathways in genes with increased transcripts following treatment of MV4;11 cells with C16, mivebresib, or the combination. See <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref> for complete output of enrichment analyses.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Peak synergy and antagonism scores for MV4:11 and MOLM13 cells treated with C16 in combination with 11 agents.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Output of RNA-seq analysis of MV4;11 cells treated with C16, mivebresib, or both.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig5-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>Enrichment analysis of differentially expressed genes in RNA-seq of MV4;11 cells treated with C16, mivebresib, or both.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig5-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>C16 is synergistic with multiple agents in MV4;11 cells.</title><p>(<bold>A</bold>) Heatmaps of MV4;11 cell growth inhibition at each dose of C16 and the indicated five compounds. (<bold>B</bold>) Heatmaps of δ scores from MV4;11 cells at each dose combination of C16 and the indicated agents.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>C16 is synergistic with multiple agents in MOLM13 cells.</title><p>(<bold>A</bold>) Heatmaps of MOLM13 cell growth inhibition at each dose of C16 and the indicated five compounds. (<bold>B</bold>) Heatmaps of δ scores from MOLM13 cells at each dose combination of C16 and the indicated agents.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Impact of C16 and mivebresib on RPG and p53 target gene expression.</title><p>(<bold>A</bold>) Transcript level changes in WDR5-bound (left) and non-bound (right) RPGs elicited by C16 (top), mivebresib (Mivb; middle), or the combination (bottom). (<bold>B</bold>) Heatmap, showing significant changes in the expression of consensus p53 target genes (<xref ref-type="bibr" rid="bib41">Fischer, 2017</xref>) induced by C16, mivebresib (Mivb; middle) or the combination (bottom) in MV4;11 cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig5-figsupp3-v1.tif"/></fig></fig-group><p>In MV4;11 cells, we observe synergy with mivebresib, pemrametostat, pinometostat, etoposide, harmine, and venetoclax. Within this group are three agents selected based on sensitizing targets from the CRISPR screen, providing additional support for the role of DRYK1A, BCL-2/BAX, and BRD3 in the responsiveness to WINi. Of the three agents connected to the DDR, only etoposide displays significant synergy. Agents that target protein synthesis and homeostasis yield mixed results—we observe potent antagonism with the mTOR inhibitor (<xref ref-type="bibr" rid="bib93">Raught et al., 2001</xref>) rapamycin (peak δ-score –16), while the HSP90 inhibitor alvespimycin (<xref ref-type="bibr" rid="bib100">Schnur et al., 1995</xref>) is either antagonistic or synergistic, depending on dose (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Finally, we note that—of the agents displaying synergy—four are particularly strong (peak δ-scores &gt; 10) and observed at agent doses consistent with on-target activity (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), suggesting that mivebresib, pemrametostat, pinometostat, and venetoclax should be prioritized for in vivo testing. Focusing on these agents is further justified by our finding that all four are synergistic with C16 in MOLM13 cells (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>, <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A and B</xref>).</p><p>To understand how combination with another agent impacts the response to WINi, we transcriptionally profiled MV4;11 cells treated for 48 hr with C16 and mivebresib, either as single agents or in combination, at concentrations that yield peak synergy between them (100 nM C16 and 2.5 nM mivebresib). Spike-in controls were not included. By RNA-seq (<xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>), it is clear that the functional synergy between C16 and mivebresib is apparent at the transcript level, with more than 6,200 gene expression changes in the combination treatment, compared to less than 1,800 for C16 and 2700 for mivebresib (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Notable are the very distinct transcriptional profiles induced by each agent alone, with fewer than 200 shared gene expression changes in each direction (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). The impact on RPG expression of both agents is additive (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3A</xref>), but in general we find that the combination of C16 and mivebresib dysregulates similar categories of genes for each agent alone, but with substantially more genes in each category (<xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>). This is clear for genes linked to translation (<xref ref-type="fig" rid="fig5">Figure 5G</xref>), p53 (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3B</xref>), and the induction of apoptosis (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). Thus, although further investigation is needed, this analysis is consistent with the idea that synergy between C16 and mivebresib results from alterations in the expression of distinct but complementary sets of genes that ultimately conspire to augment induction of p53.</p></sec><sec id="s2-6"><title>WINi inactivate MDM4 in an RPL22-dependent manner</title><p>Despite the importance of p53 in the response to WINi, WINi cause only a slight increase, if any, in p53 levels (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>; <xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>). Interestingly, inactivation or loss of <italic>RPL22</italic> in cancer is associated with increased expression of <italic>RPL22L1</italic> and inclusion of exon 6 in MDM4 (<xref ref-type="bibr" rid="bib44">Ghandi et al., 2019</xref>), an event that promotes MDM4 expression by preventing formation of a ‘short’ MDM4 mRNA isoform (MDM4s) that is destroyed by nonsense-mediated decay (<xref ref-type="bibr" rid="bib92">Rallapalli et al., 1999</xref>). MDM4 is intriguing because it can suppress p53 without altering its stability (<xref ref-type="bibr" rid="bib43">Francoz et al., 2006</xref>). It is also intriguing because skipping of exon 6 in the <italic>MDM4</italic> mRNA is stimulated by ZMAT3 (<xref ref-type="bibr" rid="bib10">Bieging-Rolett et al., 2020</xref>; <xref ref-type="bibr" rid="bib82">Muys et al., 2021</xref>) and antagonized by RPL22L1 (<xref ref-type="bibr" rid="bib65">Larionova et al., 2022</xref>)—two genes that are oppositely regulated by WINi. We therefore asked if WINi induce changes in the levels of mRNA splice isoforms and if this includes MDM4.</p><p>RNA-seq data (<xref ref-type="fig" rid="fig1">Figure 1</xref>) were interrogated for alternative splicing events (<xref ref-type="bibr" rid="bib102">Shen et al., 2014</xref>). At an FDR &lt; 0.05 and a threshold of ≥5% change in exon inclusion (<italic>∆ψ</italic>), C6 and C16 each result in changes in ~1,000 differentially spliced mRNAs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>), ~250 of which are shared between the two inhibitors (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Many of these changes reflect events with low read counts or at minor splice sites (<xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>), representative examples of which are presented in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C and D</xref>. That said, WINi clearly promote accumulation of <italic>MDM4</italic> transcripts in which exon 6 is skipped (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). We also observe splicing changes at <italic>RPL22L1</italic> itself (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>), where WINi leads to the depletion of transcripts in which exon 2 is spliced to a distal 3′ acceptor site in exon 3. This splicing event encodes the RPL22L1a isoform that is incorporated into ribosomes (<xref ref-type="bibr" rid="bib65">Larionova et al., 2022</xref>). Splicing to the proximal 3′ acceptor site, which generates a non-ribosomal RPL22L1b isoform that modulates splicing, is insensitive to WINi. We confirmed the impact of C16 on <italic>MDM4</italic> and <italic>RPL22L1</italic> splice isoforms by semi-quantitative RT-PCR (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>, <xref ref-type="supplementary-material" rid="fig6sdata3">Figure 6—source data 3</xref>) and quantitative RT-PCR (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G</xref>). Based on these observations, we conclude that treatment of MLLr cells with WINi promotes the selective loss of transcripts encoding RPL22L1a and MDM4.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>WIN site inhibitors (WINi) inactivate MDM4 in an RPL22-dependent manner.</title><p>(<bold>A</bold>) Differential alternative splicing events affected by C6/C16 treatment of MV4;11 cells were quantified by rMATS. The types of alternative splicing events are cartooned at left, and the number of significantly different events (&gt;5% <italic>∆ψ</italic>; false discovery rate [FDR] &lt; 0.05) common to C6/C16 depicted in the graph. See <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref> for output of rMATS analysis. (<bold>B</bold>) Sashimi plot quantifying read junctions that span exons 5–7 of <italic>MDM4</italic> in MV4;11 cells treated with DMSO (green) or C16 (blue). Numbers in the arcs display junction depth. The location of exons 5, 6, and 7 is depicted at the bottom; skipped exon 6 is highlighted in orange. (<bold>C</bold>) Viabilities of control (non-targeting: NT) and RPL22 knock out (KO) MV4;11, MOLM13, and K562 cells treated with a serial dilution range of C16 for 72 hr, relative to viability of DMSO-treated cells (n = 3; mean ± SEM). (<bold>D</bold>) Western blot analysis of p53 levels in control (NT) and RPL22 knockout (KO) MV4;11 and MOLM13 cells treated with either 0.1% DMSO or C16 (MV4;11, 200 nM; MOLM13, 400 nM) for 72 hr. α-Actinin is loading control. Representative images from three biological replicates shown. Raw unprocessed gel images are presented in <xref ref-type="supplementary-material" rid="fig6sdata5">Figure 6—source data 5</xref>. (<bold>E</bold>) Heatmap, showing significant changes in the expression of consensus p53 target genes (<xref ref-type="bibr" rid="bib41">Fischer, 2017</xref>) between the indicated pairwise comparisons of RNA-seq datasets. Note that only consensus p53 target genes altered in expression by C16 in control (NT) cells are represented. (<bold>F</bold>) Sashimi plot quantifying read junctions that span exons 5–7 of <italic>MDM4</italic> in RPL22KO MV4;11 cells treated with DMSO or C16. Numbers in the arcs display junction depth. The location of exons 5, 6, and 7 is depicted at the bottom; skipped exon 6 is highlighted in orange. Corresponding NT images are presented alongside RPL22KO images in <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3B</xref>. (<bold>G</bold>) Western blots, comparing the effects of 72 hr of DMSO (DM) or C16 treatment (MV4;11, 200 nM; MOLM13, 400 nM) of control (NT) or RPL22 knockout (KO) MV4;11 (left) or MOLM13 (right) cells on levels of MDM4, p21, RPL22L1, RPL22, and GAPDH (loading control). Representative images from three biological replicates are shown. Raw unprocessed gel images are presented in <xref ref-type="supplementary-material" rid="fig6sdata9">Figure 6—source data 9</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw unprocessed gel images corresponding to <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-90683-fig6-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Output of rMATS analysis of MV4;11 cells treated with C6/C16.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig6-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>Raw unprocessed gel images corresponding to <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-90683-fig6-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6sdata4"><label>Figure 6—source data 4.</label><caption><title>Raw unprocessed gel images corresponding to <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-90683-fig6-data4-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6sdata5"><label>Figure 6—source data 5.</label><caption><title>Raw unprocessed gel images corresponding to <xref ref-type="fig" rid="fig6">Figure 6D</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-90683-fig6-data5-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig6sdata6"><label>Figure 6—source data 6.</label><caption><title>Output of RNA-seq analysis of NT and RPL22KO MV4;11 cells treated with C16.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig6-data6-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata7"><label>Figure 6—source data 7.</label><caption><title>GSEA Hallmark and GOBP enrichment analysis of differentially expressed genes in RNA-seq of NT and RPL22KO MV4;11 cells treated with C16.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig6-data7-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata8"><label>Figure 6—source data 8.</label><caption><title>Output of rMATS analysis of NT and RPL22KO MV4;11 cells treated with C16.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-90683-fig6-data8-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata9"><label>Figure 6—source data 9.</label><caption><title>Raw unprocessed gel images corresponding to <xref ref-type="fig" rid="fig6">Figure 6G</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-90683-fig6-data9-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>WIN site inhibitors (WINi) alter the abundance of alternatively spliced mRNA isoforms.</title><p>(<bold>A</bold>) Western blots comparing the effects of 72 hr DMSO (DM) or C16 treatment of MV4;11 (top) or MOLM13 (bottom) cells on levels of p53 and GAPDH (loading control). Representative images from three biological replicates are shown. Raw unprocessed gel images are presented in <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>. (<bold>B</bold>) Differential alternative splicing events impacted by C6 (red) or C16 (blue) treatment of MV4;11 cells were quantified by rMATS. The number of significantly different events (&gt;5% <italic>∆ψ</italic>; false discovery rate [FDR] &lt; 0.05) for each WINi are depicted in the graph. ‘RI’ is retained intron; ‘MEX’ is mutually exclusive exons; ‘A3SS’ is alternative 3' splice site; ‘A5SS’ is alternative 5' splice site; ‘SE’ is skipped exon. See <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref> for output of rMATS analysis. (<bold>C</bold>) Sashimi plot quantifying read junctions that span exons 12–17 of <italic>KRBA1</italic> in MV4;11 cells treated with DMSO (green) or C16 (blue). Numbers in the arcs display junction depth. Skipped exon 15 is highlighted in orange. (<bold>D</bold>) As in (<bold>C</bold>) but for read junctions that span exons 20–22 of <italic>TTF2</italic>. Skipped exon 21 is highlighted in orange. (<bold>E</bold>) As in (<bold>C</bold>), but for read junctions that span exons 2 and 3 of <italic>RPL22L1</italic>. The location of exons 2 and 3 is depicted at the bottom. Splicing of exon 2 to the distal acceptor site in exon 3 results in an mRNA encoding RPL22L1a (orange); splicing to the proximal acceptor site in exon 3 results in an mRNA encoding RPL22L1b (yellow). (<bold>F</bold>) Left: representation of amplicons used to discriminate between different <italic>MDM4</italic> (top) and <italic>RPL22L1</italic> (bottom) isoforms via semi-quantitative PCR. Right: results of semi-quantitative PCR analysis for the various isoforms of <italic>MDM4</italic> and <italic>RPL22L1,</italic> and a <italic>GAPDH</italic> control, in MV4;11 or MOLM13 cells treated for 48 hr with DMSO or C16 (MV4;11, 100 nM; MOLM13, 250 nM; n = 3). All three biological replicates for DMSO and C16 are shown. Raw unprocessed gel images for the data in (<bold>F</bold>) are presented in <xref ref-type="supplementary-material" rid="fig6sdata3">Figure 6—source data 3</xref>. (<bold>G</bold>) Left: representation of amplicons used to discriminate between <italic>MDM4</italic> (top) and <italic>RPL22L1</italic> (bottom) isoforms via RT-qPCR. Right: results of RT-qPCR analysis for the various isoforms of <italic>MDM4</italic> (top) and <italic>RPL22L1</italic> (bottom) in MV4;11 or MOLM13 cells treated for 48 hr with DMSO or C16 (MV4;11, 100 nM; MOLM13, 250 nM; n = 3; mean ± SEM). For each amplicon, isoform levels are expressed relative to the DMSO control. p-Values calculated by Student’s <italic>t</italic>-tests are represented by asterisks: *≤0.05, **≤0.01, ***≤0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Impact of RPL22 loss on the response of MLLr cells to WIN site inhibitors (WINi).</title><p>(<bold>A</bold>) Western blot analysis of RPL22 expression in MV4;11, MOLM13, and K562 cells electroporated with Cas9 and either scrambled non-targeting (NT) control or <italic>RPL22</italic>-targeting sgRNAs. GAPDH and α-actinin are loading controls. Representative images from three biological replicates shown. Raw unprocessed gel images are presented in <xref ref-type="supplementary-material" rid="fig6sdata4">Figure 6—source data 4</xref>. (<bold>B</bold>) GI50 values of C16 in non-targeted (NT) and RPL22 knock out (KO) MV4;11, MOLM13, and K562 cells in a 72 hr assay (n <italic>=</italic> 3; mean ± SEM). (<bold>C</bold>) Number of genes with significantly (false discovery rate [FDR] &lt; 0.05) altered transcript levels following treatment of RPL22KO or control (NT) cells treated with DMSO or 100 nM C16 for 48 hr, as determined by RNA-seq (n = 4). See <xref ref-type="supplementary-material" rid="fig6sdata6">Figure 6—source data 6</xref> for complete output of RNA-seq analysis. (<bold>D</bold>) Volcano plots, showing pairwise transcript level alterations in NT (control) and RPL22KO MV4;11 cells treated 48 hr with DMSO or 100 nM C16 (red indicates FDR &lt; 0.05). The locations of transcripts from <italic>ZMAT3</italic> and <italic>RPL22L1</italic> are indicated. (<bold>E</bold>) Transcript level changes in WDR5-bound (left) and non-bound (right) RPGs in each of the indicated pairwise comparisons of RNA-seq datasets. (<bold>F</bold>) Enrichment analysis of genes differentially induced by C16 in RPL22KO cells compared to control (NT) cells. KEGG and Hallmark.MSigDB pathways are shown. Fold enrichment of indicated pathways is presented on the x-axis, the number of genes is shown in italics in each bar, and colors represent -Log10 FDR. See <xref ref-type="supplementary-material" rid="fig6sdata7">Figure 6—source data 7</xref> for complete enrichment analyses. (<bold>G</bold>) As in (<bold>F</bold>) but for suppressed genes. (<bold>H</bold>) Transcript level changes in mitochondrial ribosomal protein genes elicited by C16 in NT or RPL22KO cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Impact of RPL22 loss on the abundance of alternatively-spliced mRNA isoforms in MV4;11 cells.</title><p>(<bold>A</bold>) Differential alternative splicing events affected by C16 treatment of control (NT) or RPL22 knockout (KO) MV4;11 cells were quantified by rMATS. The types of alternative splicing events are cartooned at left, and the number of significantly different events (&gt;5% <italic>∆ψ</italic>; false discovery rate [FDR] &lt; 0.05) depicted in the graph. See <xref ref-type="supplementary-material" rid="fig6sdata8">Figure 6—source data 8</xref> for output of rMATS analysis. (<bold>B</bold>) Sashimi plot quantifying read junctions that span exons 5–7 of <italic>MDM4</italic> in NT or RPL22KO MV4;11 cells treated with DMSO or C16. Numbers in the arcs display junction depth. The location of exons 5, 6, and 7 is depicted at the bottom; skipped exon 6 is highlighted in orange. Note that RPL22KO images are also represented in <xref ref-type="fig" rid="fig6">Figure 6F</xref>. (<bold>C</bold>) As in (<bold>B</bold>) but for read junctions that span exons 2 and 3 of <italic>RPL22L1</italic>. The location of exons 2 and 3 is depicted at the bottom. Splicing of exon 2 to the distal acceptor site in exon 3 results in an mRNA encoding RPL22L1a (orange); splicing to the proximal acceptor site in exon 3 results in an mRNA encoding RPL22L1b (yellow).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-90683-fig6-figsupp3-v1.tif"/></fig></fig-group><p>The association of <italic>RPL22</italic> loss with increased expression of <italic>RPL22L1</italic> and inclusion of exon 6 in <italic>MDM4</italic> (<xref ref-type="bibr" rid="bib44">Ghandi et al., 2019</xref>) prompted us to ask how <italic>RPL22</italic> contributes to the response of MLLr cells to WINi. Knockout (KO) of <italic>RPL22</italic> (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A</xref>, <xref ref-type="supplementary-material" rid="fig6sdata4">Figure 6—source data 4</xref>) decreases the sensitivity of MV4;11 and MOLM13 cells to C16 by three- to fivefold compared to non-targeted (NT) control cells (<xref ref-type="fig" rid="fig6">Figure 6C</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2B</xref>), as well as attenuating the modest induction of p53 protein observed in the MV4;11 line (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, <xref ref-type="supplementary-material" rid="fig6sdata5">Figure 6—source data 5</xref>). The response of relatively insensitive (p53-null) K562 cells, in contrast, is unaffected by <italic>RPL22</italic> disruption (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). RNA-seq analysis, performed without spike-in controls, (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C and D</xref>, <xref ref-type="supplementary-material" rid="fig6sdata6">Figure 6—source data 6</xref>) reveals that disruption of <italic>RPL22</italic> does not impact the effect of WINi on WDR5-bound RPGs (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2E</xref>), but it does block the effects of C16 on expression of <italic>RPL22L1</italic> and <italic>ZMAT3</italic> (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2D</xref>), as well as tempering its ability to suppress genes connected to the cell cycle, mTORC1 signaling, and MYC (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2F</xref>, <xref ref-type="supplementary-material" rid="fig6sdata7">Figure 6—source data 7</xref>). Notably, <italic>RPL22</italic> loss also impairs induction of genes involved in p53 signaling (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2G</xref>). We also observe that mitochondrial RPGs are induced by WINi uniquely in <italic>RPL22</italic>-null cells (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2H</xref>). We conclude that RPL22 is needed for a majority of the characteristic responses of MLLr cells to WINi, including activation of p53.</p><p>Finally, we asked if <italic>RPL22</italic> knockout alters patterns of alternative splicing induced by WINi. Thousands of differences were detected in splice isoforms between the various pairwise comparisons (<xref ref-type="supplementary-material" rid="fig6sdata8">Figure 6—source data 8</xref>). In general, <italic>RPL22KO</italic> cells show fewer C16-induced changes in alternative splicing patterns than NT cells (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A</xref>). As we observed above, a majority of the changes reflect events with low read counts or at minor splice sites, with two notable exceptions: <italic>MDM4</italic> and <italic>RPL22L1</italic>. In the absence of WINi, disruption of <italic>RPL22</italic> promotes exon 6 retention in <italic>MDM4</italic> (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3B</xref>) and induces expression of the mRNA splice isoform encoding RPL22La (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3C</xref>). In the presence of C16, disruption of <italic>RPL22</italic> mitigates skipping of exon 6 in <italic>MDM4</italic> (<xref ref-type="fig" rid="fig6">Figure 6F</xref>) and largely blocks suppression of the RPL22L1a-encoding mRNA isoform (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3C</xref>). Importantly, these changes in mRNA isoforms manifest at the protein level (<xref ref-type="fig" rid="fig6">Figure 6G</xref>, <xref ref-type="supplementary-material" rid="fig6sdata9">Figure 6—source data 9</xref>) as we observe that both MDM4 and RPL22L1 protein expression is suppressed by C16, that RPL22L1 is induced by RPL22 disruption, and that loss of RPL22 blocks a majority of the ability of C16 to reduce expression of the MDM4 and RPL22L1 proteins. We also note that loss of RPL22 blocks induction of the p53 target, p21. Taken together, these data demonstrate that RPL22 loss can cause the induction of RPL22L1 and inclusion of exon 6 in MDM4 observed in cancer (<xref ref-type="bibr" rid="bib44">Ghandi et al., 2019</xref>) and reveal that splicing-driven suppression of MDM4 is an important mechanism through which WINi activate p53 in MLLr cells.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we describe an integrated multi-omic approach to characterize the mechanism of action of WDR5 WINi in MLL-rearranged cancer cells. By combining transcriptional, translational, and proteomic profiling with genome-wide loss-of-function screens, we demonstrate the broad impact of WINi on the ribosomal protein complement and translational capacity of MLLr cells, reveal the importance of multiple arms of the p53 response pathway in cellular inhibition, and uncover a role for alternative splicing of MDM4 in activating p53 in this setting. Collectively, these data cast WINi as a novel ribosome-directed anticancer therapy and provide insight into patient selection criteria, mechanisms of resistance, and strategies to improve WINi efficacy in the clinic.</p><p>The primary targets of WINi, we propose, are the cohort of ~40 RPGs that are bound by WDR5 in all cell types examined (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>; <xref ref-type="bibr" rid="bib15">Bryan et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Florian et al., 2022</xref>). These RPGs are rapidly transcriptionally suppressed in response to WIN site blockade (<xref ref-type="bibr" rid="bib15">Bryan et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Florian et al., 2022</xref>; <xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>) or WDR5 degradation (<xref ref-type="bibr" rid="bib107">Siladi et al., 2022</xref>), and show sustained suppression at the mRNA level. These same RPGs are suppressed by disruption of the MYC–WDR5 interaction (<xref ref-type="bibr" rid="bib115">Thomas et al., 2019</xref>), implying that the function of WDR5 at these genes is to recruit MYC, a prominent target of MLL-fusion oncoproteins (<xref ref-type="bibr" rid="bib2">Ahmadi et al., 2021</xref>). Previously, we posited that suppression of half the RPGs would lead to a ribosomal subunit imbalance (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>), but our analysis shows that WINi deplete the entire ribosomal inventory. Part of this depletion is driven by decreased translation of ribosomal mRNAs, although it is also possible that ubiquitin-mediated quality control mechanisms or ribophagy (<xref ref-type="bibr" rid="bib128">Zhao et al., 2022</xref>) degrade ribosomal proteins under these conditions.</p><p>The effects of WINi on ribosomal protein levels are extensive in terms of the number of impacted subunits, but not the magnitude of change, which caps at around a 30% decrease by 72 hr. This cap could be set by the maximal contribution of MYC–WDR5 to the expression of target RPGs, which is twofold as determined by genetic disruption of the MYC–WDR5 interaction (<xref ref-type="bibr" rid="bib115">Thomas et al., 2019</xref>), degradation of WDR5 (<xref ref-type="bibr" rid="bib107">Siladi et al., 2022</xref>), or WIN site blockade. Although modest, it should be noted that a 30% decrease in ribosomal protein levels corresponds to a loss of up to 3 million ribosomes per cell (<xref ref-type="bibr" rid="bib105">Shore and Albert, 2022</xref>), and in that light it is not surprising that WINi result in reduced translational efficiencies of about half of all actively translated mRNAs. Unlike perturbations such as ER stress (<xref ref-type="bibr" rid="bib1">Advani and Ivanov, 2019</xref>), WINi does not promote preferential translation of stress-responsive mRNAs, although there is some specificity in terms of the translational consequences. Messenger RNAs carrying 5'TOP motifs, for example, are spared from the full translational impact of C6/C16, and we see distinct biological clustering of mRNAs with decreased translation efficiency. Whether these patterns are intrinsic to WINi, or a general response of MV4;11 cells to translational stress, remains to be determined. Overall, we conclude that WINi do not trigger extensive translational reprogramming, but rather act to induce a widespread yet restrained translational choke.</p><p>In addition to ribosomal protein attrition, we also find that WINi trigger a progressive decline in rRNA expression, which we suggest is a secondary effect resulting from the tight coordination between RPG and rRNA transcription (<xref ref-type="bibr" rid="bib37">Dörner et al., 2023</xref>). As previously reported (<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>), we confirm that they promote a shift in the relative abundance of NPM1 in the nucleoplasm versus the nucleolus, indicative of a nucleolar stress response. Given that we recovered multiple DDR components in our two-tier CRISPR screen, and that agents such as the RNA polymerase I inhibitor CX-5461 induce DNA damage (<xref ref-type="bibr" rid="bib89">Quin et al., 2016</xref>; <xref ref-type="bibr" rid="bib40">El Hassouni et al., 2019</xref>), we had expected to see some evidence of ɣ-H2A.X induction in the nucleolus or the nucleoplasm in response to WINi. Yet we only observe ɣ-H2A.X induction in apoptotic cells. The difference in this aspect of the response to what are overtly two different ways to inhibit protein synthesis in cancer cells—RPG versus rRNA inhibition—may relate to the different primary mechanism of action of these agents or the magnitude of their effects, which are more subtle with WINi. Alternatively, because not all rRNA inhibitors induce DNA damage (e.g., <xref ref-type="bibr" rid="bib85">Peltonen et al., 2014</xref>), induction of DNA damage may be specific to CX-5461. Further investigation, especially into the significance of DDR components in the response to WINi, is warranted.</p><p>Activation of p53 is, however, a major point of convergence of WDR5 and rRNA inhibitors. Not only do we detect activation of p53 target genes in response to WIN site blockade, but we observe synergistic activation of p53 target genes with the BET bromodomain inhibitor mivebresib and suppression of p53 targets upon deletion of <italic>RPL22</italic>; both of which correlate with cellular sensitivity. We also recover multiple components of the p53 signaling pathway as ‘resistance’ genes in our CRISPR screens, including p53 itself and the splicing factor ZMAT3. Inhibition of rRNA synthesis is thought to activate p53 by generating excess ribosomal proteins that bind to and inactivate MDM2 (<xref ref-type="bibr" rid="bib87">Pfister, 2019</xref>). It is likely that inhibition of MDM2 contributes to p53 activation in response to C6/C16, as we see a modest increase in p53 levels in MV4;11 cells exposed to WINi, and find that loss of the MDM2 inhibitor p14<sup>ARF</sup> renders MV4;11 cells less sensitive to C6/C16. Here, however, we also find that there is a second route of p53 activation at work, in which WINi promote accumulation of alternatively spliced isoforms of <italic>MDM4</italic> mRNA in which exon 6 is skipped, driving down MDM4 protein levels. Because MDM4 inhibits p53 via proteolysis-independent mechanisms (<xref ref-type="bibr" rid="bib43">Francoz et al., 2006</xref>), these findings explain how WINi can induce a robust p53 target gene signature in the absence of frank induction of p53 protein. They also point to a dominant role of the MDM4–p53 axis in mediating the response of MLLr cells to WIN site blockade. Whether rRNA inhibition triggers p53 activation by a similar mechanism has, to our knowledge, yet to be reported.</p><p>In considering the mechanism through which WINi inactivate MDM4, it is possible that the balance of RPL22L1 and ZMAT3, which are oppositely regulated in response to WIN site inhibition, governs the extent of MDM4 exon 6 inclusion. ZMAT3 is induced in response to p53 activation and promotes skipping of exon 6 in MDM4 (<xref ref-type="bibr" rid="bib10">Bieging-Rolett et al., 2020</xref>). RPL22L1, in contrast, which is potently suppressed by WINi, promotes exon 6 inclusion (<xref ref-type="bibr" rid="bib65">Larionova et al., 2022</xref>). Any process that tips the balance in favor of ZMAT3, therefore, would be expected to inhibit MDM4, activate p53, and initiate a feed-forward mechanism that drives ZMAT3 expression, fortifies p53 induction, and commits cells to an apoptotic outcome. Induction of ZMAT3 alone should be sufficient to trigger this circuit, but the conspicuous suppression of RPL22L1 by WINi suggests that this may also contribute to the response. Paradoxically, the isoform of RPL22L1 that is suppressed by WIN site blockade, RPL22L1a, is linked in glioblastoma cells to ribosome function, not splicing (<xref ref-type="bibr" rid="bib65">Larionova et al., 2022</xref>), while the splicing-relevant RPL22L1b isoform is resistant to WINi. One possibility is that, despite its recurrence and prominence, suppression of RPL22L1a by C6/C16 does not contribute to MDM4 suppression, and induction of ZMAT3 is the critical driving factor. Alternatively, RPL22L1a may indeed act to control splicing in MLLr cells, in contrast to what has been reported in glioblastoma. Further investigation is required.</p><p>The RPL22–RPL22L1–MDM4 nexus we encountered has been inferred by genome-wide studies of the Cancer Cell Line Encyclopedia (CCLE; <xref ref-type="bibr" rid="bib44">Ghandi et al., 2019</xref>), and our work here demonstrates that loss of <italic>RPL22</italic> causes induction of RPL22L1 and promotes inclusion of exon 6 in MDM4. We have no evidence that RPL22 itself plays a role in the response to WINi in otherwise unperturbed MLLr cells. Rather, we suggest that its recovery as a resistance gene in our CRISPR screen is tied to its ability to suppress <italic>RPL22L1</italic> expression (<xref ref-type="bibr" rid="bib84">O’Leary et al., 2013</xref>), and the ectopic effect of its deletion on preventing WINi-induced RPL22L1a decline. That said, RPL22 status is likely to be highly relevant in terms of patient selection criteria. <italic>RPL22</italic> is frequently inactivated or deleted in primary cancer samples (<xref ref-type="bibr" rid="bib55">Kandoth et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Goudarzi and Lindström, 2016</xref>; <xref ref-type="bibr" rid="bib44">Ghandi et al., 2019</xref>), as well as 7% of lines in the CCLE (<xref ref-type="bibr" rid="bib18">Cao et al., 2017</xref>). Unlike other RPGs, mutation or deletion of <italic>RPL22</italic> is not associated with mutational inactivation of p53, and indeed there is a strong tendency for wild-type p53 to be retained in <italic>RPL22</italic> mutant/deletion lines (<xref ref-type="bibr" rid="bib18">Cao et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Ghandi et al., 2019</xref>). In practical terms, therefore, cancers that retain wild-type p53 but otherwise are mutated/deleted for <italic>RPL22</italic>, or overexpress <italic>RPL22L1</italic>, would not be expected to robustly respond to WINi.</p><p>Although p53 is important for the action of WINi in MLLr cells, there are likely other stress response mechanisms that mediate cellular inhibition by these agents. A number of p53-independent nucleolar stress responses have been identified, but these remain mechanistically opaque compared to p53-dependent responses (<xref ref-type="bibr" rid="bib12">Boglev et al., 2013</xref>; <xref ref-type="bibr" rid="bib86">Pfister et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Jayaraman et al., 2017</xref>). Conversely, we might also expect cells to be able to mount protective responses to WIN site blockade. In this regard, it is curious that four resistance genes identified in our CRISPR screen—UBA6, BIRC6, KCMF1, and UBR4—encode members of a newly identified BIRC6 ubiquitin-ligase complex (<xref ref-type="bibr" rid="bib19">Cervia et al., 2023</xref>), the function of which is to prevent aberrant activation of the integrated stress response (ISR). The ISR is a central regulator of protein homeostasis (<xref ref-type="bibr" rid="bib29">Costa-Mattioli and Walter, 2020</xref>) that drives protective translational reprogramming in response to multiple cellular stresses. There is no indication that the ISR is activated by WINi; indeed, the master regulator of ISR, ATF4, is suppressed by C6/C16 at the mRNA and translational levels. But the finding that loss of all four members of the BIRC6 complex blunts the response to WINi implies that ISR activation can be a mechanism through which cells evade the full impact of these agents.</p><p>As with most monotherapies, future single-agent WINi treatment paradigms are likely to encounter resistance either by activation of protective responses such as those proposed above or by mutations in one or more of the resistance genes recovered in our CRISPR screen. Identification of agents that can be used in combination with WINi to increase cancer cell inhibition is thus crucial. Our relatively limited synergy screening identified a number of combinations that should be prioritized for in vivo testing. We found that WINi act synergistically with the BCL-2 inhibitor venetoclax (<xref ref-type="bibr" rid="bib109">Souers et al., 2013</xref>). This is rationalized by our recovery of BAX as a resistance gene and is noteworthy because venetoclax is an approved therapy for several blood-borne cancers. We also identified notable synergies with experimental agents targeting BET bromodomain family members, DOT1L, and PRMT5. The combination with mivebresib is rationalized based on identification of BRD3 as a sensitizing gene and likely results from the ability of C16 and mivebresib to inhibit distinct sets of genes connected to translation, the impact of which is to enhance p53 induction. BET bromodomain inhibitors have struggled somewhat in clinical trials due to dose-limiting toxicities (<xref ref-type="bibr" rid="bib106">Shorstova et al., 2021</xref>), but their combination with WINi could form the basis of a more effective therapy with less side effects. Moreover, given the mechanism underlying synergy between C16 and BET inhibitors, we would expect this combination to be effective in other wild-type p53 cancer settings where WINi are active, such as neuroblastoma (<xref ref-type="bibr" rid="bib15">Bryan et al., 2020</xref>) and rhabdoid tumors (<xref ref-type="bibr" rid="bib42">Florian et al., 2022</xref>). Expanded synergy screening is needed to identify and understand the full spectrum of combination approaches that could be used to ultimately enhance and extend the clinical utility of WINi.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Key resources</title><p>All key resources are provided in Appendix 1—key resources table.</p></sec><sec id="s4-2"><title>Materials availability</title><p>Plasmids and cell lines generated in this study are available upon request from the corresponding author (william.p.tansey@vanderbilt.edu).</p></sec><sec id="s4-3"><title>Cell lines</title><p>MV4;11 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0064">CVCL_0064</ext-link>), MOLM13 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_2119">CVCL_2119</ext-link>), and K562 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0004">CVCL_0004</ext-link>) cell lines and their derivatives were cultured in RPMI-1640 media with 10% FBS, 10 U/mL penicillin, and 10 µg/mL streptomycin at 37°C and 5% CO<sub>2</sub>. HEK293T (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_1926">CVCL_1926</ext-link>) cells were cultured in DMEM media with 10% FBS, 10 U/mL penicillin, and 10 µg/mL streptomycin at 37°C and 5% CO<sub>2</sub>. MV4;11 and MOLM13 cell lines are male. K562 and HEK293T cell lines are female. Cell lines were split every 2–4 d and suspension cells maintained between 1 × 10<sup>5</sup> and 1 × 10<sup>6</sup> cells/mL. Cell line identity was authenticated by STR profiling. All cell lines tested negative for mycoplasma.</p></sec><sec id="s4-4"><title>Generation of <italic>RPL22</italic>-null cell lines</title><p>MV4;11, MOLM13, and K562 control (NT) and <italic>RPL22</italic> knockout (KO) cell lines were generated by CRISPR using the multi-guide Synthego Gene Knockout System. Briefly, ribonucleoprotein (RNP) complexes containing Cas9-2NLS (Synthego) and either non-targeting (NT) control sgRNA#1 (Synthego) or RPL22 sgRNAs (Synthego Gene Knockout Kit v2 – human – RPL22) were formed by incubating 90 pmol sgRNA and 10 pmol Cas9-2NLS in Buffer R (Component of Neon Transfection System Kit; Thermo Scientific) at room temperature (RT) for 10 min. MV4;11, MOLM13, or K562 cells were electroporated (2 × 10<sup>5</sup> cells per reaction) with RNP complexes using the Neon Transfection System (Thermo Fisher Scientific) with the following parameters using Buffer R in 10 µL reactions: MV4;11 cells: 1175 V pulse, 40 ms pulse width, one pulse; MOLM13 cells: 1075 V pulse, 30 ms pulse width, two pulses; K562 cells: 1450 V pulse, 10 ms pulse width, three pulses. Cells recovered undisturbed in media absent of antibiotics for 48 hr before expansion and screening for loss of RPL22 expression by western blot analysis.</p></sec><sec id="s4-5"><title>Multiplex gene expression assays</title><p>Cells were treated with 0.1% DMSO or varying concentrations of C6 or C16 for 24 hr. A custom QuantiGene Plex panel (Thermo Fisher Scientific) was used in conjunction with the QuantiGene Sample Processing Kit for cultured cells (Thermo Fisher Scientific), and QuantiGene Plex Assay kit (Thermo Fisher Scientific) to quantify transcripts following the manufacturer’s instructions. Probe regions and accession numbers are as follows: <italic>RPS24</italic> (NM_001026, region 5-334)<italic>, RPL35</italic> (NM_007209, region 2-430)<italic>, RPL26</italic> (NM_000987, region 37-445)<italic>, RPS14</italic> (NM_005617, region 61-552)<italic>, RPL32</italic> (NM_000994, region 95-677)<italic>, RPS11</italic> (NM_001015, region 139-634)<italic>, RPL14</italic> (NM_003973, region 108-530)<italic>,</italic> and <italic>GAPDH</italic> (NM_002046, region 2-407). The average net mean fluorescence intensity was read on a Luminex FLEXMAP 3D System (Invitrogen). Signals from RPGs were normalized internally to those from <italic>GAPDH</italic>, and then to the DMSO control. Dose–response curves from the mean of biological replicates were calculated with the R package <italic>drc</italic> (<xref ref-type="bibr" rid="bib94">Ritz et al., 2015</xref>).</p></sec><sec id="s4-6"><title>Western blot analysis</title><p>Cells were collected by centrifugation and washed once with ice-cold PBS. Cells were lysed in either RIPA buffer (50 mM Tris, pH 8.0; 150 mM NaCl; 5 mM EDTA; 1.0% NP-40; 0.5% sodium deoxycholate; 0.1% SDS) or Triton-X buffer (50 mM Tris, pH 8.0; 150 mM NaCl; 5 mM EDTA; 1% Triton X-100), each supplemented with protease and phosphatase inhibitors (2× cOmplete, EDTA-free, Protease Inhibitor Cocktail [Roche]; 1× PhosSTOP Phosphatase Inhibitor [Roche]; 100 µg/mL Pefabloc SC [Roche]), while incubating on ice for 10 min. Chromatin was sheared by brief sonication at 25% on ice, insoluble material cleared by centrifugation, and protein quantified by Pierce BCA Protein Assay (Thermo Scientific). Protein samples were diluted to equal concentrations in lysis buffer and boiled for 5 min in 1× Laemmli Sample Buffer. Samples were run on 4–20% TGX Precast Polyacrylamide Gels (Bio-Rad) or hand-cast single percentage polyacrylamide gels, wet transferred to Amersham Protran Western Blotting Nitrocellulose Membrane (Cytiva) for 1 hr at 100 V in Towbin Buffer (25 mM Tris; 192 mM glycine; 10% methanol), and blocked in 5% milk in TBS-T before incubation overnight with one of the following primary antibodies: anti-p53 (Santa Cruz Biotechnology, Cat# sc-126), anti-RPL22 (Santa Cruz Biotechnology, Cat# sc136413), anti-RPL22L1 (Thermo Fisher Scientific, Cat# PA5-63266), anti-MDM4 (Sigma-Aldrich, Cat# M0445), anti-p21 (Cell Signaling Technology, Cat# 2947), anti-⍺-actinin (Cell Signaling Technology, Cat# 12413), or anti-GAPDH (Cell Signaling Technology, Cat# 8884). Membranes were washed three times with TBS-T and, if required, incubated with anti-mouse-HRP secondary antibody (Jackson ImmunoResearch Laboratories, Inc, Cat# 115-035-174) or anti-rabbit-HRP (Cell Signaling Technology, Cat# 7074) for 1 hr. Blots were developed with Clarity ECL Western Blotting Substrate (Bio-Rad) and imaged on a ChemiDoc Imaging System (Bio-Rad).</p></sec><sec id="s4-7"><title>Immunohistochemistry</title><p>MV4;11 cells were treated with 0.1% DMSO (vehicle) or C16 (100 nM) for up to 72 hr or actinomycin D (5 nM) for 6 hr. Cells were fixed in 4% paraformaldehyde (PFA) for 10 min, washed three times with PBS, then cytospun onto slides. Cells were permeabilized with 0.5% Triton X-100 in PBS (PBSTx) for 15 min then blocked with 1% bovine serum albumin in PBSTx (blocking buffer) and immunostained with antibodies against NPM1 (Abcam, ab10530) and gH2A.X pSer139 (Cell Signaling Technologies, 9718). Cells were washed with PBSTx then stained with secondary antibodies (Thermo Fisher, A11001 and A11037). Following PBSTx washes, cells were counterstained with Hoechst (Thermo Fisher, H3570), washed with PBS, then mounted with ProLong Antifade Gold (Thermo Fisher). Images were acquired on using a Plan Fluor ×40 Oil DIC H N2 (NA 1.3, WD 240 mm) objective on a Nikon Ti-2 microscope with a Nikon D-LEDI light source and a Prime BSI Express Scientific sCMOS camera in the Vanderbilt University Cell Imaging Shared Resource. Images were processed and analyzed using NIS-Elements (version 5.42.03) and FIJI (version 2.3.0/1.53q). Images presented are single z-sections of representative cells. To quantify nucleolar localization of NPM1, masks of nuclei were generated from Hoechst channel and nucleolar NPM1 was manually thresholded. The integrated fluorescence intensity of nucleolar NPM1 was then divided by total nuclear NPM1. p-Values were calculated by Student’s <italic>t</italic>-tests comparing treatment samples to DMSO samples within each timepoint.</p></sec><sec id="s4-8"><title>Protein synthesis assays</title><p>Bulk protein synthesis was measured using the OP-PURO labeling method (<xref ref-type="bibr" rid="bib77">Liu et al., 2012</xref>). MV4;11 cells were treated with either 0.1% DMSO, 2 µM C6, or 100 nM C16 for 24, 48, or 96 hr. For a positive control for inhibition of protein synthesis, MV4;11 cells were treated with 100 µg/mL cycloheximide (Research Products International) for 30 min. Following treatments, 2 × 10<sup>6</sup> cells were pulsed with 50 µM O-propargyl-puromycin (Invitrogen, Cat# C10459), or 0.1% DMSO for the ‘No OPP’ unlabeled control, for 1 hr at 37°C. Cells were collected, washed with ice-cold PBS, and cross-linked in 500 µL Cross-Linking Buffer (1× PBS, 1% formaldehyde) for 15 min on ice. Cross-linked cells were washed with ice-cold PBS and permeabilized in 500 µL Permeabilization Buffer (1× PBS, 3% FBS, 10% saponin) for 5 min at RT. Click-iT reactions containing cells in 500 µL Click-iT Reaction Cocktail (Invitrogen) with 5 µM Alexa Fluor 647 Azide (Invitrogen) were performed for 30 min at RT while protected from light. Cells were washed with PBS + 3% FBS and resuspended in PBS. Fluorescence intensities from Alexa Fluor 647 were measured using a BD LSRFortessa Cell Analyzer and geometric means calculated from 10,000 cells per sample with FlowJo software (BD Bioscience). Experiments were repeated in biological triplicate. Normalized fluorescence values were calculated by setting fluorescence from cycloheximide-treated samples as the baseline. p-Values were calculated by Student’s <italic>t</italic>-tests comparing treatment samples to DMSO samples within each timepoint. Flow Cytometry experiments were performed in the VUMC Flow Cytometry Shared Resource.</p></sec><sec id="s4-9"><title>In-gel fluorescence assays for metabolically labeled rRNA</title><p>Metabolic labeling of rRNA was performed as previously described, with some modifications (<xref ref-type="bibr" rid="bib120">Wang et al., 2020</xref>). MV4;11 cells were treated with either 0.1% DMSO, 2 µM C6, or 100 nM C16 for 24, 48, or 96 hr. For a positive control treatment for inhibited rRNA transcription, MV4;11 cells were treated with 5 nM actinomycin D (Cayman Chemical Company) for 60 min. Following treatment, cultures were pulsed with 1 mM 2’-azido-2’-deoxycytidine (Biosynth), or 0.1% DMSO for an unlabeled control, for 12 hr and total RNA isolated using TRIzol Reagent (Invitrogen) as per the manufacturer’s instructions. Pelleted RNA was resuspended in 20 µL nuclease-free water and treated with DNase I (New England BioLabs) for 10 min at 37°C in the presence of RNasin Ribonuclease Inhibitor (Promega). DNase-treated RNA was purified with the RNA Clean and Concentrator-25 Kit (Zymo Research) as per the manufacturer’s instructions. SPAAC reactions containing 12.5 µg RNA, 100 µM MB 680R DBCO (Vector Laboratories), 20 U RNasin Ribonuclease Inhibitor (Promega), and 1× PBS were incubated for 2 hr at 37°C, and then RNA purified with the RNA Clean and Concentrator-25 Kit (Zymo Research) as per the manufacturer’s instructions. RNA was subjected to electrophoretic separation on 1% TAE-agarose gels and MB 680R-labeled RNA imaged on an Odyssey CLx Imager (LI-COR). Total RNA was stained with SYBR Safe DNA Gel Stain (Invitrogen) and imaged on a ChemiDoc Imaging System (Bio-Rad). Fluorescence signals from 28S and 18S bands were quantified using Empiria Studio (LI-COR).</p></sec><sec id="s4-10"><title>Ribo-seq</title><p>Ribo-seq was performed as previously described with some modifications (<xref ref-type="bibr" rid="bib81">McGlincy and Ingolia, 2017</xref>). MV4;11 cells treated for 48 hr with either 0.1% DMSO, 2 µM C6, or 100 nM C16 were washed with ice-cold PBS and lysed in 400 µL Lysis Buffer (20 mM Tris, pH 7.4; 150 mM NaCl; 15 mM MgCl<sub>2</sub>; 1 mM DTT; 100 µg/mL cycloheximide; 1% Triton X-100; 25 U/mL Turbo DNase I) by incubation on ice for 10 min followed by homogenization by syringe. Lysates were cleared by centrifugation at 4°C, and RNA quantified by Qubit RNA HS Assay (Invitrogen) following the manufacturer’s instructions. 30 µg RNA was diluted in 200 µL Polysome Buffer (20 mM Tris, pH 7.4; 150 mM NaCl; 5 mM MgCl<sub>2</sub>; 1 mM DTT; 100 µg/mL cycloheximide) and incubated with 15 U RNase I (Lucigen) for 45 min while rotating at RT. RNA digestion was quenched with 10 µL SUPERaseIn RNase Inhibitor (Invitrogen) and samples transferred to 13 mm × 51 mm ultracentrifuge tubes (Beckman-Coulter), underlaid with 900 µL 1 M sucrose in polysome buffer supplemented with 20 U/mL SUPERaseIn RNase Inhibitor, and centrifuged at 540,628 × <italic>g</italic> 1 hr at 4°C. Ribosome pellets were suspended in TRIzol Reagent (Invitrogen), and RNA extracted from ribosome pellets by Direct-zol RNA MiniPrep Kit (Zymo Research). RNA and carrier glycogen were precipitated by adding 1.5 volumes 100% isopropanol supplemented with 0.12 M NaOAc, pH 5.5, followed by incubation on dry ice for 30 min and centrifugation at 16,800 × <italic>g</italic> for 30 min at 4°C. RNA was resuspended in 5 µL 10 mM Tris, pH 8.0, and 1× Denaturing Sample Loading Buffer (98% formamide; 10 mM EDTA; 300 µg/mL bromophenol blue) and subjected to electrophoresis on 15% polyacrylamide TBE-Urea gels (Invitrogen). Gels were stained briefly with 1× SYBR Gold (Invitrogen), 17–34 nucleotide fragments excised, and RNA fragments extracted by mechanical disruption, suspension in 500 µL RNA Gel Extraction Buffer (300 mM NaOAc, pH 5.5; 1 mM EDTA; 0.25% SDS), freezing on dry ice for 30 min, and rotating overnight at RT. Polyacrylamide was removed by centrifugation through Costar Spin-X columns (Corning) and RNA precipitated with isopropanol as described above. RNA was dephosphorylated by incubation with 5 U T4 Polynucleotide Kinase in 1× T4 PNK Buffer (New England BioLabs) supplemented with SUPERaseIn RNase Inhibitor for 1 hr at 37°C and ligated to bar-coded linkers (NI-810: /5Phos/<named-content content-type="sequence">NNNNNATCGTAGATCGGAAGAGCACACGTCTGAA</named-content>/3ddC/; NI-811: /5Phos/<named-content content-type="sequence">NNNNNAGCTAAGATCGGAAGAGCACACGTCTGAA</named-content>/3ddC/; NI-812: /5Phos/<named-content content-type="sequence">NNNNNCGTAAAGATCGGAAGAGCACACGTCTGAA/3ddC/</named-content>) pre-adenylated with 100 U of T4 RNA Ligase 2, truncated K227Q, in 1X T4 RNA Ligase Buffer (New England BioLabs) supplemented with 35% w/v PEG-8000 and incubated at 37°C for 3 hr. Ligation was verified by electrophoresis, samples combined, and linker-ligated RNA precipitated with isopropanol as described above. Ribosomal RNA was depleted from samples using the RiboCop rRNA Depletion Kit (Lexogen) and RNA precipitated with isopropanol as described above. Linker-ligated RNA was reverse transcribed with 200 U SuperScript III in 1× First Strand Buffer (Invitrogen), dNTPs, DTT, 10 U SUPERaseIn RNase Inhibitor and primer NI-802 (/5Phos/<named-content content-type="sequence">NNAGATCGGAAGAGCGTCGTGTAGGGAAAGAG</named-content>/iSp18/<named-content content-type="sequence">GTGACTGGAGTTCAGACGTGTGCTC</named-content>). RNA template was hydrolyzed for 15 min at 98°C in the presence of 0.1 M NaOH and cDNA precipitated with isopropanol as described previously. Reverse-transcribed DNA was subjected to electrophoresis on 15% polyacrylamide Novex TBE-Urea gels (Invitrogen) and the 105-nucleotide reverse-transcription product excised from polyacrylamide as described above, except with DNA Gel Extraction Buffer (300 mM NaCl; 10 mM Tris, pH 8.0; 1 mM EDTA). cDNA was circularized with 100 U CircLigase ssDNA Ligase (Lucigen) in the presence of 1× CircLigase Buffer, ATP, and MnCl<sub>2</sub> at 60°C for 1 hr followed by 80°C for 10 min. Circularized cDNA was quantified by qPCR, amplified using Phusion Polymerase (New England BioLabs) with unique dual-indexed primers (UDI0050_i5: <named-content content-type="sequence">AATGATACGGCGACCACCGAGATCTACACGCTCCGACACACTCTTTCCCTACACGACGCTCTTCCGATCT</named-content>; UDI0050_i7: <named-content content-type="sequence">CAAGCAGAAGACGGCATACGAGATTAGAGC</named-content><named-content content-type="sequence">GCGTGACTGGAGTTCAGACGTGT</named-content>; UDI0051_i5: <named-content content-type="sequence">AATGATACGGCGACCACCGAGATCTACACATACCAAGACACTCTTTCCCTACACGACGCTCTTCCGATCT</named-content>; UDI0051_i7: <named-content content-type="sequence">CAAGCAGAAGACGGCATACGAGATAACCTGTTGTGACTGGAGTTCAGACGTGT</named-content>; UDI0052_i5: <named-content content-type="sequence">AATGATACGGCGACCACCGAGATCTACACGCGTTGGAACACTCTTTCCCTACACGACGCTCTTCCGATCT</named-content>; UDI0052_i7: <named-content content-type="sequence">CAAGCAGAAGACGGCATACGAGATGGTTCACCGTGACTGGAGTTCAGACGTGT</named-content>), amplicons subjected to electrophoresis on 8% polyacrylamide Novex gels (Invitrogen), and products &gt;160 bp excised as described. Libraries were submitted to VANTAGE (Vanderbilt Technologies for Advanced Genomics) for sequencing on a NovaSeq 6000.</p></sec><sec id="s4-11"><title>Ribo-seq data analysis</title><p>Adapters were trimmed from reads using <italic>cutadapt</italic> (<xref ref-type="bibr" rid="bib80">Martin, 2011</xref>), and UMIs removed from reads and attached to read IDs using <italic>UMI-tools</italic> (<xref ref-type="bibr" rid="bib108">Smith et al., 2017</xref>). Reads were demultiplexed using <italic>sabre</italic> and aligned against ribosomal RNA using <italic>bowtie2</italic> (<xref ref-type="bibr" rid="bib64">Langmead and Salzberg, 2012</xref>). Reads not mapping to rRNA were mapped to the hg19 transcriptome using <italic>STAR</italic> (<xref ref-type="bibr" rid="bib35">Dobin et al., 2013</xref>) and deduplicated using <italic>UMI-tools</italic> (<xref ref-type="bibr" rid="bib108">Smith et al., 2017</xref>). Count tables for reads mapping to central ORFs were generated using the coverage command from <italic>bedtools</italic> (<xref ref-type="bibr" rid="bib90">Quinlan and Hall, 2010</xref>). After batch removal, Ribo-seq read counts were normalized to mRNA read counts using <italic>Xtail</italic> (<xref ref-type="bibr" rid="bib123">Xiao et al., 2016</xref>) to calculate translation efficiencies and statistics. FDR values were calculated using the Cochran–Mantel–Haenszel test (CMH). Genes with significantly altered translation efficiencies were those with FDR &lt; 0.05 and absolute log2FC &gt; 0.25. Identification of optimal RPF P-site offsets, RPF triplet periodicity, and RPF localization to CDS and UTR regions was performed with the R package <italic>riboWaltz</italic> (<xref ref-type="bibr" rid="bib66">Lauria et al., 2018</xref>).</p></sec><sec id="s4-12"><title>RNA-seq</title><p>For RNA-seq performed in parallel with Ribo-seq, RNA was isolated by Direct-zol RNA MiniPrep Kit (Zymo Research) from 100 µL of cell lysates after homogenization by syringe and clearing by centrifugation. For combination WINi/BETi treatment, MV4;11 cells were treated for 48 hr with either 0.2% DMSO, 100 nM C16, 2.5 nM mivebresib, or combined 100 nM C16 and 2.5 nM mivebresib, and RNA isolated by Direct-zol RNA MiniPrep Kit (Zymo Research) with on-column DNAse-treatment. For RNA-seq in MV4;11 NT and RPL22 KO cells, cultures were treated for 48 hr with either 0.1% DMSO or 100 nM C16 before RNA isolation as described above for WINi/BETi RNA-seq. For all RNA-seq experiments, RNA was submitted to the Vanderbilt Technologies for Advanced Genomics (VANTAGE) core facility for library preparation with rRNA-depletion using standard Illumina protocols and sequencing on an Illumina NovaSeq 6000.</p></sec><sec id="s4-13"><title>RNA-seq data analysis</title><p>Adapters were trimmed from RNA-seq reads using <italic>cutadapt</italic> (<xref ref-type="bibr" rid="bib80">Martin, 2011</xref>) and reads aligned to the hg19 genome using <italic>STAR</italic> (<xref ref-type="bibr" rid="bib35">Dobin et al., 2013</xref>). Gene expression was quantified using <italic>featureCounts</italic> (<xref ref-type="bibr" rid="bib72">Liao et al., 2014</xref>) and differential analysis performed using <italic>DESeq2</italic> (<xref ref-type="bibr" rid="bib78">Love et al., 2014</xref>) which calculates p-values through the Wald test and adjusts p-values by the Benjamini–Hochberg procedure to calculate FDR. Changes in levels of alternative splicing events were quantified using <italic>rMATS,</italic> which calculates changes in exon inclusion levels (<italic>∆ψ</italic>), and p-values through a likelihood-ratio test. Genes with significantly altered transcript levels are those with FDR &lt; 0.05. Significant changes in alternative splicing events are those with FDR &lt; 0.05 and <italic>∆ψ</italic> &gt; 5%.</p></sec><sec id="s4-14"><title>Generation of Cas9-expressing MV4;11 cells</title><p>To generate Cas9 expression lentivirus, HEK293T cells were transfected with the viral transfer plasmid lentiCas9-Blast (<xref ref-type="bibr" rid="bib99">Sanjana et al., 2014</xref>) (gift from Feng Zhang; Addgene plasmid # 52962), the viral packaging plasmid psPAX2 (gift from Didier Trono; Addgene plasmid # 12260), and the viral envelope plasmid pMD2.G (gift from Didier Trono; Addgene plasmid # 12259) using Lipofectamine 3000 Transfection Reagent (Invitrogen). After 48 hr, virus-containing media was collected and used to transduce MV4;11 cells by spinfection (2 hr; 1000 × <italic>g</italic>; RT; 8 µg/mL hexadimethrine bromide). Following spinfection, virus-containing media was replaced with fresh media and cells allowed to recover for 48 hr before selection with 10 µg/mL blasticidin (Research Products International). A clonal MV4;11 Cas9 cell line was established by serial dilution of the population and screening for retention of WINi sensitivity.</p></sec><sec id="s4-15"><title>Tier 1 CRISPR screen</title><p>Tier 1 CRISPR screens were performed essentially as described (<xref ref-type="bibr" rid="bib53">Joung et al., 2017</xref>). Briefly, the Human GeCKOv2 CRISPR Knockout Pooled Library (A+B) in the lentiGuide-Puro vector backbone (gift from Feng Zhang; Addgene plasmid # 1000000048) was amplified and purified as directed by Addgene. Lentiviral particles were generated by transfecting HEK293T cells with the GeCKOv2 CRISPR Knockout Pooled Plasmid Library, psPAX2 (gift from Didier Trono; Addgene plasmid # 12260), and pMD2.G (gift from Didier Trono; Addgene plasmid # 12259) using Lipofectamine 3000 Transfection Reagent (Invitrogen). After 48 hr, viral media was collected, aliquoted, and stored at –80°C. In duplicate, clonal Cas9-expressing MV4;11 cells were transduced by spinfection (2 hr; 1000 × <italic>g</italic>; RT; 8 µg/mL hexadimethrine bromide) with a volume of virus-containing media sufficient to infect 30% of cells and at a scale to generate &gt;200 transduced cells per sgRNA in the library. Cells recovered in fresh media overnight, were split 1:2, and selected with 1 µg/mL puromycin for 48 hr to generate the MV4;11 Cas9+GeCKOv2 population.</p><p>MV4;11 Cas9 and MV4;11 Cas9+GeCKOv2 cells were treated with either 0.1% DMSO or 2 µM C6, replenished every 3 d with fresh media and C6, and counted daily by trypan blue exclusion. DMSO-treated populations were grown until cultures reached &gt;8 × 10<sup>5</sup> cells/mL to verify C6-treatment efficacy. C6-treated MV4;11 Cas9+GeCKOv2 populations were maintained below 8 × 10<sup>5</sup> cells/mL and grown until a resistant population emerged relative to C6-treated MV4;11 Cas9 cells. Genomic DNA was isolated from MV4;11 Cas9+GeCKOv2 cells collected before and following sustained C6 treatment using the Quick-gDNA MidiPrep Kit (Zymo Research) as per the manufacturer’s directions. Sequencing libraries were generated by amplifying sgRNA sequences from genomic DNA using bar-coded Illumina-compatible adapter-containing primers and NEBNext High-Fidelity 2× PCR Master Mix (New England BioLabs). PCR products were pooled and purified with a ZymoSpin V column with Reservoir (Zymo Research). Libraries were sequenced on an Illumina NextSeq 500 in the Vanderbilt Technologies for Advanced Genomics (VANTAGE) core facility.</p></sec><sec id="s4-16"><title>Cloning targeted sgRNA library for second-tier screen</title><p>The tier 2 sgRNA plasmid library was generated as previously described with some modifications (<xref ref-type="bibr" rid="bib53">Joung et al., 2017</xref>). Briefly, sgRNA sequences against a curated collection of genes and 200 non-targeting control sgRNA sequences were extracted from the Brunello sgRNA Library (<xref ref-type="bibr" rid="bib36">Doench et al., 2016</xref>). For genes of interest not included in the Brunello library, four sgRNAs targeting each gene were designed with the CHOPCHOP sgRNA design tool (<xref ref-type="bibr" rid="bib59">Labun et al., 2019</xref>). sgRNA sequences were appended with 5′ and 3′ flanking sequences and synthesized as an Oligo Pool (<xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>; Twist Bioscience) followed by PCR amplification using NEBNext HiFidelity 2× Master Mix (New England BioLabs) with Fwd primer (<named-content content-type="sequence">GTAACTTGAAAGTATTTCGATTTCTTG</named-content><named-content content-type="sequence">GCTTTATATATCTTGTGGAAAGGACGAAACACC</named-content>) and KO Rev primer (<named-content content-type="sequence">ACTTTTTCAAGTTGATAAC</named-content><named-content content-type="sequence">GGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC</named-content>). PCR amplicons were subjected to agarose gel size selection using the NucleoSpin Gel and PCR Clean-up Kit (Macherey-Nagel). Amplicons were cloned into BsmBIv2-digested (New England BioLabs) lentiGuide-PURO plasmid (gift from Feng Zhang; Addgene plasmid # 52963) via Gibson Assembly (New England BioLabs). Gibson Assembly products were precipitated with isopropanol and electroporated into Endura ElectroCompetent <italic>Escherichia coli</italic> (Lexogen). Amplified plasmids were isolated from <italic>E. coli</italic> using the Nucleobond Xtra Maxi EF Kit (Macherey-Nagel) and adequate representation of sgRNAs in the library was verified by next-generation sequencing and analysis with the Python script <italic>count_spacers.py</italic> (<xref ref-type="bibr" rid="bib53">Joung et al., 2017</xref>).</p></sec><sec id="s4-17"><title>Tier 2 CRISPR screen</title><p>Tier 2 sgRNA Library lentiviral particles were generated and MV4;11 Cas9 cells transduced as described above for the tier 1 screen at a scale to achieve &gt;500 cells per sgRNA in the library. MV4;11 Cas9+Targeted sgRNA Library populations were treated with either 0.1% DMSO, 2 µM C6, or 100 nM C16 for 15 d. Cultures were maintained below 8 × 10<sup>5</sup> cells/mL and cultures replenished every 3 d with media and fresh DMSO, C6, or C16. Genomic DNA was isolated, and Illumina-compatible next-generation sequencing libraries generated as described above for the tier 1 screen. Libraries were sequenced on an Illumina NovaSeq 6000 in the Vanderbilt Technologies for Advanced Genomics (VANTAGE) core facility.</p></sec><sec id="s4-18"><title>CRISPR screen data analysis</title><p>Adapters were trimmed from reads using <italic>cutadapt</italic> (<xref ref-type="bibr" rid="bib80">Martin, 2011</xref>). Generation of sgRNA count tables and determination of significant gene-level alterations in sgRNA representation were performed using <italic>MAGeCK</italic> (<xref ref-type="bibr" rid="bib68">Li et al., 2014</xref>), which utilizes a negative binomial model to determine p-values of sgRNA changes and ranks sgRNAs by significance. Gene-level alterations and p-values were calculated from the ranked list of sgRNAs using the modified robust ranking aggregation (α-RRA) algorithm and FDR values calculated by the Benjamini–Hochberg procedure. Tier 1 screen analysis compared populations before and after C6 treatment. Tier 2 screen analysis compared DMSO-treated populations to C6- or C16-treated populations. Significantly enriched or depleted genes were those with FDR &lt;0.05.</p></sec><sec id="s4-19"><title>Cell viability assays</title><p>Opaque 384-well plates were seeded with 250 cells per well in 25 µL media supplemented with either 0.1% DMSO or a threefold dilution series of C6 or C16, all in technical quadruplicate wells. Cells were grown for 72 hr before equilibrating to RT and addition of 12.5 µL CellTiter-Glo Luminescent Cell Viability Assay reagent (Promega). At RT and protected from light, plates were rocked for 5 min, incubated for 20 min, and luminescence measured on a GloMax Explorer Multimode Microplate Reader (Promega). To calculate relative cell viability, mean fluorescence from quadruplicate treatment wells was divided by mean fluorescence from quadruplicate DMSO wells. Dose–response curves, GI<sub>50</sub> concentrations, and standard error values were calculated from at least three biological replicates with the R package <italic>drc</italic> (<xref ref-type="bibr" rid="bib94">Ritz et al., 2015</xref>).</p></sec><sec id="s4-20"><title>Synergy assays</title><p>Opaque 384-well plates were seeded with 250 cells per well in 25 µL media supplemented with either 0.2% DMSO, a threefold dilution series of either C16 or compound 2, or a combination of threefold dilutions of both C16 and compound 2 covering a 7 × 7 dose matrix, all in quadruplicate wells. Compound 2 consisted of either nutlin-3a (Cayman Chemical Company), rapamycin (MedChem Express), pinometostat (Cayman Chemical Company), harmine (Sigma-Aldrich), mivebresib (Cayman Chemical Company), venetoclax (Cayman Chemical Company), etoposide (Cayman Chemical Company), olaparib (Cayman Chemical Company), VE-821 (Cayman Chemical Company), pemrametostat (Selleck Chemicals), or alvespimycin (Cayman Chemical Company). Following 72 hr, plates were equilibrated to room temperature and 12.5 µL CellTiter-Glo Cell Viability Assay (Promega) reagent added to each well. While protected from light, plates were rocked for 5 min, incubated for 20 min, and luminescence measured on a GloMax Explorer Multimode Microplate Reader (Promega).</p></sec><sec id="s4-21"><title>Synergy assay data analysis</title><p>Technical replicate wells were averaged and resulting means used to calculate relative cell viability by dividing drug treatment by DMSO treatment. Mean δ-scores and standard deviations were calculated from three biological replicates via <italic>SynergyFinder Plus</italic> (<xref ref-type="bibr" rid="bib129">Zheng et al., 2022</xref>) using the ZIP model (<xref ref-type="bibr" rid="bib125">Yadav et al., 2015</xref>). ZIP δ-scores represent the percent of growth inhibition beyond that expected if the agents do not potentiate one another. δ-scores greater than zero are synergistic, δ-scores of zero are additive, and δ-scores less than zero are antagonistic. Statistical significances of peak synergistic and antagonistic δ-scores were calculated by one-sample <italic>t</italic>-tests using the <italic>tsum.test</italic> function from the R package <italic>PASWR</italic>. Significant synergy and antagonism δ-scores were those with p&lt;0.05.</p></sec><sec id="s4-22"><title>Quantitative proteomics</title><p>In quadruplicate, MV4;11 cells were seeded at 2 × 10<sup>5</sup> cells/mL and treated with 0.1% DMSO or 250 nM C16 for either 24 or 72 hr. Cells were collected by centrifugation and washed three times with ice-cold 1× PBS before lysis on ice in SDS Lysis Buffer (5% SDS; 50 mM ammonium bicarbonate). Chromatin was sheared by brief sonication at 25% on ice and insoluble material cleared by centrifugation. Soluble proteins were quantified by Pierce BCA Protein Assay (Thermo Scientific). Of note, protein was isolated from equivalent cell numbers at 24 hr as changes in proliferation are not observed until beyond 24 hr WINi treatment in MV4;11 cells. At 24 hr, DMSO-treated cultures yielded 344.75 ± 21.7 µg total soluble protein and C16-treated cultures yielded 366.50 ± 15.8 µg total soluble protein (mean ± SEM).</p><p>Protein samples for LC-MS/MS analyses were prepared by S-Trap (ProtiFi) digestion. Protein samples (50 µg) were reduced with DTT (MilliporeSigma) at a final concentration of 20 mM at 95°C for 10 min and alkylated with iodoacetamide (MilliporeSigma) at a final concentration of 40 mM at RT for 30 min in the dark. Aqueous phosphoric acid (Fisher Scientific) was added to the samples at a final concentration of 1.2% followed by 90% methanol containing 100 mM TEAB at 6.6 times the volume of the sample. The samples were loaded on the S-Trap micro columns and centrifuged at 4000 × <italic>g</italic> until all the volume was passed through the column. The columns were washed four times with 150 µL 90% methanol containing 100 mM TEAB, pH 7.1. Proteins were digested with trypsin gold (Promega) at 1:50 enzyme to protein ratio in 50 mM TEAB, pH 8.0, for 1 hr at 47°C. Peptides were eluted by serial addition of 40 µL each of 50 mM TEAB, 0.2% formic acid, and 35 µL of 0.2% formic acid in 50% acetonitrile. Eluted peptides were dried in a speed-vac concentrator, resuspended in aqueous 0.1% formic acid, and analyzed by LC-coupled tandem mass spectrometry (LC-MS/MS).</p><p>An analytical column (360 µm O.D. × 100 µm I.D.) was packed with 25 cm of C18 reverse-phase material (Jupiter, 3 µm beads, 300 Å; Phenomenex) directly into a laser-pulled emitter tip. Peptides were loaded on the reverse phase column using a Dionex Ultimate 3000 nanoLC and autosampler. The mobile phase solvents consisted of 0.1% formic acid, 99.9% water (solvent A) and 0.1% formic acid, 99.9% acetonitrile (solvent B). Peptides were gradient eluted at a flow rate of 350 nL/min using a 120 min gradient. The gradient consisted of the following: 1–100 min, 2–38% B; 100–108 min, 38–90% B; 108–110 min, 90% B; 110–111 min, 90–2% B; 111–120 min (column re-equilibration), 2% B. Upon gradient elution, peptides were analyzed using a data-dependent method on an Orbitrap Exploris 480 mass spectrometer (Thermo Scientific), equipped with a nanoelectrospray ionization source. The instrument method consisted of MS1 using an MS AGC target value of 3 × 10<sup>6</sup>, followed by up to 15 MS/MS scans of the most abundant ions detected in the preceding MS scan. The intensity threshold for triggering data-dependent scans was set to 1 × 10<sup>4</sup>, the MS2 AGC target was set to 1 × 10<sup>5</sup>, dynamic exclusion was set to 20 s, and HCD collision energy was set to 30 nce.</p></sec><sec id="s4-23"><title>Quantitative proteomics data analysis</title><p>For identification of peptides, LC-MS/MS data were searched with <italic>Maxquant,</italic> version 2.0.1.0 (<xref ref-type="bibr" rid="bib30">Cox and Mann, 2008</xref>). MS/MS spectra were searched with the <italic>Andromeda</italic> search engine (<xref ref-type="bibr" rid="bib31">Cox et al., 2011</xref>) against a human database created from the UniprotKB protein database (<xref ref-type="bibr" rid="bib8">Bateman et al., 2021</xref>) and the default <italic>Maxquant</italic> contaminants. Default parameters were used for <italic>Maxquant,</italic> with the addition of selecting LFQ and match between runs as a global parameter. <italic>Maxquant</italic> parameters included first and main search mass tolerances of 20 ppm and 4.5 ppm, respectively. Variable modifications included methionine oxidation and N-terminal acetylation, and carbamidomethyl cysteine was selected as a fixed modification. A maximum of two missed cleavages was allowed. The false discovery rate (FDR) was set to 0.01 for peptide and protein identifications. Label-free quantitative (LFQ) analysis of identified proteins was performed with the <italic>MSstats</italic> R package (<xref ref-type="bibr" rid="bib28">Choi et al., 2014</xref>), version 4.0.1, using default parameters, which include the following: equalize medians for the normalization method, log2 transformation, Tukey’s median polish as the summary method, and model-based imputation. Protein fold changes were considered as significant with adjusted p-values ≤0.05.</p></sec><sec id="s4-24"><title>RNA isolation and cDNA synthesis</title><p>Cell pellets were suspended in TRIzol Reagent (Invitrogen), rotated for 15 min at RT, and insoluble cellular debris pelleted by centrifugation. The soluble fraction was mixed with equal volume of 100% ethanol and RNA was isolated using the Direct-zol RNA Miniprep Kit (Zymo Research) according to the manufacturer’s instructions, including on-column DNA digestion. Complementary DNA (cDNA) was synthesized in 20 μL cDNA reactions containing 1 μg RNA, Random Hexamers (Invitrogen), and SuperScript III Reverse Transcriptase (Invitrogen) as per the manufacturer’s instructions. Final cDNA products were diluted fivefold with nuclease-free water before use in semi-quantitative RT-PCR or quantitative RT-PCR.</p></sec><sec id="s4-25"><title>Semi-quantitative RT-PCR</title><p>PCR reactions were performed with 2 μL cDNA template using primers amplifying splicing variants of <italic>RPL22L1</italic> (RPL22L1_RTPCR_F: <named-content content-type="sequence">ATGGCGCCGCAGAAAGAC</named-content>; RPL22L1_RTPCR_R: <named-content content-type="sequence">CTAGTCCTCCGACTCTGATT</named-content>) or <italic>MDM4</italic> (MDM4_RTPCR_F: <named-content content-type="sequence">GAAAGACCCAAGCCCTCTCT</named-content>; MDM4_RT_PCR_F: <named-content content-type="sequence">GCAGTGTGGGGATATCGTCT</named-content>), or within <italic>GAPDH</italic> (GAPDH_RTPCR_F: <named-content content-type="sequence">TCACCAGGGCTGCTTTTAAC</named-content>; GAPDH_RTPCR_R: <named-content content-type="sequence">ATCGCCCCACTTGATTTTGG</named-content>) using Taq DNA Polymerase (New England BioLabs) with primer-specific annealing temperatures and cycle numbers (RPL22L1: 50°C, 30 cycles; MDM4: 54°C, 33 cycles; GAPDH: 52°C, 27 cycles). PCR products were electrophoretically separated on 2% agarose gels in TBE buffer, gels incubated 30 min in TBE buffer containing 1× SYBR Safe DNA Stain (Invitrogen) with agitation, and imaged on a ChemiDoc Imaging System (Bio-Rad).</p></sec><sec id="s4-26"><title>Quantitative RT-PCR</title><p>qPCR reactions containing 1× KAPA SYBR Fast qPCR Master Mix (Roche), transcript-specific primers, and 2 μL cDNA template were performed in technical duplicate wells on a C1000 Touch Thermal Cycler (Bio-Rad) with a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Primer pairs targeted total <italic>RPL22L1</italic> (RPL22L1ab_qPCR_F: <named-content content-type="sequence">tcgagtggttgcatctgaca</named-content>; RPL22L1ab_qPCR_R: <named-content content-type="sequence">tcctccgactctgattcatct</named-content>), <italic>RPL22L1a</italic> (RPL22L1a_qPCR_F: <named-content content-type="sequence">cgccgcagaaagacaggaa</named-content>; RPL22L1a_qPCR_R: <named-content content-type="sequence">ctcccgtagaaattgctcaaaat</named-content>), <italic>RPL22L1b</italic> (RPL22L1b_qPCR_F: <named-content content-type="sequence">cgcagaaagacaggaagcc</named-content>; RPL22L1b_qPCR_R: <named-content content-type="sequence">tgcaaaactagggaagagaacc</named-content>), <italic>MDM4</italic> exon 5–6 junction (MDM4_Jnct_5_6_qPCR_F: <named-content content-type="sequence">AGAATCTTGTCACTTTAGCCACT</named-content>; MDM4_Jnct_5_6_qPCR_R: <named-content content-type="sequence">CGAGAGTCTGAGCAGCATCT</named-content>), <italic>MDM4</italic> exon 6–7 junction (MDM4_Jnct_6_7_qPCR_F: <named-content content-type="sequence">TCAAGACCAACTGAAGCAAAGT</named-content>; MDM4_Jnct_6_7_qPCR_R: <named-content content-type="sequence">TAGGCAGTGTGGGGATATCG</named-content>), <italic>MDM4</italic> exon 4 (MDM4_Ex_4_qPCR_F: <named-content content-type="sequence">AGCAACTTTATGATCAGCAGGAG</named-content>; MDM4_Ex_4_qPCR_R: <named-content content-type="sequence">GACGTCCCAGTAGTTCTCCC</named-content>), <italic>MDM4</italic> exon 7 (MDM4_Ex_7_qPCR_F: <named-content content-type="sequence">AGAGGAAAGTTCCACTTCCAGA</named-content>; MDM4_Ex_7_qPCR_R: <named-content content-type="sequence">ATGCTCTGAGGTAGGCAGTG</named-content>), or <italic>GAPDH</italic> (GAPDH_qPCR_F: <named-content content-type="sequence">AAGGTGAAGGTCGGAGTCAAC</named-content>; GAPDH_qPCR_R: <named-content content-type="sequence">GTTGAGGTCAATGAAGGGGTC</named-content>). Ct values for each well were determined by the Bio-Rad CFX Manager Software v3.1 using the regression model, and mean Ct values from technical replicate wells used for subsequent calculations. Relative isoform levels were calculated via the 2<sup>(-ΔΔCt)</sup> algorithm by internally normalizing isoform-specific Ct values to GAPDH Ct values, then relative to DMSO-treatment.</p></sec><sec id="s4-27"><title>Quantification and statistical analysis</title><p>The statistical test, threshold for statistical significance, and <italic>n</italic> for each experiment, representing biological replicates, can be found in the figure legends.</p></sec><sec id="s4-28"><title>Structure alignment</title><p>Images of C6 and C16 bound to the WIN-Site of WDR5 and overlaid structures in WDR5-binding conformations were generated with <italic>PyMOL</italic> using published X-ray crystal structures (C6, PDB: 6E23 [<xref ref-type="bibr" rid="bib3">Aho et al., 2019a</xref>]; C16, PDB: 6UCS [<xref ref-type="bibr" rid="bib116">Tian et al., 2020</xref>]).</p></sec><sec id="s4-29"><title>GSEA and ORA</title><p>Gene set enrichment analyses (GSEA) and over-representation analyses (ORA) were performed with the R package <italic>fgsea</italic> (<xref ref-type="bibr" rid="bib58">Korotkevich et al., 2021</xref>) using the Molecular Signatures Database v7.4 (<xref ref-type="bibr" rid="bib110">Subramanian et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Liberzon et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Liberzon et al., 2015</xref>). Significantly enriched or depleted gene sets were those with FDR &lt; 0.05.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Receives research funding from ALX Oncology, Astex, Incyte, Takeda and TG Therapeutics; has stock in Karyopharm and Ryvu; serves on advisory boards or consults for BMS, CTI, Forma, Geron, GSK, Karyopharm, Rigel, Ryvu, Taiho and Treadwell</p></fn><fn fn-type="COI-statement" id="conf3"><p>Patents: Lee T, Alvarado J, Tian J, Meyers KM, Han C, Mills JJ, Teuscher KB, Stauffer SR, Fesik SW. WDR5 inhibitors and modulators. WO 2020086857. 30 April 2020; Lee T, Han C, Mills JJ, Teuscher KB, Tian J, Meyers KM, Chowdhury S, Fesik SW. WDR5 inhibitors and modulators. WO 2020247679. 10 December 2020; Lee T, Teuscher KB, Tian J, Meyers KM, Chowdhury S, Fesik SW. WDR5 Inhibitors and modulators. WO 2021092525. 14 May 2021; Lee T, Teuscher KB, Chowdhury S, Tian J, Meyers KM, Fesik SW. WDR5 Inhibitors and modulators. WO2022236101. 10 November 2022</p></fn><fn fn-type="COI-statement" id="conf4"><p>Patents: Fesik SW, Stauffer SR, Salovich JM, Tansey WP, Wang F, Phan J, Olejniczak ET, inventors. WDR5 inhibitors and modulators. United States Patent US 10,501,466. 10 December 2019; Fesik SW, Stauffer SR, Tansey WP, Olejniczak ET, Phan J, Wang F, Jeon K, Gogliotti RD, inventors. WDR5 inhibitors and modulators. United States Patent US 10,160,763. 25 December 2018</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Visualization, Writing – original draft, Investigation, Funding acquisition, Software, Supervision, Formal analysis, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Formal analysis, Visualization, Investigation</p></fn><fn fn-type="con" id="con3"><p>Visualization, Writing – original draft, Investigation, Funding acquisition, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Software, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Supervision, Investigation</p></fn><fn fn-type="con" id="con16"><p>Formal analysis, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Visualization, Investigation</p></fn><fn fn-type="con" id="con18"><p>Supervision, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con19"><p>Data curation, Software, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Investigation</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-90683-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Ribo-Seq, RNA-Seq, and CRISPR screen data are deposited at Gene Expression Omnibus (GEO) with accession number GSE206931. Quantitative proteomics data are deposited at the ProteomeXchange Consortium via the PRIDE partner repository with identifier PXD035129. All these data are publicly available.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Multiomic characterization of WDR5 WIN site inhibition reveals actionable synergies for MLL-rearranged leukemia</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE206931">GSE206931</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Proteome alterations in MLL-rearranged leukemia cells following WIN Site inhibition</data-title><source>ProteomeXchange</source><pub-id pub-id-type="accession" xlink:href="https://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD035129">PXD035129</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>For reagents, we thank D Trono and F Zhang. For assistance, we thank Lu Chen, David Cortez, Rachel Green, Matthew Hall, Ian Macara, Kavi Mehta, Bill Moore, Jonathan Shrimp, and Jamie Wangen. The VANTAGE Shared Resource is supported by the CTSA Grant (RR024975), the Vanderbilt Ingram Cancer Center (CA068485), the Vanderbilt Vision Center (EY008126), and NIH/NCRR (RR030956). Core services for QuantiGene assays performed through Vanderbilt University Medical Center’s Digestive Disease Research Center were supported by NIH grant DK058404. The VUMC Flow Cytometry Shared Resource is supported by the Vanderbilt Cell Imaging Shared Resource and the Vanderbilt Ingram Cancer Center and the Vanderbilt Digestive Disease Research Center. We acknowledge support of the Vanderbilt Proteomics Core in the Mass Spectrometry Research Center, supported in part by the Vanderbilt Ingram Cancer Center. This work was supported by awards from the NIH/NCI—under Chemical Biology Consortium Contract No. HHSN261200800001E (SWF and WPT), and CA200709 (WPT)—as well as grants from the Robert J Kleberg, Jr., and Helen C Kleberg Foundation (WPT and SWF). BCG was supported by the Brock Family Fellowship, the NCI (CA217834/CA268703), and an American Society for Clinical Oncology Young Investigator’s Award.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Advani</surname><given-names>VM</given-names></name><name><surname>Ivanov</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Translational control under stress: Reshaping the translatome</article-title><source>BioEssays</source><volume>41</volume><elocation-id>e1900009</elocation-id><pub-id pub-id-type="doi">10.1002/bies.201900009</pub-id><pub-id pub-id-type="pmid">31026340</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmadi</surname><given-names>SE</given-names></name><name><surname>Rahimi</surname><given-names>S</given-names></name><name><surname>Zarandi</surname><given-names>B</given-names></name><name><surname>Chegeni</surname><given-names>R</given-names></name><name><surname>Safa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies</article-title><source>Journal of Hematology &amp; Oncology</source><volume>14</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1186/s13045-021-01111-4</pub-id><pub-id pub-id-type="pmid">34372899</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aho</surname><given-names>ER</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gogliotti</surname><given-names>RD</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Acharya</surname><given-names>P</given-names></name><name><surname>Macdonald</surname><given-names>JD</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Wenzel</surname><given-names>S</given-names></name><name><surname>Foshage</surname><given-names>AM</given-names></name><name><surname>Alvarado</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Vakoc</surname><given-names>CR</given-names></name><name><surname>Hall</surname><given-names>MD</given-names></name><name><surname>Hiebert</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Stauffer</surname><given-names>SR</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Displacement of WDR5 from chromatin by a WIN site inhibitor with picomolar affinity</article-title><source>Cell Reports</source><volume>26</volume><fpage>2916</fpage><lpage>2928</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.047</pub-id><pub-id pub-id-type="pmid">30865883</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aho</surname><given-names>ER</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Targeting WDR5: a WINning anti-cancer strategy?</article-title><source>Epigenetics Insights</source><volume>12</volume><elocation-id>2516865719865282</elocation-id><pub-id pub-id-type="doi">10.1177/2516865719865282</pub-id><pub-id pub-id-type="pmid">31360909</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Veeranki</surname><given-names>SN</given-names></name><name><surname>Chinchole</surname><given-names>A</given-names></name><name><surname>Tyagi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MLL/WDR5 complex regulates Kif2A localization to ensure chromosome congression and proper spindle assembly during mitosis</article-title><source>Developmental Cell</source><volume>41</volume><fpage>605</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.05.023</pub-id><pub-id pub-id-type="pmid">28633016</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alicea-Velázquez</surname><given-names>NL</given-names></name><name><surname>Shinsky</surname><given-names>SA</given-names></name><name><surname>Loh</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Skalnik</surname><given-names>DG</given-names></name><name><surname>Cosgrove</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Targeted disruption of the interaction between WD-40 repeat protein 5 (WDR5) and mixed lineage leukemia (MLL)/SET1 family proteins specifically inhibits MLL1 and SETd1A methyltransferase complexes</article-title><source>The Journal of Biological Chemistry</source><volume>291</volume><fpage>22357</fpage><lpage>22372</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.752626</pub-id><pub-id pub-id-type="pmid">27563068</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Arnholt</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Paswr</data-title><version designator="1.3">1.3</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/cran/PASWR">https://github.com/cran/PASWR</ext-link></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>M-J</given-names></name><name><surname>Orchard</surname><given-names>S</given-names></name><name><surname>Magrane</surname><given-names>M</given-names></name><name><surname>Agivetova</surname><given-names>R</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Alpi</surname><given-names>E</given-names></name><name><surname>Bowler-Barnett</surname><given-names>EH</given-names></name><name><surname>Britto</surname><given-names>R</given-names></name><name><surname>Bursteinas</surname><given-names>B</given-names></name><name><surname>Bye-A-Jee</surname><given-names>H</given-names></name><name><surname>Coetzee</surname><given-names>R</given-names></name><name><surname>Cukura</surname><given-names>A</given-names></name><name><surname>Da Silva</surname><given-names>A</given-names></name><name><surname>Denny</surname><given-names>P</given-names></name><name><surname>Dogan</surname><given-names>T</given-names></name><name><surname>Ebenezer</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>LG</given-names></name><name><surname>Garmiri</surname><given-names>P</given-names></name><name><surname>Georghiou</surname><given-names>G</given-names></name><name><surname>Gonzales</surname><given-names>L</given-names></name><name><surname>Hatton-Ellis</surname><given-names>E</given-names></name><name><surname>Hussein</surname><given-names>A</given-names></name><name><surname>Ignatchenko</surname><given-names>A</given-names></name><name><surname>Insana</surname><given-names>G</given-names></name><name><surname>Ishtiaq</surname><given-names>R</given-names></name><name><surname>Jokinen</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>V</given-names></name><name><surname>Jyothi</surname><given-names>D</given-names></name><name><surname>Lock</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Luciani</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Lussi</surname><given-names>Y</given-names></name><name><surname>MacDougall</surname><given-names>A</given-names></name><name><surname>Madeira</surname><given-names>F</given-names></name><name><surname>Mahmoudy</surname><given-names>M</given-names></name><name><surname>Menchi</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Moulang</surname><given-names>K</given-names></name><name><surname>Nightingale</surname><given-names>A</given-names></name><name><surname>Oliveira</surname><given-names>CS</given-names></name><name><surname>Pundir</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>G</given-names></name><name><surname>Raj</surname><given-names>S</given-names></name><name><surname>Rice</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>MR</given-names></name><name><surname>Saidi</surname><given-names>R</given-names></name><name><surname>Sampson</surname><given-names>J</given-names></name><name><surname>Sawford</surname><given-names>T</given-names></name><name><surname>Speretta</surname><given-names>E</given-names></name><name><surname>Turner</surname><given-names>E</given-names></name><name><surname>Tyagi</surname><given-names>N</given-names></name><name><surname>Vasudev</surname><given-names>P</given-names></name><name><surname>Volynkin</surname><given-names>V</given-names></name><name><surname>Warner</surname><given-names>K</given-names></name><name><surname>Watkins</surname><given-names>X</given-names></name><name><surname>Zaru</surname><given-names>R</given-names></name><name><surname>Zellner</surname><given-names>H</given-names></name><name><surname>Bridge</surname><given-names>A</given-names></name><name><surname>Poux</surname><given-names>S</given-names></name><name><surname>Redaschi</surname><given-names>N</given-names></name><name><surname>Aimo</surname><given-names>L</given-names></name><name><surname>Argoud-Puy</surname><given-names>G</given-names></name><name><surname>Auchincloss</surname><given-names>A</given-names></name><name><surname>Axelsen</surname><given-names>K</given-names></name><name><surname>Bansal</surname><given-names>P</given-names></name><name><surname>Baratin</surname><given-names>D</given-names></name><name><surname>Blatter</surname><given-names>M-C</given-names></name><name><surname>Bolleman</surname><given-names>J</given-names></name><name><surname>Boutet</surname><given-names>E</given-names></name><name><surname>Breuza</surname><given-names>L</given-names></name><name><surname>Casals-Casas</surname><given-names>C</given-names></name><name><surname>de Castro</surname><given-names>E</given-names></name><name><surname>Echioukh</surname><given-names>KC</given-names></name><name><surname>Coudert</surname><given-names>E</given-names></name><name><surname>Cuche</surname><given-names>B</given-names></name><name><surname>Doche</surname><given-names>M</given-names></name><name><surname>Dornevil</surname><given-names>D</given-names></name><name><surname>Estreicher</surname><given-names>A</given-names></name><name><surname>Famiglietti</surname><given-names>ML</given-names></name><name><surname>Feuermann</surname><given-names>M</given-names></name><name><surname>Gasteiger</surname><given-names>E</given-names></name><name><surname>Gehant</surname><given-names>S</given-names></name><name><surname>Gerritsen</surname><given-names>V</given-names></name><name><surname>Gos</surname><given-names>A</given-names></name><name><surname>Gruaz-Gumowski</surname><given-names>N</given-names></name><name><surname>Hinz</surname><given-names>U</given-names></name><name><surname>Hulo</surname><given-names>C</given-names></name><name><surname>Hyka-Nouspikel</surname><given-names>N</given-names></name><name><surname>Jungo</surname><given-names>F</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name><name><surname>Kerhornou</surname><given-names>A</given-names></name><name><surname>Lara</surname><given-names>V</given-names></name><name><surname>Le Mercier</surname><given-names>P</given-names></name><name><surname>Lieberherr</surname><given-names>D</given-names></name><name><surname>Lombardot</surname><given-names>T</given-names></name><name><surname>Martin</surname><given-names>X</given-names></name><name><surname>Masson</surname><given-names>P</given-names></name><name><surname>Morgat</surname><given-names>A</given-names></name><name><surname>Neto</surname><given-names>TB</given-names></name><name><surname>Paesano</surname><given-names>S</given-names></name><name><surname>Pedruzzi</surname><given-names>I</given-names></name><name><surname>Pilbout</surname><given-names>S</given-names></name><name><surname>Pourcel</surname><given-names>L</given-names></name><name><surname>Pozzato</surname><given-names>M</given-names></name><name><surname>Pruess</surname><given-names>M</given-names></name><name><surname>Rivoire</surname><given-names>C</given-names></name><name><surname>Sigrist</surname><given-names>C</given-names></name><name><surname>Sonesson</surname><given-names>K</given-names></name><name><surname>Stutz</surname><given-names>A</given-names></name><name><surname>Sundaram</surname><given-names>S</given-names></name><name><surname>Tognolli</surname><given-names>M</given-names></name><name><surname>Verbregue</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Arighi</surname><given-names>CN</given-names></name><name><surname>Arminski</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Garavelli</surname><given-names>JS</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Laiho</surname><given-names>K</given-names></name><name><surname>McGarvey</surname><given-names>P</given-names></name><name><surname>Natale</surname><given-names>DA</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Vinayaka</surname><given-names>CR</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yeh</surname><given-names>L-S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ruch</surname><given-names>P</given-names></name><name><surname>Teodoro</surname><given-names>D</given-names></name><collab>The UniProt Consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>UniProt: the universal protein knowledgebase in 2021</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D480</fpage><lpage>D489</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1100</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernt</surname><given-names>KM</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Targeting epigenetic programs in MLL-rearranged leukemias</article-title><source>Hematology. American Society of Hematology. Education Program</source><volume>2011</volume><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1182/asheducation-2011.1.354</pub-id><pub-id pub-id-type="pmid">22160057</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bieging-Rolett</surname><given-names>KT</given-names></name><name><surname>Kaiser</surname><given-names>AM</given-names></name><name><surname>Morgens</surname><given-names>DW</given-names></name><name><surname>Boutelle</surname><given-names>AM</given-names></name><name><surname>Seoane</surname><given-names>JA</given-names></name><name><surname>Van Nostrand</surname><given-names>EL</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Houlihan</surname><given-names>SL</given-names></name><name><surname>Mello</surname><given-names>SS</given-names></name><name><surname>Yee</surname><given-names>BA</given-names></name><name><surname>McClendon</surname><given-names>J</given-names></name><name><surname>Pierce</surname><given-names>SE</given-names></name><name><surname>Winters</surname><given-names>IP</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Connolly</surname><given-names>AJ</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Curtis</surname><given-names>C</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Winslow</surname><given-names>MM</given-names></name><name><surname>Bassik</surname><given-names>MC</given-names></name><name><surname>Attardi</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Zmat3 is a key splicing regulator in the p53 tumor suppression program</article-title><source>Molecular Cell</source><volume>80</volume><fpage>452</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.10.022</pub-id><pub-id pub-id-type="pmid">33157015</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackford</surname><given-names>AN</given-names></name><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response</article-title><source>Molecular Cell</source><volume>66</volume><fpage>801</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.05.015</pub-id><pub-id pub-id-type="pmid">28622525</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boglev</surname><given-names>Y</given-names></name><name><surname>Badrock</surname><given-names>AP</given-names></name><name><surname>Trotter</surname><given-names>AJ</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Richardson</surname><given-names>EJ</given-names></name><name><surname>Parslow</surname><given-names>AC</given-names></name><name><surname>Markmiller</surname><given-names>SJ</given-names></name><name><surname>Hall</surname><given-names>NE</given-names></name><name><surname>de Jong-Curtain</surname><given-names>TA</given-names></name><name><surname>Ng</surname><given-names>AY</given-names></name><name><surname>Verkade</surname><given-names>H</given-names></name><name><surname>Ober</surname><given-names>EA</given-names></name><name><surname>Field</surname><given-names>HA</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>CH</given-names></name><name><surname>Hannan</surname><given-names>KM</given-names></name><name><surname>Hannan</surname><given-names>RD</given-names></name><name><surname>Pearson</surname><given-names>RB</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Ess</surname><given-names>KC</given-names></name><name><surname>Lieschke</surname><given-names>GJ</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Heath</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autophagy induction is a Tor- and Tp53-independent cell survival response in a zebrafish model of disrupted ribosome biogenesis</article-title><source>PLOS Genetics</source><volume>9</volume><elocation-id>e1003279</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003279</pub-id><pub-id pub-id-type="pmid">23408911</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolshan</surname><given-names>Y</given-names></name><name><surname>Getlik</surname><given-names>M</given-names></name><name><surname>Kuznetsova</surname><given-names>E</given-names></name><name><surname>Wasney</surname><given-names>GA</given-names></name><name><surname>Hajian</surname><given-names>T</given-names></name><name><surname>Poda</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>KT</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Dombrovski</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Senisterra</surname><given-names>G</given-names></name><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Brown</surname><given-names>PJ</given-names></name><name><surname>Al-Awar</surname><given-names>R</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name><name><surname>Smil</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Synthesis, optimization, and evaluation of novel small molecules as antagonists of WDR5-MLL interaction</article-title><source>ACS Medicinal Chemistry Letters</source><volume>4</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1021/ml300467n</pub-id><pub-id pub-id-type="pmid">24900672</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruno</surname><given-names>PM</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>GY</given-names></name><name><surname>Murai</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>CE</given-names></name><name><surname>Eisen</surname><given-names>TJ</given-names></name><name><surname>Pritchard</surname><given-names>JR</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name><name><surname>Lippard</surname><given-names>SJ</given-names></name><name><surname>Hemann</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress</article-title><source>Nature Medicine</source><volume>23</volume><fpage>461</fpage><lpage>471</lpage><pub-id pub-id-type="doi">10.1038/nm.4291</pub-id><pub-id pub-id-type="pmid">28263311</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryan</surname><given-names>AF</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Guarnaccia</surname><given-names>AD</given-names></name><name><surname>Woodley</surname><given-names>CM</given-names></name><name><surname>Aho</surname><given-names>ER</given-names></name><name><surname>Rellinger</surname><given-names>EJ</given-names></name><name><surname>Matlock</surname><given-names>BK</given-names></name><name><surname>Flaherty</surname><given-names>DK</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Chung</surname><given-names>DH</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>WDR5 is a conserved regulator of protein synthesis gene expression</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>2924</fpage><lpage>2941</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa051</pub-id><pub-id pub-id-type="pmid">31996893</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>WL</given-names></name><name><surname>Chen</surname><given-names>JF-Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wingrove</surname><given-names>E</given-names></name><name><surname>Kurley</surname><given-names>SJ</given-names></name><name><surname>Chan</surname><given-names>LH</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Arnal-Estape</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Balabaki</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Krop</surname><given-names>ED</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Westbrook</surname><given-names>TF</given-names></name><name><surname>Nguyen</surname><given-names>DX</given-names></name><name><surname>Yan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation</article-title><source>eLife</source><volume>11</volume><elocation-id>e78163</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.78163</pub-id><pub-id pub-id-type="pmid">36043466</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Townsend</surname><given-names>EC</given-names></name><name><surname>Karatas</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ouillette</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>JL</given-names></name><name><surname>Atadja</surname><given-names>P</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>ZS</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia</article-title><source>Molecular Cell</source><volume>53</volume><fpage>247</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.12.001</pub-id><pub-id pub-id-type="pmid">24389101</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>Z</given-names></name><name><surname>Liao</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit</article-title><source>Oncotarget</source><volume>8</volume><fpage>90651</fpage><lpage>90661</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.21544</pub-id><pub-id pub-id-type="pmid">29207594</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cervia</surname><given-names>LD</given-names></name><name><surname>Shibue</surname><given-names>T</given-names></name><name><surname>Borah</surname><given-names>AA</given-names></name><name><surname>Gaeta</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Leung</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Moyer</surname><given-names>SM</given-names></name><name><surname>Shim</surname><given-names>BH</given-names></name><name><surname>Dumont</surname><given-names>N</given-names></name><name><surname>Gonzalez</surname><given-names>A</given-names></name><name><surname>Bick</surname><given-names>NR</given-names></name><name><surname>Kazachkova</surname><given-names>M</given-names></name><name><surname>Dempster</surname><given-names>JM</given-names></name><name><surname>Krill-Burger</surname><given-names>JM</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Udeshi</surname><given-names>ND</given-names></name><name><surname>Olive</surname><given-names>ME</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>McFarland</surname><given-names>JM</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>A ubiquitination cascade regulating the integrated stress response and survival in carcinomas</article-title><source>Cancer Discovery</source><volume>13</volume><fpage>766</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-1230</pub-id><pub-id pub-id-type="pmid">36576405</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chacón Simon</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Macdonald</surname><given-names>JD</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Schlund</surname><given-names>C</given-names></name><name><surname>Payne</surname><given-names>W</given-names></name><name><surname>Creighton</surname><given-names>J</given-names></name><name><surname>Stauffer</surname><given-names>SR</given-names></name><name><surname>Waterson</surname><given-names>AG</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery of WD repeat-containing protein 5 (WDR5)-MYC inhibitors using fragment-based methods and structure-based design</article-title><source>Journal of Medicinal Chemistry</source><volume>63</volume><fpage>4315</fpage><lpage>4333</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00224</pub-id><pub-id pub-id-type="pmid">32223236</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>MicroRNA regulatory network analysis using miRNet 2.0</article-title><source>Methods in Molecular Biology</source><volume>2594</volume><fpage>185</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2815-7_14</pub-id><pub-id pub-id-type="pmid">36264497</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan Penebre</surname><given-names>E</given-names></name><name><surname>Kuplast</surname><given-names>KG</given-names></name><name><surname>Majer</surname><given-names>CR</given-names></name><name><surname>Boriack-Sjodin</surname><given-names>PA</given-names></name><name><surname>Wigle</surname><given-names>TJ</given-names></name><name><surname>Johnston</surname><given-names>LD</given-names></name><name><surname>Rioux</surname><given-names>N</given-names></name><name><surname>Munchhof</surname><given-names>MJ</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Jacques</surname><given-names>SL</given-names></name><name><surname>West</surname><given-names>KA</given-names></name><name><surname>Lingaraj</surname><given-names>T</given-names></name><name><surname>Stickland</surname><given-names>K</given-names></name><name><surname>Ribich</surname><given-names>SA</given-names></name><name><surname>Raimondi</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>MP</given-names></name><name><surname>Waters</surname><given-names>NJ</given-names></name><name><surname>Pollock</surname><given-names>RM</given-names></name><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Barbash</surname><given-names>O</given-names></name><name><surname>Pappalardi</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>TF</given-names></name><name><surname>Nurse</surname><given-names>K</given-names></name><name><surname>Oza</surname><given-names>KP</given-names></name><name><surname>Gallagher</surname><given-names>KT</given-names></name><name><surname>Kruger</surname><given-names>R</given-names></name><name><surname>Moyer</surname><given-names>MP</given-names></name><name><surname>Copeland</surname><given-names>RA</given-names></name><name><surname>Chesworth</surname><given-names>R</given-names></name><name><surname>Duncan</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models</article-title><source>Nature Chemical Biology</source><volume>11</volume><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1810</pub-id><pub-id pub-id-type="pmid">25915199</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charrier</surname><given-names>J-D</given-names></name><name><surname>Durrant</surname><given-names>SJ</given-names></name><name><surname>Golec</surname><given-names>JMC</given-names></name><name><surname>Kay</surname><given-names>DP</given-names></name><name><surname>Knegtel</surname><given-names>RMA</given-names></name><name><surname>MacCormick</surname><given-names>S</given-names></name><name><surname>Mortimore</surname><given-names>M</given-names></name><name><surname>O’Donnell</surname><given-names>ME</given-names></name><name><surname>Pinder</surname><given-names>JL</given-names></name><name><surname>Reaper</surname><given-names>PM</given-names></name><name><surname>Rutherford</surname><given-names>AP</given-names></name><name><surname>Wang</surname><given-names>PSH</given-names></name><name><surname>Young</surname><given-names>SC</given-names></name><name><surname>Pollard</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents</article-title><source>Journal of Medicinal Chemistry</source><volume>54</volume><fpage>2320</fpage><lpage>2330</lpage><pub-id pub-id-type="doi">10.1021/jm101488z</pub-id><pub-id pub-id-type="pmid">21413798</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ZW</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>NW</given-names></name><name><surname>Xu</surname><given-names>YH</given-names></name><name><surname>Ye</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>ZM</given-names></name><name><surname>Niu</surname><given-names>XM</given-names></name><name><surname>Shen</surname><given-names>SP</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>11560</fpage><lpage>11569</lpage><pub-id pub-id-type="doi">10.1093/nar/gku876</pub-id><pub-id pub-id-type="pmid">25249620</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Anastassiadis</surname><given-names>K</given-names></name><name><surname>Kranz</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>AF</given-names></name><name><surname>Arndt</surname><given-names>K</given-names></name><name><surname>Waskow</surname><given-names>C</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Neff</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Ernst</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MLL2, Not MLL1, plays a major role in sustaining MLL-rearranged acute myeloid leukemia</article-title><source>Cancer Cell</source><volume>31</volume><fpage>755</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.05.002</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Long</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>You</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity</article-title><source>European Journal of Medicinal Chemistry</source><volume>223</volume><elocation-id>113677</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2021.113677</pub-id><pub-id pub-id-type="pmid">34225179</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>You</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Discovery of DDO-2213 as a potent and orally bioavailable inhibitor of the WDR5-mixed lineage leukemia 1 protein-protein interaction for the treatment of MLL fusion leukemia</article-title><source>Journal of Medicinal Chemistry</source><volume>64</volume><fpage>8221</fpage><lpage>8245</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00091</pub-id><pub-id pub-id-type="pmid">34105966</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>C-Y</given-names></name><name><surname>Clough</surname><given-names>T</given-names></name><name><surname>Broudy</surname><given-names>D</given-names></name><name><surname>Killeen</surname><given-names>T</given-names></name><name><surname>MacLean</surname><given-names>B</given-names></name><name><surname>Vitek</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2524</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu305</pub-id><pub-id pub-id-type="pmid">24794931</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa-Mattioli</surname><given-names>M</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The integrated stress response: from mechanism to disease</article-title><source>Science</source><volume>368</volume><elocation-id>eaat5314</elocation-id><pub-id pub-id-type="doi">10.1126/science.aat5314</pub-id><pub-id pub-id-type="pmid">32327570</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title><source>Nature Biotechnology</source><volume>26</volume><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id><pub-id pub-id-type="pmid">19029910</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Neuhauser</surname><given-names>N</given-names></name><name><surname>Michalski</surname><given-names>A</given-names></name><name><surname>Scheltema</surname><given-names>RA</given-names></name><name><surname>Olsen</surname><given-names>JV</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Andromeda: a peptide search engine integrated into the MaxQuant environment</article-title><source>Journal of Proteome Research</source><volume>10</volume><fpage>1794</fpage><lpage>1805</lpage><pub-id pub-id-type="doi">10.1021/pr101065j</pub-id><pub-id pub-id-type="pmid">21254760</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J</given-names></name><name><surname>Hein</surname><given-names>MY</given-names></name><name><surname>Luber</surname><given-names>CA</given-names></name><name><surname>Paron</surname><given-names>I</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>13</volume><fpage>2513</fpage><lpage>2526</lpage><pub-id pub-id-type="doi">10.1074/mcp.M113.031591</pub-id><pub-id pub-id-type="pmid">24942700</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daigle</surname><given-names>SR</given-names></name><name><surname>Olhava</surname><given-names>EJ</given-names></name><name><surname>Therkelsen</surname><given-names>CA</given-names></name><name><surname>Majer</surname><given-names>CR</given-names></name><name><surname>Sneeringer</surname><given-names>CJ</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Johnston</surname><given-names>LD</given-names></name><name><surname>Scott</surname><given-names>MP</given-names></name><name><surname>Smith</surname><given-names>JJ</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Kuntz</surname><given-names>KW</given-names></name><name><surname>Chesworth</surname><given-names>R</given-names></name><name><surname>Moyer</surname><given-names>MP</given-names></name><name><surname>Bernt</surname><given-names>KM</given-names></name><name><surname>Tseng</surname><given-names>JC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Copeland</surname><given-names>RA</given-names></name><name><surname>Richon</surname><given-names>VM</given-names></name><name><surname>Pollock</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor</article-title><source>Cancer Cell</source><volume>20</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.06.009</pub-id><pub-id pub-id-type="pmid">21741596</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Vona</surname><given-names>C</given-names></name><name><surname>Bezdan</surname><given-names>D</given-names></name><name><surname>Islam</surname><given-names>A</given-names></name><name><surname>Salichs</surname><given-names>E</given-names></name><name><surname>López-Bigas</surname><given-names>N</given-names></name><name><surname>Ossowski</surname><given-names>S</given-names></name><name><surname>de la Luna</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase</article-title><source>Molecular Cell</source><volume>57</volume><fpage>506</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.12.026</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Fusi</surname><given-names>N</given-names></name><name><surname>Sullender</surname><given-names>M</given-names></name><name><surname>Hegde</surname><given-names>M</given-names></name><name><surname>Vaimberg</surname><given-names>EW</given-names></name><name><surname>Donovan</surname><given-names>KF</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Tothova</surname><given-names>Z</given-names></name><name><surname>Wilen</surname><given-names>C</given-names></name><name><surname>Orchard</surname><given-names>R</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name><name><surname>Listgarten</surname><given-names>J</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nbt.3437</pub-id><pub-id pub-id-type="pmid">26780180</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dörner</surname><given-names>K</given-names></name><name><surname>Ruggeri</surname><given-names>C</given-names></name><name><surname>Zemp</surname><given-names>I</given-names></name><name><surname>Kutay</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ribosome biogenesis factors-from names to functions</article-title><source>The EMBO Journal</source><volume>42</volume><elocation-id>e112699</elocation-id><pub-id pub-id-type="doi">10.15252/embj.2022112699</pub-id><pub-id pub-id-type="pmid">36762427</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drygin</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Bliesath</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>CB</given-names></name><name><surname>O’Brien</surname><given-names>SE</given-names></name><name><surname>Proffitt</surname><given-names>C</given-names></name><name><surname>Omori</surname><given-names>M</given-names></name><name><surname>Haddach</surname><given-names>M</given-names></name><name><surname>Schwaebe</surname><given-names>MK</given-names></name><name><surname>Siddiqui-Jain</surname><given-names>A</given-names></name><name><surname>Streiner</surname><given-names>N</given-names></name><name><surname>Quin</surname><given-names>JE</given-names></name><name><surname>Sanij</surname><given-names>E</given-names></name><name><surname>Bywater</surname><given-names>MJ</given-names></name><name><surname>Hannan</surname><given-names>RD</given-names></name><name><surname>Ryckman</surname><given-names>D</given-names></name><name><surname>Anderes</surname><given-names>K</given-names></name><name><surname>Rice</surname><given-names>WG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth</article-title><source>Cancer Research</source><volume>71</volume><fpage>1418</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1728</pub-id><pub-id pub-id-type="pmid">21159662</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eischer</surname><given-names>N</given-names></name><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Emerging roles of BET proteins in transcription and co-transcriptional RNA processing</article-title><source>Wiley Interdisciplinary Reviews. RNA</source><volume>14</volume><elocation-id>e1734</elocation-id><pub-id pub-id-type="doi">10.1002/wrna.1734</pub-id><pub-id pub-id-type="pmid">35491403</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Hassouni</surname><given-names>B</given-names></name><name><surname>Mantini</surname><given-names>G</given-names></name><name><surname>Immordino</surname><given-names>B</given-names></name><name><surname>Peters</surname><given-names>GJ</given-names></name><name><surname>Giovannetti</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CX-5461 inhibits pancreatic ductal adenocarcinoma cell growth</article-title><source>Migration and Induces DNA Damage. Molecules</source><volume>24</volume><elocation-id>4445</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24244445</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Census and evaluation of p53 target genes</article-title><source>Oncogene</source><volume>36</volume><fpage>3943</fpage><lpage>3956</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.502</pub-id><pub-id pub-id-type="pmid">28288132</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florian</surname><given-names>AC</given-names></name><name><surname>Woodley</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Grieb</surname><given-names>BC</given-names></name><name><surname>Slota</surname><given-names>MJ</given-names></name><name><surname>Guerrazzi</surname><given-names>K</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Matlock</surname><given-names>BK</given-names></name><name><surname>Flaherty</surname><given-names>DK</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells</article-title><source>NAR Cancer</source><volume>4</volume><elocation-id>zcac007</elocation-id><pub-id pub-id-type="doi">10.1093/narcan/zcac007</pub-id><pub-id pub-id-type="pmid">35252869</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francoz</surname><given-names>S</given-names></name><name><surname>Froment</surname><given-names>P</given-names></name><name><surname>Bogaerts</surname><given-names>S</given-names></name><name><surname>De</surname><given-names>S</given-names></name><name><surname>Maetens</surname><given-names>M</given-names></name><name><surname>Doumont</surname><given-names>G</given-names></name><name><surname>Bellefroid</surname><given-names>E</given-names></name><name><surname>Marine</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo</article-title><source>PNAS</source><volume>103</volume><fpage>3232</fpage><lpage>3237</lpage><pub-id pub-id-type="doi">10.1073/pnas.0508476103</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Jané-Valbuena</surname><given-names>J</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Lo</surname><given-names>CC</given-names></name><name><surname>McDonald</surname><given-names>ER</given-names><suffix>III</suffix></name><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Gelfand</surname><given-names>ET</given-names></name><name><surname>Bielski</surname><given-names>CM</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>K</given-names></name><name><surname>Andreev-Drakhlin</surname><given-names>AY</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hess</surname><given-names>JM</given-names></name><name><surname>Haas</surname><given-names>BJ</given-names></name><name><surname>Aguet</surname><given-names>F</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Rothberg</surname><given-names>MV</given-names></name><name><surname>Paolella</surname><given-names>BR</given-names></name><name><surname>Lawrence</surname><given-names>MS</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Tiv</surname><given-names>HL</given-names></name><name><surname>Gokhale</surname><given-names>PC</given-names></name><name><surname>de Weck</surname><given-names>A</given-names></name><name><surname>Mansour</surname><given-names>AA</given-names></name><name><surname>Oh</surname><given-names>C</given-names></name><name><surname>Shih</surname><given-names>J</given-names></name><name><surname>Hadi</surname><given-names>K</given-names></name><name><surname>Rosen</surname><given-names>Y</given-names></name><name><surname>Bistline</surname><given-names>J</given-names></name><name><surname>Venkatesan</surname><given-names>K</given-names></name><name><surname>Reddy</surname><given-names>A</given-names></name><name><surname>Sonkin</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Lehar</surname><given-names>J</given-names></name><name><surname>Korn</surname><given-names>JM</given-names></name><name><surname>Porter</surname><given-names>DA</given-names></name><name><surname>Jones</surname><given-names>MD</given-names></name><name><surname>Golji</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>JE</given-names></name><name><surname>Dunning</surname><given-names>CM</given-names></name><name><surname>Creech</surname><given-names>AL</given-names></name><name><surname>Warren</surname><given-names>AC</given-names></name><name><surname>McFarland</surname><given-names>JM</given-names></name><name><surname>Zamanighomi</surname><given-names>M</given-names></name><name><surname>Kauffmann</surname><given-names>A</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Maruvka</surname><given-names>YE</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Jaffe</surname><given-names>JD</given-names></name><name><surname>Lane</surname><given-names>AA</given-names></name><name><surname>Weinstock</surname><given-names>DM</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Morrissey</surname><given-names>MP</given-names></name><name><surname>Stegmeier</surname><given-names>F</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Next-generation characterization of the cancer cell line encyclopedia</article-title><source>Nature</source><volume>569</volume><fpage>503</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1186-3</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Göckler</surname><given-names>N</given-names></name><name><surname>Jofre</surname><given-names>G</given-names></name><name><surname>Papadopoulos</surname><given-names>C</given-names></name><name><surname>Soppa</surname><given-names>U</given-names></name><name><surname>Tejedor</surname><given-names>FJ</given-names></name><name><surname>Becker</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation</article-title><source>The FEBS Journal</source><volume>276</volume><fpage>6324</fpage><lpage>6337</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07346.x</pub-id><pub-id pub-id-type="pmid">19796173</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goudarzi</surname><given-names>KM</given-names></name><name><surname>Lindström</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of ribosomal protein mutations in tumor development (Review)</article-title><source>International Journal of Oncology</source><volume>48</volume><fpage>1313</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.3892/ijo.2016.3387</pub-id><pub-id pub-id-type="pmid">26892688</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grebien</surname><given-names>F</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name><name><surname>Getlik</surname><given-names>M</given-names></name><name><surname>Giambruno</surname><given-names>R</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name><name><surname>Avellino</surname><given-names>R</given-names></name><name><surname>Skucha</surname><given-names>A</given-names></name><name><surname>Vittori</surname><given-names>S</given-names></name><name><surname>Kuznetsova</surname><given-names>E</given-names></name><name><surname>Smil</surname><given-names>D</given-names></name><name><surname>Barsyte-Lovejoy</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Poda</surname><given-names>G</given-names></name><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Senisterra</surname><given-names>G</given-names></name><name><surname>Stukalov</surname><given-names>A</given-names></name><name><surname>Huber</surname><given-names>KVM</given-names></name><name><surname>Schönegger</surname><given-names>A</given-names></name><name><surname>Marcellus</surname><given-names>R</given-names></name><name><surname>Bilban</surname><given-names>M</given-names></name><name><surname>Bock</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>PJ</given-names></name><name><surname>Zuber</surname><given-names>J</given-names></name><name><surname>Bennett</surname><given-names>KL</given-names></name><name><surname>Al-Awar</surname><given-names>R</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Nerlov</surname><given-names>C</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia</article-title><source>Nature Chemical Biology</source><volume>11</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1859</pub-id><pub-id pub-id-type="pmid">26167872</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarnaccia</surname><given-names>A</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Moonlighting with WDR5: a cellular multitasker</article-title><source>Journal of Clinical Medicine</source><volume>7</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.3390/jcm7020021</pub-id><pub-id pub-id-type="pmid">29385767</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarnaccia</surname><given-names>AD</given-names></name><name><surname>Rose</surname><given-names>KL</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Popay</surname><given-names>TM</given-names></name><name><surname>Wang</surname><given-names>CE</given-names></name><name><surname>Guerrazzi</surname><given-names>K</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Woodley</surname><given-names>CM</given-names></name><name><surname>Hansen</surname><given-names>TJ</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Payne</surname><given-names>WG</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of WIN site inhibitor on the WDR5 interactome</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108636</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108636</pub-id><pub-id pub-id-type="pmid">33472061</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janouskova</surname><given-names>H</given-names></name><name><surname>El Tekle</surname><given-names>G</given-names></name><name><surname>Bellini</surname><given-names>E</given-names></name><name><surname>Udeshi</surname><given-names>ND</given-names></name><name><surname>Rinaldi</surname><given-names>A</given-names></name><name><surname>Ulbricht</surname><given-names>A</given-names></name><name><surname>Bernasocchi</surname><given-names>T</given-names></name><name><surname>Civenni</surname><given-names>G</given-names></name><name><surname>Losa</surname><given-names>M</given-names></name><name><surname>Svinkina</surname><given-names>T</given-names></name><name><surname>Bielski</surname><given-names>CM</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Cascione</surname><given-names>L</given-names></name><name><surname>Napoli</surname><given-names>S</given-names></name><name><surname>Enchev</surname><given-names>RI</given-names></name><name><surname>Mutch</surname><given-names>DG</given-names></name><name><surname>Carney</surname><given-names>ME</given-names></name><name><surname>Berchuck</surname><given-names>A</given-names></name><name><surname>Winterhoff</surname><given-names>BJN</given-names></name><name><surname>Broaddus</surname><given-names>RR</given-names></name><name><surname>Schraml</surname><given-names>P</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Bertoni</surname><given-names>F</given-names></name><name><surname>Catapano</surname><given-names>CV</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Wild</surname><given-names>PJ</given-names></name><name><surname>Theurillat</surname><given-names>J-PP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors</article-title><source>Nature Medicine</source><volume>23</volume><fpage>1046</fpage><lpage>1054</lpage><pub-id pub-id-type="doi">10.1038/nm.4372</pub-id><pub-id pub-id-type="pmid">28805821</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayaraman</surname><given-names>S</given-names></name><name><surname>Chittiboyina</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Abad</surname><given-names>PC</given-names></name><name><surname>Vidi</surname><given-names>P-A</given-names></name><name><surname>Stauffacher</surname><given-names>CV</given-names></name><name><surname>Lelièvre</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The nuclear mitotic apparatus protein NuMA controls rDNA transcription and mediates the nucleolar stress response in a p53-independent manner</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>11725</fpage><lpage>11742</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx782</pub-id><pub-id pub-id-type="pmid">28981686</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Joung</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Screening_Protocols_Manuscript</data-title><version designator="5207995">5207995</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/fengzhanglab/Screening_Protocols_manuscript">https://github.com/fengzhanglab/Screening_Protocols_manuscript</ext-link></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Konermann</surname><given-names>S</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Brigham</surname><given-names>MD</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening</article-title><source>Nature Protocols</source><volume>12</volume><fpage>828</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.016</pub-id><pub-id pub-id-type="pmid">28333914</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Woo</surname><given-names>SR</given-names></name><name><surname>Cha</surname><given-names>HJ</given-names></name><name><surname>Yoon</surname><given-names>Y</given-names></name><name><surname>Suh</surname><given-names>KS</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>IC</given-names></name><name><surname>Jin</surname><given-names>YW</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>An</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>E3 ubiquitin ligase Hades negatively regulates the exonuclear function of p53</article-title><source>Cell Death and Differentiation</source><volume>18</volume><fpage>1865</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1038/cdd.2011.57</pub-id><pub-id pub-id-type="pmid">21597459</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>McLellan</surname><given-names>MD</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>McMichael</surname><given-names>JF</given-names></name><name><surname>Wyczalkowski</surname><given-names>MA</given-names></name><name><surname>Leiserson</surname><given-names>MDM</given-names></name><name><surname>Miller</surname><given-names>CA</given-names></name><name><surname>Welch</surname><given-names>JS</given-names></name><name><surname>Walter</surname><given-names>MJ</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Ley</surname><given-names>TJ</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mutational landscape and significance across 12 major cancer types</article-title><source>Nature</source><volume>502</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature12634</pub-id><pub-id pub-id-type="pmid">24132290</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karatas</surname><given-names>H</given-names></name><name><surname>Townsend</surname><given-names>EC</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Bernard</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction</article-title><source>Journal of the American Chemical Society</source><volume>135</volume><fpage>669</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1021/ja306028q</pub-id><pub-id pub-id-type="pmid">23210835</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karatas</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Bernard</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Townsend</surname><given-names>EC</given-names></name><name><surname>Cao</surname><given-names>F</given-names></name><name><surname>Ran</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Stuckey</surname><given-names>JA</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Dou</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of a highly potent, cell-permeable macrocyclic peptidomimetic (MM-589) targeting the WD repeat domain 5 protein (WDR5)-mixed lineage leukemia (MLL) protein-protein interaction</article-title><source>Journal of Medicinal Chemistry</source><volume>60</volume><fpage>4818</fpage><lpage>4839</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01796</pub-id><pub-id pub-id-type="pmid">28603984</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Korotkevich</surname><given-names>G</given-names></name><name><surname>Sukhov</surname><given-names>V</given-names></name><name><surname>Budin</surname><given-names>N</given-names></name><name><surname>Shpak</surname><given-names>B</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Sergushichev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Fast gene set enrichment analysis</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/060012</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labun</surname><given-names>K</given-names></name><name><surname>Montague</surname><given-names>TG</given-names></name><name><surname>Krause</surname><given-names>M</given-names></name><name><surname>Torres Cleuren</surname><given-names>YN</given-names></name><name><surname>Tjeldnes</surname><given-names>H</given-names></name><name><surname>Valen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W171</fpage><lpage>W174</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz365</pub-id><pub-id pub-id-type="pmid">31106371</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laham</surname><given-names>AJ</given-names></name><name><surname>Saber-Ayad</surname><given-names>M</given-names></name><name><surname>El-Awady</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis</article-title><source>Cellular and Molecular Life Sciences</source><volume>78</volume><fpage>603</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03626-4</pub-id><pub-id pub-id-type="pmid">32870330</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laham-Karam</surname><given-names>N</given-names></name><name><surname>Pinto</surname><given-names>GP</given-names></name><name><surname>Poso</surname><given-names>A</given-names></name><name><surname>Kokkonen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcription and translation inhibitors in cancer treatment</article-title><source>Frontiers in Chemistry</source><volume>8</volume><elocation-id>276</elocation-id><pub-id pub-id-type="doi">10.3389/fchem.2020.00276</pub-id><pub-id pub-id-type="pmid">32373584</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Kennedy</surname><given-names>BK</given-names></name><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Bertos</surname><given-names>NR</given-names></name><name><surname>Yang</surname><given-names>XJ</given-names></name><name><surname>Theberge</surname><given-names>MC</given-names></name><name><surname>Tsai</surname><given-names>SC</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kuzmichev</surname><given-names>A</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Reinberg</surname><given-names>D</given-names></name><name><surname>Harlow</surname><given-names>E</given-names></name><name><surname>Branton</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>2918</fpage><lpage>2932</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.8.2918-2932.2001</pub-id><pub-id pub-id-type="pmid">11283269</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>F</given-names></name><name><surname>Bayliss</surname><given-names>PE</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Whetstine</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Iwase</surname><given-names>S</given-names></name><name><surname>Alpatov</surname><given-names>R</given-names></name><name><surname>Issaeva</surname><given-names>I</given-names></name><name><surname>Canaani</surname><given-names>E</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A histone H3 lysine 27 demethylase regulates animal posterior development</article-title><source>Nature</source><volume>449</volume><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1038/nature06192</pub-id><pub-id pub-id-type="pmid">17851529</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with Bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larionova</surname><given-names>TD</given-names></name><name><surname>Bastola</surname><given-names>S</given-names></name><name><surname>Aksinina</surname><given-names>TE</given-names></name><name><surname>Anufrieva</surname><given-names>KS</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shender</surname><given-names>VO</given-names></name><name><surname>Andreev</surname><given-names>DE</given-names></name><name><surname>Kovalenko</surname><given-names>TF</given-names></name><name><surname>Arapidi</surname><given-names>GP</given-names></name><name><surname>Shnaider</surname><given-names>PV</given-names></name><name><surname>Kazakova</surname><given-names>AN</given-names></name><name><surname>Latyshev</surname><given-names>YA</given-names></name><name><surname>Tatarskiy</surname><given-names>VV</given-names></name><name><surname>Shtil</surname><given-names>AA</given-names></name><name><surname>Moreau</surname><given-names>P</given-names></name><name><surname>Giraud</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Rubtsova</surname><given-names>MP</given-names></name><name><surname>Dontsova</surname><given-names>OA</given-names></name><name><surname>Condro</surname><given-names>M</given-names></name><name><surname>Ellingson</surname><given-names>BM</given-names></name><name><surname>Shakhparonov</surname><given-names>MI</given-names></name><name><surname>Kornblum</surname><given-names>HI</given-names></name><name><surname>Nakano</surname><given-names>I</given-names></name><name><surname>Pavlyukov</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Alternative RNA splicing modulates ribosomal composition and determines the spatial phenotype of glioblastoma cells</article-title><source>Nature Cell Biology</source><volume>24</volume><fpage>1541</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1038/s41556-022-00994-w</pub-id><pub-id pub-id-type="pmid">36192632</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauria</surname><given-names>F</given-names></name><name><surname>Tebaldi</surname><given-names>T</given-names></name><name><surname>Bernabò</surname><given-names>P</given-names></name><name><surname>Groen</surname><given-names>EJN</given-names></name><name><surname>Gillingwater</surname><given-names>TH</given-names></name><name><surname>Viero</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>riboWaltz: Optimization of ribosome P-site positioning in ribosome profiling data</article-title><source>PLOS Computational Biology</source><volume>14</volume><elocation-id>e1006169</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006169</pub-id><pub-id pub-id-type="pmid">30102689</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenard</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>HM</given-names></name><name><surname>Pastuer</surname><given-names>T</given-names></name><name><surname>Shank</surname><given-names>T</given-names></name><name><surname>Libbrecht</surname><given-names>C</given-names></name><name><surname>Kingsley</surname><given-names>M</given-names></name><name><surname>Riedel</surname><given-names>SS</given-names></name><name><surname>Yuan</surname><given-names>ZF</given-names></name><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Neff</surname><given-names>T</given-names></name><name><surname>Bernt</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epigenetic regulation of protein translation in KMT2A-rearranged AML</article-title><source>Experimental Hematology</source><volume>85</volume><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2020.04.007</pub-id><pub-id pub-id-type="pmid">32437908</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>554</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0554-4</pub-id><pub-id pub-id-type="pmid">25476604</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>DD</given-names></name><name><surname>Chen</surname><given-names>WL</given-names></name><name><surname>Xu</surname><given-names>XL</given-names></name><name><surname>Jiang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>YY</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Guo</surname><given-names>XK</given-names></name><name><surname>You</surname><given-names>QD</given-names></name><name><surname>Sun</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5</article-title><source>European Journal of Medicinal Chemistry</source><volume>118</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.04.032</pub-id><pub-id pub-id-type="pmid">27116709</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Mageck</data-title><source>SourceForge</source><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/p/mageck/wiki/Home/">https://sourceforge.net/p/mageck/wiki/Home/</ext-link></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Kottur</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Storey</surname><given-names>AJ</given-names></name><name><surname>Tsai</surname><given-names>YH</given-names></name><name><surname>Uryu</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Byrum</surname><given-names>SD</given-names></name><name><surname>Edmondson</surname><given-names>RD</given-names></name><name><surname>Mackintosh</surname><given-names>SG</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Aggarwal</surname><given-names>AK</given-names></name><name><surname>Tackett</surname><given-names>AJ</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic</article-title><source>Oncogene</source><volume>41</volume><fpage>3328</fpage><lpage>3340</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02340-8</pub-id><pub-id pub-id-type="pmid">35525905</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Pinchback</surname><given-names>R</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular signatures database (MSigDB) 3.0</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1739</fpage><lpage>1740</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr260</pub-id><pub-id pub-id-type="pmid">21546393</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular signatures database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Uziel</surname><given-names>T</given-names></name><name><surname>Hessler</surname><given-names>P</given-names></name><name><surname>Albert</surname><given-names>DH</given-names></name><name><surname>Roberts-Rapp</surname><given-names>LA</given-names></name><name><surname>McDaniel</surname><given-names>KF</given-names></name><name><surname>Kati</surname><given-names>WM</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues</article-title><source>Molecular Cancer Therapeutics</source><volume>16</volume><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0475</pub-id><pub-id pub-id-type="pmid">27903752</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litovchick</surname><given-names>L</given-names></name><name><surname>Florens</surname><given-names>LA</given-names></name><name><surname>Swanson</surname><given-names>SK</given-names></name><name><surname>Washburn</surname><given-names>MP</given-names></name><name><surname>DeCaprio</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>801</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1101/gad.2034211</pub-id><pub-id pub-id-type="pmid">21498570</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Stoleru</surname><given-names>D</given-names></name><name><surname>Salic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin</article-title><source>PNAS</source><volume>109</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1073/pnas.1111561108</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>JD</given-names></name><name><surname>Chacón Simon</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Howes</surname><given-names>JE</given-names></name><name><surname>Sai</surname><given-names>J</given-names></name><name><surname>Yuh</surname><given-names>JP</given-names></name><name><surname>Camper</surname><given-names>D</given-names></name><name><surname>Alicie</surname><given-names>BM</given-names></name><name><surname>Alvarado</surname><given-names>J</given-names></name><name><surname>Nikhar</surname><given-names>S</given-names></name><name><surname>Payne</surname><given-names>W</given-names></name><name><surname>Aho</surname><given-names>ER</given-names></name><name><surname>Bauer</surname><given-names>JA</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Rossanese</surname><given-names>OW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name><name><surname>Waterson</surname><given-names>AG</given-names></name><name><surname>Stauffer</surname><given-names>SR</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Discovery and optimization of salicylic acid-derived sulfonamide inhibitors of the WD repeat-containing protein 5-MYC protein-protein interaction</article-title><source>Journal of Medicinal Chemistry</source><volume>62</volume><fpage>11232</fpage><lpage>11259</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01411</pub-id><pub-id pub-id-type="pmid">31724864</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet.Journal</source><volume>17</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGlincy</surname><given-names>NJ</given-names></name><name><surname>Ingolia</surname><given-names>NT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptome-wide measurement of translation by ribosome profiling</article-title><source>Methods</source><volume>126</volume><fpage>112</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2017.05.028</pub-id><pub-id pub-id-type="pmid">28579404</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muys</surname><given-names>BR</given-names></name><name><surname>Anastasakis</surname><given-names>DG</given-names></name><name><surname>Claypool</surname><given-names>D</given-names></name><name><surname>Pongor</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>XL</given-names></name><name><surname>Grammatikakis</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Prasanth</surname><given-names>KV</given-names></name><name><surname>Aladjem</surname><given-names>MI</given-names></name><name><surname>Lal</surname><given-names>A</given-names></name><name><surname>Hafner</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma</article-title><source>Genes &amp; Development</source><volume>35</volume><fpage>102</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1101/gad.342634.120</pub-id><pub-id pub-id-type="pmid">33334821</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>E</given-names></name><name><surname>Mark</surname><given-names>KG</given-names></name><name><surname>Mocciaro</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>ER</given-names></name><name><surname>Prabu</surname><given-names>JR</given-names></name><name><surname>Cha</surname><given-names>DD</given-names></name><name><surname>Kampmann</surname><given-names>M</given-names></name><name><surname>Gamarra</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>CY</given-names></name><name><surname>Rape</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Gene expression and cell identity controlled by anaphase-promoting complex</article-title><source>Nature</source><volume>579</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2034-1</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Leary</surname><given-names>MN</given-names></name><name><surname>Schreiber</surname><given-names>KH</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Duc</surname><given-names>A-CE</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Hale</surname><given-names>JS</given-names></name><name><surname>Academia</surname><given-names>EC</given-names></name><name><surname>Shah</surname><given-names>SR</given-names></name><name><surname>Morton</surname><given-names>JF</given-names></name><name><surname>Holstein</surname><given-names>CA</given-names></name><name><surname>Martin</surname><given-names>DB</given-names></name><name><surname>Kaeberlein</surname><given-names>M</given-names></name><name><surname>Ladiges</surname><given-names>WC</given-names></name><name><surname>Fink</surname><given-names>PJ</given-names></name><name><surname>Mackay</surname><given-names>VL</given-names></name><name><surname>Wiest</surname><given-names>DL</given-names></name><name><surname>Kennedy</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1</article-title><source>PLOS Genetics</source><volume>9</volume><elocation-id>e1003708</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003708</pub-id><pub-id pub-id-type="pmid">23990801</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltonen</surname><given-names>K</given-names></name><name><surname>Colis</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Trivedi</surname><given-names>R</given-names></name><name><surname>Moubarek</surname><given-names>MS</given-names></name><name><surname>Moore</surname><given-names>HM</given-names></name><name><surname>Bai</surname><given-names>B</given-names></name><name><surname>Rudek</surname><given-names>MA</given-names></name><name><surname>Bieberich</surname><given-names>CJ</given-names></name><name><surname>Laiho</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A targeting modality for destruction of RNA polymerase I that possesses anticancer activity</article-title><source>Cancer Cell</source><volume>25</volume><fpage>77</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.12.009</pub-id><pub-id pub-id-type="pmid">24434211</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>AS</given-names></name><name><surname>Keil</surname><given-names>M</given-names></name><name><surname>Kühl</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Wnt Target Protein Peter Pan Defines a Novel p53-independent Nucleolar Stress-Response Pathway</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>10905</fpage><lpage>10918</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.634246</pub-id><pub-id pub-id-type="pmid">25759387</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Emerging role of the nucleolar stress response in autophagy</article-title><source>Frontiers in Cellular Neuroscience</source><volume>13</volume><elocation-id>156</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2019.00156</pub-id><pub-id pub-id-type="pmid">31114481</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philippe</surname><given-names>L</given-names></name><name><surname>van den Elzen</surname><given-names>AMG</given-names></name><name><surname>Watson</surname><given-names>MJ</given-names></name><name><surname>Thoreen</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Global analysis of LARP1 translation targets reveals tunable and dynamic features of 5′ TOP motifs</article-title><source>PNAS</source><volume>117</volume><fpage>5319</fpage><lpage>5328</lpage><pub-id pub-id-type="doi">10.1073/pnas.1912864117</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quin</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>KT</given-names></name><name><surname>Devlin</surname><given-names>JR</given-names></name><name><surname>Cameron</surname><given-names>DP</given-names></name><name><surname>Diesch</surname><given-names>J</given-names></name><name><surname>Cullinane</surname><given-names>C</given-names></name><name><surname>Ahern</surname><given-names>J</given-names></name><name><surname>Khot</surname><given-names>A</given-names></name><name><surname>Hein</surname><given-names>N</given-names></name><name><surname>George</surname><given-names>AJ</given-names></name><name><surname>Hannan</surname><given-names>KM</given-names></name><name><surname>Poortinga</surname><given-names>G</given-names></name><name><surname>Sheppard</surname><given-names>KE</given-names></name><name><surname>Khanna</surname><given-names>KK</given-names></name><name><surname>Johnstone</surname><given-names>RW</given-names></name><name><surname>Drygin</surname><given-names>D</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Pearson</surname><given-names>RB</given-names></name><name><surname>Sanij</surname><given-names>E</given-names></name><name><surname>Hannan</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling</article-title><source>Oncotarget</source><volume>7</volume><fpage>49800</fpage><lpage>49818</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.10452</pub-id><pub-id pub-id-type="pmid">27391441</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radzisheuskaya</surname><given-names>A</given-names></name><name><surname>Shliaha</surname><given-names>PV</given-names></name><name><surname>Grinev</surname><given-names>V</given-names></name><name><surname>Lorenzini</surname><given-names>E</given-names></name><name><surname>Kovalchuk</surname><given-names>S</given-names></name><name><surname>Shlyueva</surname><given-names>D</given-names></name><name><surname>Gorshkov</surname><given-names>V</given-names></name><name><surname>Hendrickson</surname><given-names>RC</given-names></name><name><surname>Jensen</surname><given-names>ON</given-names></name><name><surname>Helin</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>26</volume><fpage>999</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1038/s41594-019-0313-z</pub-id><pub-id pub-id-type="pmid">31611688</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rallapalli</surname><given-names>R</given-names></name><name><surname>Strachan</surname><given-names>G</given-names></name><name><surname>Cho</surname><given-names>B</given-names></name><name><surname>Mercer</surname><given-names>WE</given-names></name><name><surname>Hall</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A novel MDMX transcript expressed in A variety of transformed cell lines encodes A truncated protein with potent p53 repressive activity</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>8299</fpage><lpage>8308</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.12.8299</pub-id><pub-id pub-id-type="pmid">10075736</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raught</surname><given-names>B</given-names></name><name><surname>Gingras</surname><given-names>AC</given-names></name><name><surname>Sonenberg</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The target of rapamycin (TOR) proteins</article-title><source>PNAS</source><volume>98</volume><fpage>7037</fpage><lpage>7044</lpage><pub-id pub-id-type="doi">10.1073/pnas.121145898</pub-id><pub-id pub-id-type="pmid">11416184</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritz</surname><given-names>C</given-names></name><name><surname>Baty</surname><given-names>F</given-names></name><name><surname>Streibig</surname><given-names>JC</given-names></name><name><surname>Gerhard</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dose-response analysis using R</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0146021</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0146021</pub-id><pub-id pub-id-type="pmid">26717316</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Ritz</surname><given-names>C</given-names></name><name><surname>Streibig</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>drc</data-title><version designator="3.0.6">3.0.6</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/DoseResponse/drc">https://github.com/DoseResponse/drc</ext-link></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogakou</surname><given-names>EP</given-names></name><name><surname>Nieves-Neira</surname><given-names>W</given-names></name><name><surname>Boon</surname><given-names>C</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name><name><surname>Bonner</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>9390</fpage><lpage>9395</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.13.9390</pub-id><pub-id pub-id-type="pmid">10734083</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>A</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ribosomal proteins control or bypass p53 during nucleolar stress</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><elocation-id>140</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18010140</pub-id><pub-id pub-id-type="pmid">28085118</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanij</surname><given-names>E</given-names></name><name><surname>Hannan</surname><given-names>KM</given-names></name><name><surname>Xuan</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Ahern</surname><given-names>JE</given-names></name><name><surname>Trigos</surname><given-names>AS</given-names></name><name><surname>Brajanovski</surname><given-names>N</given-names></name><name><surname>Son</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>KT</given-names></name><name><surname>Kondrashova</surname><given-names>O</given-names></name><name><surname>Lieschke</surname><given-names>E</given-names></name><name><surname>Wakefield</surname><given-names>MJ</given-names></name><name><surname>Frank</surname><given-names>D</given-names></name><name><surname>Ellis</surname><given-names>S</given-names></name><name><surname>Cullinane</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>J</given-names></name><name><surname>Poortinga</surname><given-names>G</given-names></name><name><surname>Nag</surname><given-names>P</given-names></name><name><surname>Deans</surname><given-names>AJ</given-names></name><name><surname>Khanna</surname><given-names>KK</given-names></name><name><surname>Mileshkin</surname><given-names>L</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Soong</surname><given-names>J</given-names></name><name><surname>Berns</surname><given-names>EMJJ</given-names></name><name><surname>Hannan</surname><given-names>RD</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Sheppard</surname><given-names>KE</given-names></name><name><surname>Pearson</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2641</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16393-4</pub-id><pub-id pub-id-type="pmid">32457376</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id><pub-id pub-id-type="pmid">25075903</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnur</surname><given-names>RC</given-names></name><name><surname>Corman</surname><given-names>ML</given-names></name><name><surname>Gallaschun</surname><given-names>RJ</given-names></name><name><surname>Cooper</surname><given-names>BA</given-names></name><name><surname>Dee</surname><given-names>MF</given-names></name><name><surname>Doty</surname><given-names>JL</given-names></name><name><surname>Muzzi</surname><given-names>ML</given-names></name><name><surname>Moyer</surname><given-names>JD</given-names></name><name><surname>DiOrio</surname><given-names>CI</given-names></name><name><surname>Barbacci</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives</article-title><source>Journal of Medicinal Chemistry</source><volume>38</volume><fpage>3806</fpage><lpage>3812</lpage><pub-id pub-id-type="doi">10.1021/jm00019a010</pub-id><pub-id pub-id-type="pmid">7562911</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senisterra</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Allali-Hassani</surname><given-names>A</given-names></name><name><surname>Wasney</surname><given-names>GA</given-names></name><name><surname>Barsyte-Lovejoy</surname><given-names>D</given-names></name><name><surname>Dombrovski</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>KT</given-names></name><name><surname>Smil</surname><given-names>D</given-names></name><name><surname>Bolshan</surname><given-names>Y</given-names></name><name><surname>Hajian</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Seitova</surname><given-names>A</given-names></name><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Poda</surname><given-names>G</given-names></name><name><surname>Couture</surname><given-names>JF</given-names></name><name><surname>Brown</surname><given-names>PJ</given-names></name><name><surname>Al-Awar</surname><given-names>R</given-names></name><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5</article-title><source>The Biochemical Journal</source><volume>449</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1042/BJ20121280</pub-id><pub-id pub-id-type="pmid">22989411</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Henry</surname><given-names>MD</given-names></name><name><surname>Wu</surname><given-names>YN</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data</article-title><source>PNAS</source><volume>111</volume><fpage>E5593</fpage><lpage>E5601</lpage><pub-id pub-id-type="doi">10.1073/pnas.1419161111</pub-id><pub-id pub-id-type="pmid">25480548</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherr</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The INK4a/ARF network in tumour suppression</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>2</volume><fpage>731</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/35096061</pub-id><pub-id pub-id-type="pmid">11584300</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinsky</surname><given-names>SA</given-names></name><name><surname>Monteith</surname><given-names>KE</given-names></name><name><surname>Viggiano</surname><given-names>S</given-names></name><name><surname>Cosgrove</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>6361</fpage><lpage>6375</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.627646</pub-id><pub-id pub-id-type="pmid">25561738</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shore</surname><given-names>D</given-names></name><name><surname>Albert</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ribosome biogenesis and the cellular energy economy</article-title><source>Current Biology</source><volume>32</volume><fpage>R611</fpage><lpage>R617</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2022.04.083</pub-id><pub-id pub-id-type="pmid">35728540</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorstova</surname><given-names>T</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Witcher</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Achieving clinical success with BET inhibitors as anti-cancer agents</article-title><source>British Journal of Cancer</source><volume>124</volume><fpage>1478</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01321-0</pub-id><pub-id pub-id-type="pmid">33723398</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siladi</surname><given-names>AJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Florian</surname><given-names>AC</given-names></name><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Creighton</surname><given-names>JH</given-names></name><name><surname>Matlock</surname><given-names>BK</given-names></name><name><surname>Flaherty</surname><given-names>DK</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>WIN site inhibition disrupts a subset of WDR5 function</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>1848</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-05947-9</pub-id><pub-id pub-id-type="pmid">35115608</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Heger</surname><given-names>A</given-names></name><name><surname>Sudbery</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>UMI-tools: modeling sequencing errors in unique molecular identifiers to improve quantification accuracy</article-title><source>Genome Research</source><volume>27</volume><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1101/gr.209601.116</pub-id><pub-id pub-id-type="pmid">28100584</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souers</surname><given-names>AJ</given-names></name><name><surname>Leverson</surname><given-names>JD</given-names></name><name><surname>Boghaert</surname><given-names>ER</given-names></name><name><surname>Ackler</surname><given-names>SL</given-names></name><name><surname>Catron</surname><given-names>ND</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Dayton</surname><given-names>BD</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Enschede</surname><given-names>SH</given-names></name><name><surname>Fairbrother</surname><given-names>WJ</given-names></name><name><surname>Huang</surname><given-names>DCS</given-names></name><name><surname>Hymowitz</surname><given-names>SG</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Khaw</surname><given-names>SL</given-names></name><name><surname>Kovar</surname><given-names>PJ</given-names></name><name><surname>Lam</surname><given-names>LT</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Maecker</surname><given-names>HL</given-names></name><name><surname>Marsh</surname><given-names>KC</given-names></name><name><surname>Mason</surname><given-names>KD</given-names></name><name><surname>Mitten</surname><given-names>MJ</given-names></name><name><surname>Nimmer</surname><given-names>PM</given-names></name><name><surname>Oleksijew</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>CH</given-names></name><name><surname>Park</surname><given-names>C-M</given-names></name><name><surname>Phillips</surname><given-names>DC</given-names></name><name><surname>Roberts</surname><given-names>AW</given-names></name><name><surname>Sampath</surname><given-names>D</given-names></name><name><surname>Seymour</surname><given-names>JF</given-names></name><name><surname>Smith</surname><given-names>ML</given-names></name><name><surname>Sullivan</surname><given-names>GM</given-names></name><name><surname>Tahir</surname><given-names>SK</given-names></name><name><surname>Tse</surname><given-names>C</given-names></name><name><surname>Wendt</surname><given-names>MD</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>JC</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Humerickhouse</surname><given-names>RA</given-names></name><name><surname>Rosenberg</surname><given-names>SH</given-names></name><name><surname>Elmore</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets</article-title><source>Nature Medicine</source><volume>19</volume><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/nm.3048</pub-id><pub-id pub-id-type="pmid">23291630</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Temaj</surname><given-names>G</given-names></name><name><surname>Chichiarelli</surname><given-names>S</given-names></name><name><surname>Eufemi</surname><given-names>M</given-names></name><name><surname>Altieri</surname><given-names>F</given-names></name><name><surname>Hadziselimovic</surname><given-names>R</given-names></name><name><surname>Farooqi</surname><given-names>AA</given-names></name><name><surname>Yaylim</surname><given-names>I</given-names></name><name><surname>Saso</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ribosome-directed therapies in cancer</article-title><source>Biomedicines</source><volume>10</volume><elocation-id>2088</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines10092088</pub-id><pub-id pub-id-type="pmid">36140189</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teuscher</surname><given-names>KB</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name><name><surname>Meyers</surname><given-names>KM</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Sai</surname><given-names>J</given-names></name><name><surname>Van Meveren</surname><given-names>M</given-names></name><name><surname>South</surname><given-names>TM</given-names></name><name><surname>Sensintaffar</surname><given-names>JL</given-names></name><name><surname>Rietz</surname><given-names>TA</given-names></name><name><surname>Goswami</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Grieb</surname><given-names>BC</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Moore</surname><given-names>WJ</given-names></name><name><surname>Stott</surname><given-names>GM</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2211297120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2211297120</pub-id><pub-id pub-id-type="pmid">36574664</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>AT</given-names></name><name><surname>Blessington</surname><given-names>P</given-names></name><name><surname>Zou</surname><given-names>T</given-names></name><name><surname>Feather</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Ernst</surname><given-names>P</given-names></name><name><surname>Koretzky</surname><given-names>GA</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MLL-AF9-induced leukemogenesis requires coexpression of the wild-type MLL allele</article-title><source>Cancer Cell</source><volume>17</volume><fpage>148</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.12.034</pub-id><pub-id pub-id-type="pmid">20159607</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Grieb</surname><given-names>BC</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Foshage</surname><given-names>AM</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Dey</surname><given-names>S</given-names></name><name><surname>Lorey</surname><given-names>S</given-names></name><name><surname>Alicie</surname><given-names>B</given-names></name><name><surname>Howard</surname><given-names>GC</given-names></name><name><surname>Cawthon</surname><given-names>B</given-names></name><name><surname>Ess</surname><given-names>KC</given-names></name><name><surname>Eischen</surname><given-names>CM</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC</article-title><source>Molecular Cell</source><volume>58</volume><fpage>440</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.02.028</pub-id><pub-id pub-id-type="pmid">25818646</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Adams</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Creighton</surname><given-names>J</given-names></name><name><surname>Lorey</surname><given-names>SL</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Eischen</surname><given-names>CM</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance</article-title><source>PNAS</source><volume>116</volume><fpage>25260</fpage><lpage>25268</lpage><pub-id pub-id-type="doi">10.1073/pnas.1910391116</pub-id><pub-id pub-id-type="pmid">31767764</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Teuscher</surname><given-names>KB</given-names></name><name><surname>Aho</surname><given-names>ER</given-names></name><name><surname>Alvarado</surname><given-names>JR</given-names></name><name><surname>Mills</surname><given-names>JJ</given-names></name><name><surname>Meyers</surname><given-names>KM</given-names></name><name><surname>Gogliotti</surname><given-names>RD</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Macdonald</surname><given-names>JD</given-names></name><name><surname>Sai</surname><given-names>J</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Sensintaffar</surname><given-names>JL</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Rietz</surname><given-names>TA</given-names></name><name><surname>Thomas</surname><given-names>LR</given-names></name><name><surname>Payne</surname><given-names>WG</given-names></name><name><surname>Moore</surname><given-names>WJ</given-names></name><name><surname>Stott</surname><given-names>GM</given-names></name><name><surname>Kondo</surname><given-names>J</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Coffey</surname><given-names>RJ</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name><name><surname>Stauffer</surname><given-names>SR</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery and structure-based optimization of potent and selective WD repeat domain 5 (WDR5) inhibitors containing a dihydroisoquinolinone bicyclic core</article-title><source>Journal of Medicinal Chemistry</source><volume>63</volume><fpage>656</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01608</pub-id><pub-id pub-id-type="pmid">31858797</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Montgomery</surname><given-names>PG</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Kryukov</surname><given-names>G</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Harrington</surname><given-names>WF</given-names></name><name><surname>Pantel</surname><given-names>S</given-names></name><name><surname>Krill-Burger</surname><given-names>JM</given-names></name><name><surname>Meyers</surname><given-names>RM</given-names></name><name><surname>Ali</surname><given-names>L</given-names></name><name><surname>Goodale</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Gerath</surname><given-names>WFJ</given-names></name><name><surname>Howell</surname><given-names>S</given-names></name><name><surname>Merkel</surname><given-names>E</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defining a cancer dependency map</article-title><source>Cell</source><volume>170</volume><fpage>564</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id><pub-id pub-id-type="pmid">28753430</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ugarte</surname><given-names>MD</given-names></name><name><surname>Militino</surname><given-names>AF</given-names></name><name><surname>Arnholt</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2015">2015</year><source>Probability and Statistics with R</source><publisher-loc>New York</publisher-loc><publisher-name>Chapman and Hall/CRC</publisher-name><pub-id pub-id-type="doi">10.1201/b18682</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Jeon</surname><given-names>KO</given-names></name><name><surname>Salovich</surname><given-names>JM</given-names></name><name><surname>Macdonald</surname><given-names>JD</given-names></name><name><surname>Alvarado</surname><given-names>J</given-names></name><name><surname>Gogliotti</surname><given-names>RD</given-names></name><name><surname>Phan</surname><given-names>J</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Camper</surname><given-names>DV</given-names></name><name><surname>Yuh</surname><given-names>JP</given-names></name><name><surname>Shaw</surname><given-names>JG</given-names></name><name><surname>Sai</surname><given-names>J</given-names></name><name><surname>Rossanese</surname><given-names>OW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name><name><surname>Stauffer</surname><given-names>SR</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-site inhibitors using fragment-based methods and structure-based design</article-title><source>Journal of Medicinal Chemistry</source><volume>61</volume><fpage>5623</fpage><lpage>5642</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00375</pub-id><pub-id pub-id-type="pmid">29889518</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kleiner</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cell- and polymerase-selective metabolic labeling of cellular RNA with 2′-Azidocytidine</article-title><source>Journal of the American Chemical Society</source><volume>142</volume><fpage>14417</fpage><lpage>14421</lpage><pub-id pub-id-type="doi">10.1021/jacs.0c04566</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissmiller</surname><given-names>AM</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Tansey</surname><given-names>WP</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>WD repeat domain 5 inhibitors for cancer therapy: not what you think</article-title><source>Journal of Clinical Medicine</source><volume>13</volume><elocation-id>274</elocation-id><pub-id pub-id-type="doi">10.3390/jcm13010274</pub-id><pub-id pub-id-type="pmid">38202281</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Medina</surname><given-names>SG</given-names></name><name><surname>Kushawah</surname><given-names>G</given-names></name><name><surname>DeVore</surname><given-names>ML</given-names></name><name><surname>Castellano</surname><given-names>LA</given-names></name><name><surname>Hand</surname><given-names>JM</given-names></name><name><surname>Wright</surname><given-names>M</given-names></name><name><surname>Bazzini</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Translation affects mRNA stability in a codon-dependent manner in human cells</article-title><source>eLife</source><volume>8</volume><elocation-id>e45396</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.45396</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Zou</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genome-wide assessment of differential translations with ribosome profiling data</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11194</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11194</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="software"><person-group person-group-type="author"><collab>xryanglab</collab></person-group><year iso-8601-date="2016">2016</year><data-title>Xtail</data-title><version designator="1.1.5">1.1.5</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/xryanglab/xtail">https://github.com/xryanglab/xtail</ext-link></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>B</given-names></name><name><surname>Wennerberg</surname><given-names>K</given-names></name><name><surname>Aittokallio</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Searching for drug synergy in complex dose-response landscapes using an interaction potency model</article-title><source>Computational and Structural Biotechnology Journal</source><volume>13</volume><fpage>504</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2015.09.001</pub-id><pub-id pub-id-type="pmid">26949479</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Kottur</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>K-S</given-names></name><name><surname>Tsai</surname><given-names>Y-H</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Herring</surname><given-names>L</given-names></name><name><surname>Kaniskan</surname><given-names>HÜ</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Aggarwal</surname><given-names>AK</given-names></name><name><surname>Wang</surname><given-names>GG</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>eabj1578</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abj1578</pub-id><pub-id pub-id-type="pmid">34586829</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Kottur</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Herring</surname><given-names>LE</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Aggarwal</surname><given-names>AK</given-names></name><name><surname>Wang</surname><given-names>GG</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Discovery of potent and selective WDR5 proteolysis targeting chimeras as potential therapeutics for pancreatic cancer</article-title><source>Journal of Medicinal Chemistry</source><volume>66</volume><fpage>16168</fpage><lpage>16186</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c01521</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>PY</given-names></name><name><surname>Yao</surname><given-names>RQ</given-names></name><name><surname>Zhang</surname><given-names>ZC</given-names></name><name><surname>Zhu</surname><given-names>SY</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>XH</given-names></name><name><surname>Yao</surname><given-names>YM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Eukaryotic ribosome quality control system: a potential therapeutic target for human diseases</article-title><source>International Journal of Biological Sciences</source><volume>18</volume><fpage>2497</fpage><lpage>2514</lpage><pub-id pub-id-type="doi">10.7150/ijbs.70955</pub-id><pub-id pub-id-type="pmid">35414791</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Aldahdooh</surname><given-names>J</given-names></name><name><surname>Malyutina</surname><given-names>A</given-names></name><name><surname>Shadbahr</surname><given-names>T</given-names></name><name><surname>Tanoli</surname><given-names>Z</given-names></name><name><surname>Pessia</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets</article-title><source>Genomics, Proteomics &amp; Bioinformatics</source><volume>20</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.gpb.2022.01.004</pub-id><pub-id pub-id-type="pmid">35085776</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Sammons</surname><given-names>MA</given-names></name><name><surname>Donahue</surname><given-names>G</given-names></name><name><surname>Dou</surname><given-names>Z</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name><name><surname>Getlik</surname><given-names>M</given-names></name><name><surname>Barsyte-Lovejoy</surname><given-names>D</given-names></name><name><surname>Al-awar</surname><given-names>R</given-names></name><name><surname>Katona</surname><given-names>BW</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Berger</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth</article-title><source>Nature</source><volume>525</volume><fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/nature15251</pub-id><pub-id pub-id-type="pmid">26331536</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zona</surname><given-names>S</given-names></name><name><surname>Bella</surname><given-names>L</given-names></name><name><surname>Burton</surname><given-names>MJ</given-names></name><name><surname>Nestal de Moraes</surname><given-names>G</given-names></name><name><surname>Lam</surname><given-names>EW-F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance</article-title><source>Biochimica et Biophysica Acta</source><volume>1839</volume><fpage>1316</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.09.016</pub-id><pub-id pub-id-type="pmid">25287128</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">RPL22</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">ENSEMBL:ENSG00000116251</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">RPL22L1</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">ENSEMBL:ENSG00000163584</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MDM4</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">ENSEMBL:ENSG00000198625</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">Endura ElectroCompetent Cells</td><td align="left" valign="bottom">Lucigen</td><td align="left" valign="bottom">Cat# 60242-2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">‘MV4;11’</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-9591; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0064">CVCL_0064</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">‘MV4;11 NT’</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">See ‘Generation of RPL22-null cell lines’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">‘MV4;11 RPL22 KO’</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">See ’Generation of RPL22-null cell lines’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">‘MV4;11 Cas9’</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">See ‘Generation of Cas9-expressing MV4;11 cells’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MOLM13</td><td align="left" valign="bottom">DMSZ</td><td align="left" valign="bottom">Cat# ACC554; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_2119">CVCL_2119</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MOLM13 NT</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">See ‘Generation of RPL22-null cell lines’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">MOLM13 RPL22 KO</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">See ‘Generation of RPL22-null cell lines’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">K562</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CCL-243; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0004">CVCL_0004</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">K562 NT</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">See ‘Generation of RPL22-null cell lines’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">K562 RPL22 KO</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">See ‘Generation of RPL22-null cell lines’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">Cat# CRL-11268; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_1926">CVCL_1926</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p53 (DO-1) (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-126; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_628082">AB_628082</ext-link></td><td align="char" char="." valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RPL22 (52) (mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-136413; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10658965">AB_10658965</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RPL22L1 (rabbit polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# PA5-63266; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2646731">AB_2646731</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MDMX (mouse monoclonal)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# M0445; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_532256">AB_532256</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-p21 Waf1/Cip1 (12D1) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2947; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_823586">AB_823586</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-⍺-actinin (HRP) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 12413; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2797903">AB_2797903</ext-link></td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (HRP) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 8884; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11129865">AB_11129865</ext-link></td><td align="char" char="." valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-nucleophosmin (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab10530; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_297271">AB_297271</ext-link></td><td align="char" char="." valign="bottom">(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Phospho-Histone H2A.X (Ser139) (20E3) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 9718; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2118009">AB_2118009</ext-link></td><td align="char" char="." valign="bottom">(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A-11001; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534069">AB_2534069</ext-link></td><td align="char" char="." valign="bottom">(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A-11037; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534095">AB_2534095</ext-link></td><td align="char" char="." valign="bottom">(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (HRP) (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 8884; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11129865">AB_11129865</ext-link></td><td align="char" char="." valign="bottom">(1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG, Light chain specific (HRP)</td><td align="left" valign="bottom">Jackson ImmunoResearch Laboratories, Inc</td><td align="left" valign="bottom">Cat# 115-035-174; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2338512">AB_2338512</ext-link></td><td align="char" char="." valign="bottom">(1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit IgG, HRP-linked antibody</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 7074; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2099233">AB_2099233</ext-link></td><td align="char" char="." valign="bottom">(1:5000)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiCas9-Blast</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25075903/">25075903</ext-link></td><td align="left" valign="bottom">Addgene plasmid# 52962; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_52962">Addgene_52962</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">psPAX2</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene plasmid# 12260; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12260">Addgene_12260</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pMD2.G</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Addgene plasmid# 12259; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12259">Addgene_12259</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Human GeCKOv2 CRISPR <break/>Knockout Pooled Library <break/>(A+B) in lentiGuide-PURO</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25075903/">25075903</ext-link></td><td align="left" valign="bottom">Addgene plasmid# 1000000048</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">lentiGuide-PURO</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/25075903/">25075903</ext-link></td><td align="left" valign="bottom">Addgene plasmid# 52963; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_52963">Addgene_52963</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">cOmplete, EDTA-free, Protease Inhibitor Cocktail</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 11873580001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PhosSTOP</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 4906837001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pefabloc SC</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 11429868001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TURBO DNase (2 U/µL)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# AM2238</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNase I, <italic>E. coli</italic></td><td align="left" valign="bottom">Lucigen</td><td align="left" valign="bottom">Cat# N6901K</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SUPERaseIn RNase Inhibitor</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# AM2694</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TRIzol Reagent</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 15596018</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SYBR Gold Nucleic Acid Gel Stain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# S11494</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">T4 Polynucleotide Kinase</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# M0201S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">T4 RNA Ligase 2, truncated K227Q</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# M0351S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SuperScript III Reverse Transcriptase</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 18080085</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Random Hexamers</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# N8080127</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CircLigase II ssDNA Ligase</td><td align="left" valign="bottom">Lucigen</td><td align="left" valign="bottom">Cat# CL9021K</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LD-Dithiothreitol</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# D9779</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Iodoacetamide</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# I1149</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">o-Phosphoric acid, 85%</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# A260-500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Water, Optima LC/MS Grade</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# W6-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Methanol, Optima LC/MS Grade</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# A456</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Triethylammonium bicarbonate buffer</td><td align="left" valign="bottom">MilliporeSigma</td><td align="left" valign="bottom">Cat# T7408</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Trypsin Gold, Mass Spectrometry Grade</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# V5280</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Formic Acid, LC/MS Grade</td><td align="left" valign="bottom">Thermo Scientific Pierce</td><td align="left" valign="bottom">Cat# 28905</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Acetonitrile, Optima LC/MS Grade</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# A955-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Phusion High Fidelity DNA polymerase</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# M0530S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BsmBIv2</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# R0739S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">DNase I (RNase-free)</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# M0303S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNA Clean and Concentrator-25</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# R1017</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNasin Ribonuclease Inhibitor</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# N2515</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SYBR Safe DNA Gel Stain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# S33102</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Click-iT Cell Reaction Buffer Kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# C10269</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Neon Transfection System 10 µL Kit</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# MPK1096</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Gene Knockout Kit v2 – human – RPL22</td><td align="left" valign="bottom">Synthego</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Negative Control, Scrambled <break/>sgRNA#1, mod-sgRNA</td><td align="left" valign="bottom">Synthego</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ProLong Gold Antifade Mountant</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# P36934</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Lipofectamine 3000 Transfection Reagent</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# L3000075</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QuantiGene Plex panel</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QuantiGene Sample Processing Kit for cultured cells</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# QS0100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QuantiGene Plex Assay kits</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# QP1013</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay Kit</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# PI23225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Clarity Western ECL Substrate</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# 1705061</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Qubit RNA High Sensitivity Assay Kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# Q32852</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Direct-zol RNA Miniprep</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# R2050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RiboCop rRNA Depletion Kit V1.2</td><td align="left" valign="bottom">Lexogen</td><td align="left" valign="bottom">Cat# 037.24</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Quick-DNA MidiPrep Plus Kit</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# D4075</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext High Fidelity <break/>2X PCR Master Mix</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# M0541L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Zymo-Spin V Columns with Reservoir</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">Cat# C1016-25</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NucleoSpin Gel and PCR Clean-up</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">Cat# 740609.250</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Gibson Assembly Master Mix</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# E2611S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NucleoBond Xtra Maxi EF</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">Cat# 740424.10</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Q5 DNA Polymerase</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# M0491S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Taq DNA Polymerase <break/>with Standard Taq Buffer</td><td align="left" valign="bottom">New England BioLabs</td><td align="left" valign="bottom">Cat# M0273S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SYBR Safe DNA Gel Stain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# S33102</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">KAPA SYBR Fast qPCR <break/>Master Mix (2×)</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 07959397001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTiter-Glo Luminescent <break/>Cell Viability Assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# G7572</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Blasticidin S Hydrochloride Powder</td><td align="left" valign="bottom">Research Products International</td><td align="left" valign="bottom">Cat# B12200-0.05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DMSO</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# D2650</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">C6</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/30865883/">30865883</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">C16</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/31858797/">31858797</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2’-Azido-2’-deoxycytidine</td><td align="left" valign="bottom">Biosynth</td><td align="left" valign="bottom">Cat# NA05412</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Actinomycin D</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 11421-10mg</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MB 680R DBCO</td><td align="left" valign="bottom">Vector Laboratories</td><td align="left" valign="bottom">Cat# CCT-1462</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cycloheximide</td><td align="left" valign="bottom">Research Products International</td><td align="left" valign="bottom">Cat# C81040-1.0</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">OPP (<italic>O</italic>-propargyl-puromycin)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# C10459</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hoechst 33342</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# H3570</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Alexa Fluor 647 Azide, <break/>Triethylammonium Salt</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A10277</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Cycloheximide</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# C4859-1ML</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nutlin-3a</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 18585</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Rapamycin</td><td align="left" valign="bottom">MedChem Express</td><td align="left" valign="bottom">Cat# HY-10219</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pinometostat</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 16175</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Harmine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 286044</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mivebresib</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 21033</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Venetoclax</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 16233</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Etoposide</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 12092</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Olaparib</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 10621</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">VE-821</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 17587</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pemrametostat</td><td align="left" valign="bottom">Selleck Chemicals</td><td align="left" valign="bottom">Cat# S8664</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Alvespimycin</td><td align="left" valign="bottom">Cayman Chemical Company</td><td align="left" valign="bottom">Cat# 11036</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R</td><td align="left" valign="bottom">The R Foundation</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_001905">SCR_001905</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.r-project.org">https://www.r-project.org</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">drc</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib94">Ritz et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Ritz and Streibig, 2021</xref></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/DoseResponse/drc">https://github.com/DoseResponse/drc</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CHOPCHOP</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib59">Labun et al., 2019</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015723">SCR_015723</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://chopchop.cbu.uib.no">https://chopchop.cbu.uib.no</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">count_spacers.py</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib53">Joung et al., 2017</xref>; <xref ref-type="bibr" rid="bib52">Joung, 2017</xref></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/fengzhanglab/Screening_Protocols_manuscript/blob/master/design_targeted_library.py">https://github.com/fengzhanglab/Screening_Protocols_manuscript/blob/master/design_targeted_library.py</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">SynergyFinder Plus</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib129">Zheng et al., 2022</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_019318">SCR_019318</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://synergyfinder.org/">https://synergyfinder.org/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PASWR</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib118">Ugarte et al., 2015</xref>; <xref ref-type="bibr" rid="bib7">Arnholt, 2022</xref></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/cran/PASWR">https://github.com/cran/PASWR</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">cutadapt</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib80">Martin, 2011</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011841">SCR_011841</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/marcelm/cutadapt/">https://github.com/marcelm/cutadapt/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">sabre</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_011843">SCR_011843</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/najoshi/sabre">https://github.com/najoshi/sabre</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">bowtie2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib64">Langmead and Salzberg, 2012</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016368">SCR_016368</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/BenLangmead/bowtie2">https://github.com/BenLangmead/bowtie2</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib35">Dobin et al., 2013</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004463">SCR_004463</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/alexdobin/STAR">https://github.com/alexdobin/STAR</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">UMI-tools</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib108">Smith et al., 2017</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_017048">SCR_017048</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/CGATOxford/UMI-tools">https://github.com/CGATOxford/UMI-tools</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">BEDTools</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib90">Quinlan and Hall, 2010</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006646">SCR_006646</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/arq5x/bedtools2">https://github.com/arq5x/bedtools2</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Xtail</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib123">Xiao et al., 2016</xref>; <xref ref-type="bibr" rid="bib124">xryanglab, 2016</xref></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/xryanglab/xtail">https://github.com/xryanglab/xtail</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">riboWaltz</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib66">Lauria et al., 2018</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016948">SCR_016948</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/LabTranslationalArchitectomics/riboWaltz">https://github.com/LabTranslationalArchitectomics/riboWaltz</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">featureCounts</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib72">Liao et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_012919">SCR_012919</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://bioconductor.org/packages/release/bioc/html/Rsubread.html">http://bioconductor.org/packages/release/bioc/html/Rsubread.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib78">Love et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MAGeCK</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib68">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib70">Li and Song, 2022</xref></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://sourceforge.net/p/mageck/wiki/Home/">https://sourceforge.net/p/mageck/wiki/Home/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Maxquant</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib30">Cox and Mann, 2008</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014485">SCR_014485</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cox-labs.github.io/coxdocs/maxquant_instructions.html">https://cox-labs.github.io/coxdocs/maxquant_instructions.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Andromeda</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Cox et al., 2011</xref></td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://cox-labs.github.io/coxdocs/andromeda_instructions.html">https://cox-labs.github.io/coxdocs/andromeda_instructions.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Msstats</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib28">Choi et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014353">SCR_014353</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://msstats.org/">https://msstats.org/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">fgsea</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib58">Korotkevich et al., 2021</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_020938">SCR_020938</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/fgsea.html">https://bioconductor.org/packages/release/bioc/html/fgsea.html</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Biorender</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018361">SCR_018361</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://biorender.com">https://biorender.com</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PyMOL</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_000305">SCR_000305</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">rMATS</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib102">Shen et al., 2014</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_013049">SCR_013049</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://rnaseq-mats.sourceforge.net">https://rnaseq-mats.sourceforge.net</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Molecular Signatures Database</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib73">Liberzon et al., 2011</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016863">SCR_016863</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.gsea-msigdb.org/gsea/msigdb/index.jsp">https://www.gsea-msigdb.org/gsea/msigdb/index.jsp</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Universal Protein Resource</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib8">Bateman et al., 2021</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002380">SCR_002380</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org">https://www.uniprot.org</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">NA</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SRC_008520">SRC_008520</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Empiria Studio</td><td align="left" valign="bottom">LI-COR</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_022512">SCR_022512</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.licor.com/bio/empiria-studio/">https://www.licor.com/bio/empiria-studio/</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">NIS-Elements AR 5.42.03 64-bit</td><td align="left" valign="bottom">Nikon Instruments</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_014329">SCR_014329</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.nikoninstruments.com/Products/Software">https://www.nikoninstruments.com/Products/Software</ext-link></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Fiji</td><td align="left" valign="bottom">Fiji/ImageJ</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://fiji.sc">http://fiji.sc</ext-link></td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S-Trap Micro Columns</td><td align="left" valign="bottom">ProtiFi</td><td align="left" valign="bottom">Cat# C02-micro-80</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Jupiter 3 um C18 300A, Bulk packaging</td><td align="left" valign="bottom">Phenomenex</td><td align="left" valign="bottom">Cat# 04A-4263</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Molex Polymicro Capillary <break/>100 um × 363 um</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# 50-110-8623</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Neon Transfection System</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# MPK5000</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Luminex FLEXMAP 3D System</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# APX1342</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">4–20% Mini-PROTEAN <break/>TGX Precast Gel</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# 4561096</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Amersham Protran Western Blotting Membranes, Nitrocellulose</td><td align="left" valign="bottom">Cytiva</td><td align="left" valign="bottom">Cat# GE10600001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">C1000 Touch Thermal Cycler Chassis</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# 1841100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">CFX96 Optical Reaction Module <break/>for Real-Time PCR System</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# 1845097</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">ChemiDoc Imaging System</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# 17001401</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Thick-wall Polycarbonate Tubes, <break/>13 × 51 mm</td><td align="left" valign="bottom">Beckman-Coulter</td><td align="left" valign="bottom">Cat# 349622</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Novex TBE-Urea Gels 15%, 12 well</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# EC68852BOX</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Costar Spin-X Centrifuge Tube Filters</td><td align="left" valign="bottom">Corning</td><td align="left" valign="bottom">Cat# CLS8162</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Novex TBE Gels, 8%, 15 well</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# EC62155BOX</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">GloMax Explorer Multimode Microplate Reader</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# GM3500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Orbitrap Exploris 480 Mass Spectrometer</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">Cat# BRE725533</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90683.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eilers</surname><given-names>Martin</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Würzburg</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> article reveals that one of the major roles of the WDR5 WIN site is to promote ribosome synthesis, and that by attacking the WIN site with inhibitors ribosome attrition occurs creating new vulnerabilities that can be therapeutically exploited. This deficiency of ribosomal proteins also provokes the p53 response. The data from a variety of approaches is generally very <bold>convincing</bold>, and together buttresses the authors' conclusions and interpretations quite nicely; overall, this article will provide a justification for pre-clinical and translational studies of WDR5 interaction site inhibitors.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90683.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Building on previous work from the Tansey lab, here Howard et al. characterize transcriptional and translational changes upon WIN site inhibition of WDR5 in MLL-rearranged cancer cells. They first analyze whether C16, a newer generation compound, has the same cellular effects as C6, an early generation compound. Both compounds reduce the expression of WDR5-bound RPGs in addition to the unbound RPG RPL22L1. They then investigate differential translation by ribo-seq and observe that WIN site inhibition reduces the translational RPGs and other proteins related to biomass accumulation (spliceosome, proteasome, mitochondrial ribosome). Interestingly, this reduction adds to the transcriptional changes and is not limited to RPGs whose promoters are bound by WDR5. Quantitative proteomics at two time points confirmed the downregulation of RPGs. Interestingly, the overall effects are modest, but RPL22LA is strongly affected. Unexpectedly, most differentially abundant proteins seem to be upregulated 24 h after C6 (see below). A genetic screen showed that loss of p53 rescues the effect of C6 and C16 and helped the authors to identify pathways that can be targeted by compounds together with WIN site inhibitors in a synergistic way. Finally, the authors elucidated the underlying mechanisms and analyzed the functional relevance of the RPL22, RPL22L1, p53 and MDM4 axis.</p><p>Comments on revised version:</p><p>The authors have answered my points satisfactorily and the manuscript has become clearer and more meaningful as a result. In particular, the measurement of global translation rate is important and validates the upregulation of a number of proteins following WDR5 inhibitor treatment.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90683.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The manuscript by Howard et al reports the development of high affinity WDR5-interaction site inhibitors (WINi) that engage the protein to block the arginine-dependent engagement with its partners. Treatment of MLL-rearranged leukemia cells with high-affinity WINi (C16) decreases the expression of genes encoding most ribosomal proteins and other proteins required for translation. Notably, although these targets are enriched for WDR5-ChIP-seq peaks, such peaks are not universally present in the target genes. High concordance was founded between the alterations in gene expression due to C16 treatment and the changes resulting from treatment with an earlier, lower affinity WINi (C6). Besides protein synthesis, genes involved in DNA replication or MYC responses are downregulated, while p53 targets and apoptosis genes are upregulated. Ribosome profiling reveals a global decrease in translational efficiency due to WINi with overall ribosome occupancies of mRNAs ~50% of control samples. The magnitude in the decrements of translation for most individual mRNAs exceeds the respective changes in mRNA levels genome-wide. From these results and other considerations, the authors hypothesize that WINi results in ribosome depletion. Quantitative mass spec documents the decrement in ribosomal proteins following WINi treatment along with increases in p53 targets and proteins involved in apoptosis occurring over 3 days. Notably RPL22L1 is essentially completely lost upon WINi treatment. The investigators next conduct a CRISPR screen to find moderators and cooperators with WINi. They identify components of p53 and DNA repair pathways as mediators of WINi inflicted cell death (so gRNAs against these genes permit cell survival). Next, WINi are tested in combination with a variety of other agents to explore synergistic killing to improve their expected therapeutic efficacy. The authors document loss of the p53 antagonist MDM4 (in combination with splicing alterations of RPL22L1), an observation that supports the notion that WINi killing is p53-mediated.</p><p>This is a scientifically very strong and well-written manuscript that applies a variety of state-of-the art molecular approaches to interrogate the role of the WDR5 interaction site and WINi. They reveal that the effects of WINi seem to be focused on the overall synthesis of protein components of the translation apparatus, especially ribosomal proteins-even those that do not bind WDR5 by ChIP (a question left unanswered is how such the WDR5-less genes are nevertheless WINi targeted). They convincingly show that disruption of the synthesis of these proteins occurs upon activation of p53 dependent apoptosis, likely driven by unbalanced ribosomal protein synthesis leading to MDM2 inhibition. This apoptosis is subsequently followed, as expected by ɣH2AX-activation. Pathways of possible WINi resistance and synergies with other anti-neoplastic approaches are explored. These experiments are all well-executed and strongly invite more extensive pre-clinical and translational studies of WINi in animal studies. The studies also may anticipate the use of WINi as probes of nucleolar function and ribosome synthesis though this was not really explored in the current manuscript. The current version of the manuscript documents ribosomal stress revealed by leakage of NPM1 into the nucleoplasm while nucleolar integrity is preserved. A progressive loss of rRNA synthesis occurs upon drug treatment that is presumably secondary to the decrement in ribosomal protein production.</p><p>Comments on revised version:</p><p>(1) The authors to my mind, have quite nicely and professionally addressed the comments of the reviewers and are to be congratulated on an important contribution to the elucidation of WDR5 biology and pathology.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.90683.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Howard</surname><given-names>Gregory Caleb</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jing</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Rose</surname><given-names>Kristie L</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Camden</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Purvi</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tsui</surname><given-names>Tina</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Florian</surname><given-names>Andrea C</given-names></name><role specific-use="author">Author</role><aff><institution>Belmont University</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Vlach</surname><given-names>Logan</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lorey</surname><given-names>Shelly L</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Grieb</surname><given-names>Brian C</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Brianna N</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Slota</surname><given-names>Macey J</given-names></name><role specific-use="author">Author</role><aff><institution>University of California San Francisco Medical Center</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Reynolds</surname><given-names>Elizabeth M</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Goswami</surname><given-names>Soumita</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Savona</surname><given-names>Michael R</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Mason</surname><given-names>Frank M</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Taekyu</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Fesik</surname><given-names>Stephen</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qi</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University Medical Center</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tansey</surname><given-names>William P</given-names></name><role specific-use="author">Author</role><aff><institution>Vanderbilt University School of Medicine Nashville United States</institution><addr-line><named-content content-type="city">Nashville</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><p>We are grateful to the Editors for overseeing the review of our manuscript, and to the two reviewers for their thoughtful comments and suggestions for how it can be improved.</p><p>I submit at this time a revision, as well as a detailed response (below) to each of the points raised in the first round of review.</p><p>We feel the manuscript has been significantly improved by taking the reviewers' comments to heart. In a nutshell, we added new key pieces of data (impact of WIN site inhibition on global translation, rRNA production, as well as the requested cell biology analyses showing nucleolar stress), new analyses of the proteomics to counter potential concerns with normalization, and expanded/revised verbiage in key areas to clarify parts of the text that were confusing or problematic. The main figures have not changed; all new material is included in supplements to figures 2 and 3.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Building on previous work from the Tansey lab, here Howard et al. characterize transcriptional and translational changes upon WIN site inhibition of WDR5 in MLL-rearranged cancer cells. They first analyze whether C16, a newer generation compound, has the same cellular effects as C6, an early generation compound. Both compounds reduce the expression of WDR5-bound RPGs in addition to the unbound RPG RPL22L1. They then investigate differential translation by ribo-seq and observe that WIN site inhibition reduces the translational RPGs and other proteins related to biomass accumulation (spliceosome, proteasome, mitochondrial ribosome). Interestingly, this reduction adds to the transcriptional changes and is not limited to RPGs whose promoters are bound by WDR5. Quantitative proteomics at two-time points confirmed the downregulation of RPGs. Interestingly, the overall effects are modest, but RPL22LA is strongly affected. Unexpectedly, most differentially abundant proteins seem to be upregulated 24 h after C6 (see below). A genetic screen showed that loss of p53 rescues the effect of C6 and C16 and helped the authors to identify pathways that can be targeted by compounds together with WIN site inhibitors in a synergistic way. Finally, the authors elucidated the underlying mechanisms and analyzed the functional relevance of the RPL22, RPL22L1, p53, and MDM4 axis.</p><p>While this work is not conceptually new, it is an important extension of the observations of Aho et al. The results are clearly described and, in my view, very meaningful overall.</p><p>Major points:</p><p>(1) The authors make statements about the globality/selectivity of the responses in RNA-seq, ribo-seq, and quantitative proteomics. However, as far as I can see, none of these analyses have spike-in controls. I recommend either repeating the experiments with a spike-in control or carefully measuring transcription and translation rates upon WIN site inhibition and normalizing the omics experiments with this factor.</p></disp-quote><p>The reviewer is correct that we did not include spike-in controls in our omics experiments. We would like to emphasize that none of the omics data in this manuscript have been processed in unorthodox ways, and that the major conclusions each have independent corroborating data.</p><p>The selectivity in RPG suppression observed in RNA-Seq, for example, is supported by results from our target engagement (QuantiGene) assays; suppression of RPL22L1 mRNA levels is supported by quantitative and semi-quantitative RT-PCR, by western blotting, and by the results of our proteomic profiling; alternative splicing (and expression) of MDM4—and its dependency on RPL22—is also backed up by similar RT-PCR and western blotting data. The same applies for alternative splicing of RPL22L1.</p><p>That said, we do appreciate the point the reviewer is making here, and have done our best to respond. We do not think it is a prudent investment in resources to repeat the numerous omics assays in the manuscript. We also considered normalizing for bulk transcription and translation rates as suggested, but it is not clear in practice how this would be done, and it could introduce additional variables and uncertainties that may skew the interpretation of results. Instead, to respond to this comment, we made the following changes to the manuscript:</p><p>(1) We now explicitly state, for all omics assays, that spike-in controls were not included. These statements will prompt the reader to make their own assessment of the robustness of each of our findings and interpretations.</p><p>(2) We have added new data to the manuscript (Figure 2—figure supplement 1A–B) measuring the impact of C6 and C16 on bulk translation using the OPP labeling method. These new data demonstrate that WIN site inhibitors induce a progressive yet modest decline in protein synthesis capacity. At 24 hours, there is no significant effect of either agent on protein synthesis levels. By 48 hours, a small but significant effect is observed, and by 96 hours translation levels are ~60% of what they are in vehicle-treated control cells. These new data are important because they support the idea that normalization has not blunted the responses we observe—the magnitude of the effects are consistent between the different assays and tend to cap out at two-fold in terms of RPG suppression, translation efficiency, ribosomal protein levels, and protein synthesis capacity.</p><p>(3) We have included additional analysis regarding the LFQMS, as described below, that specifically addresses the issue of normalization in our proteomics experiments.</p><disp-quote content-type="editor-comment"><p>(2) Why are the majority of proteins upregulated in the proteomics experiment after 24 h in C6 (if really true after normalization with general protein amount per cell)? This is surprising and needs further explanation.</p></disp-quote><p>The reviewer is correct in noting that (by LFQMS) ~700 proteins are induced after 24 hours of treatment of MV4:11 cells with C16 (not C6, as stated). The reviewer would like us to examine whether this apparent increase in proteins is a normalization artifact. In response to this comment, we have made the following changes to the manuscript:</p><p>(1) Our new OPP labeling experiments (Figure 2—figure supplement 1A–B) show that there is no significant reduction in overall protein synthesis following 24 hours of C16 treatment. In light of this finding, it is unlikely that normalization artifacts, resulting from diminution of the pool of highly abundant proteins, create the appearance of these 700 proteins being induced. We now explicitly make this point in the text.</p><p>(2) We now clarify in the methods how we seeded identical numbers of cells for DMSO and C16-treated cultures in these experiments, and—consistent with our finding that WIN site inhibitors have little if any effect on protein synthesis or proliferation at the 24 hour timepoint— extracted comparable amounts of proteins from these two treatment conditions (DMSO: 344.75 ± 21.7 µg; C16: 366.50 ± 15.8 µg; [Mean ± SEM]).</p><p>(3) We now include in Figure 3—figure supplement 1A a plot showing the distribution of peptide intensities for each protein detected in each run of LFQMS before and after equal median normalization. This new analysis reveals that the distribution of intensities is not appreciably changed via normalization. Specifically, there is not a reduction in peptide intensities in the unnormalized data from 24 hours of C16 treatment that is reversed or tempered by normalization. This analysis provides further support for the notion that the increase we observe is not a normalization artifact.</p><p>(4) We now include in Figure 3—figure supplement 1B–D a set of new analyses examining the relationship between the initial intensity of proteins in DMSO control samples (a crude proxy for abundance) versus the fold change in response to WIN site inhibitor. This analysis shows that we have as many &quot;highly abundant&quot; (10th decile) proteins increasing as we do decreasing in response to WINi. Thus, it appears as though the wholesale clearance of highly abundant proteins from the cell is not occurring at this early treatment timepoint. In addition, this analysis also shows that ribosomal proteins (RP) are generally the most abundant, most suppressed, proteins and that their fold-change at the protein level at 24 hours is less than two-fold, consistent again with the magnitude of transcriptional effects of C16, as measured by RNA-Seq and QuantiGene. The fact that the drop in RP levels is consistent with expectations based on other analyses provides further empirical support for the notion that protein levels inferred from LFQMS are authentic and not skewed by global changes in the proteome.</p><p>The increase in proteins at this time point, we argue, is thus most likely genuine. It is not surprising that—at a timepoint at which protein synthesis is unaffected—several hundred proteins are induced by a factor of two. How this occurs, we do not know. It may be a transient compensatory mechanism, or it may be an early part of the active response to WIN site inhibitors. Lest the reader be confused by this finding, we have now added text to this section of the manuscript discussing and explaining the phenomenon in more detail.</p><disp-quote content-type="editor-comment"><p>(3) The description of the two CRISPR screens (GECKO and targeted) is a bit confusing. Do I understand correctly that in the GECKO screen, the treated cells are not compared with nontreated cells of the same time point, but with a time point 0? If so, this screen is not very meaningful and perhaps should be omitted. Also, it is unclear to me what the advantages of the targeted screen are since the targets were not covered with more sgRNAs (data contradictory: 4 or 10 sgRNAs per target?) than in Gecko. Also, genome-wide screens are feasible in culture for multiple conditions. Overall, I find the presentation of the screening results not favorable.</p></disp-quote><p>In essence, this is a single screen performed in two tiers. In Tier 1, we screened a complete GECKO library (six sgRNA/gene) with the earliest generation (less potent) inhibitor C6, and compared sgRNA representation against the time zero population. This screen would reveal sgRNAs that are specifically associated with response to C6, as well as those that are associated with general cell fitness and viability. We then identified genes connected to these sgRNAs, removed those that are pan essential, and built a custom library for the second tier using sgRNAs from the Brunello library (four sgRNA/gene). We then screened this custom library with both C6 and the more potent inhibitor C16, this time against DMSO-treated cells from the same timepoint.</p><p>We acknowledge that this is not the most streamlined setup for a screen. But our intention was to compare two inhibitors (C6 and C16) and identify high confidence 'hits' that are disconnected from general cell viability, rather than generate an exhaustive list of all genes that, when disrupted, skew the response to WIN site inhibitor. The final result of this screen (Figure 4E) is a gene list that has been validated with two chemically distinct WIN site inhibitors and up to 10 unique sgRNAs per gene. We may not have captured every gene that can modulate response to WIN site inhibitor, but those appearing in Figure 4E are highly validated.</p><p>To answer the reviewer's specific questions: (i) we cannot omit the Tier 1 screen because then there would be no rationale for what was screened in the second Tier; and (ii) the advantage of the custom Tier 2 library is that it allowed us to screen hits from the Tier 1 screen with four completely independent sgRNAs. Although there are not more sgRNAs for each gene in the Tier 2 versus the Tier 1 library, these sgRNAs are different and thus, for C6 at least, hits surviving both screens were validated with up to 10 unique sgRNAs.</p><p>We apologize that the description of the CRISPR screens was not clearer, and have reworked this section of the manuscript to make our intent and our actions clearer.</p><disp-quote content-type="editor-comment"><p>(4) Can Re-expression of RPL22 rescue the growth arrest of C6?.</p></disp-quote><p>We have not attempted to complement the RPL22 knock out. But we do note that evidence supporting the idea that loss of RPL22 confers resistance to WIN site inhibitor is strong—six (out of six) sgRNAs against RPL22 were significantly enriched in the Tier 1 screen, and independent knock out of RPL22 with the Synthego multi-guide system in MV4;11 and MOLM13 cells increases the GI50 for C16.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>The manuscript by Howard et al reports the development of high-affinity WDR5-interaction site inhibitors (WINi) that engage the protein to block the arginine-dependent engagement with its partners. Treatment of MLL-rearranged leukemia cells with high-affinity WINi (C16) decreases the expression of genes encoding most ribosomal proteins and other proteins required for translation. Notably, although these targets are enriched for WDR5-ChIP-seq peaks, such peaks are not universally present in the target genes. High concordance was found between the alterations in gene expression due to C16 treatment and the changes resulting from treatment with an earlier, lower affinity WINi (C6). Besides protein synthesis, genes involved in DNA replication or MYC responses are downregulated, while p53 targets and apoptosis genes are upregulated. Ribosome profiling reveals a global decrease in translational efficiency due to WINi with overall ribosome occupancies of mRNAs ~50% of control samples. The magnitude of the decrements of translation for most individual mRNAs exceeds the respective changes in mRNA levels genome-wide. From these results and other considerations, the authors hypothesize that WINi results in ribosome depletion. Quantitative mass spec documents the decrement in ribosomal proteins following WINi treatment along with increases in p53 targets and proteins involved in apoptosis occurring over 3 days. Notably, RPL22L1 is essentially completely lost upon WINi treatment. The investigators next conduct a CRISPR screen to find moderators and cooperators with WINi. They identify components of p53 and DNA repair pathways as mediators of WINi-inflicted cell death (so gRNAs against these genes permit cell survival). Next, WINi are tested in combination with a variety of other agents to explore synergistic killing to improve their expected therapeutic efficacy. The authors document the loss of the p53 antagonist MDM4 (in combination with splicing alterations of RPL22L1), an observation that supports the notion that WINi killing is p53-mediated.</p><p>Strengths:</p><p>This is a scientifically very strong and well-written manuscript that applies a variety of state-ofthe art molecular approaches to interrogate the role of the WDR5 interaction site and WINi. They reveal that the effects of WINi seem to be focused on the overall synthesis of protein components of the translation apparatus, especially ribosomal proteins-even those that do not bind WDR5 by ChIP (a question left unanswered is how much the WDR5-less genes are nevertheless WINi targeted). They convincingly show that disruption of the synthesis of these proteins is accompanied by DNA damage inferred by H2AX-activation, activation of the p53pathway, and apoptosis. Pathways of possible WINi resistance and synergies with other antineoplastic approaches are explored. These experiments are all well-executed and strongly invite more extensive pre-clinical and translational studies of WINi in animal studies. The studies also may anticipate the use of WINi as probes of nucleolar function and ribosome synthesis though this was not really explored in the current manuscript.</p><p>Weaknesses:</p><p>A mild deficiency in the current manuscript is the absence of cell biological methods to complement the molecular biological and biochemical approaches so ably employed. Some microscopic observations and confirmation of nucleolar dysfunction and DNA damage would be reassuring.</p></disp-quote><p>We thank the reviewer for their comments. We agree that an absence of cell biological methods was a deficiency in the original manuscript. In response to this comment, we have now added immunofluorescence (IF) analyses, examining the impact of C16 on nucleolar integrity and nucleophosmin (NPM1) distribution (Figure 3—figure supplement 4). These new data clearly show that C16 induces nucleolar stress at 72 hours—as measured by the redistribution of NPM1 from the nucleolus to the nucleoplasm. These new data fill an important gap in the story, and we are grateful to the reviewer for prompting us to perform these experiments.</p><p>As part of the above study, we also probed for gamma-H2AX, expecting that we may see some signs of accumulation in the nucleoli (see comment #4 from Reviewer #2, below). We did not observe this response. Importantly, however, we did see that gamma-H2AX staining occurs only in what are overtly apoptotic cells. This is an important finding, because we had previously speculated that the induction of gamma-H2AX observed by Western blotting reflected part of a bona-fide response to DNA damage elicited by WIN site inhibitors. Instead, the IF data now leads us to conclude that this signal simply reflects the established fact that WIN site inhibitors induce apoptosis in this cell line (Aho et al., 2019). In response to this new finding, we have added additional discussion to the text and have removed or de-emphasized the potential contribution of DNA damage to the mechanism of action of WDR5 WIN site inhibitors. Again, we are grateful for this comment as it has prevented us from continuing to report/pursue erroneous observations.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>There is a typo in &quot;but are are linked to mRNA instability when translation is inhibited&quot;.</p></disp-quote><p>Thank you for catching this typo. It has now been corrected.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>(1) The authors report that WINi initially (at 24 hrs) increases the expression of most proteins while decreasing ribosomal proteins, but at 72 hours all proteins are depressed. The transient bump-up of non-translation-related proteins seems odd. A simple resolution to this somewhat strange observation is that there is no real increase in the other proteins, but because of the loss of a large fraction of the most abundant cellular proteins (the ribosomal proteins), the relative fraction of all other proteins is increased; that is, the increase of non-ribosomal proteins may be an artifact of normalization to a lower total protein content. Can this be explored?</p></disp-quote><p>We are grateful to the reviewer for this comment. We have tried our best to respond, as detailed above in response to Reviewer #1 Public Comment #2.</p><disp-quote content-type="editor-comment"><p>(2) It would be really nice to assess nucleolar status microscopically. Do nucleoli get bigger? Smaller? Do they have abnormal morphology? Is there nucleolar stress? What happens to rRNA synthesis and processing?</p></disp-quote><p>We agree and thank the reviewer for raising this point. As noted in our response to Reviewer #2, above, we have included new IF that shows: (i) no obvious effect on nucleolar integrity, (ii) redistribution of NPM1 to the nucleoplasm (indicative of nucleolar stress), and (iii) induction of gamma-H2AX staining in apoptotic cells (indicative of apoptosis).</p><p>Additionally, in response to this comment, we also looked at the impact of WIN site inhibitors on rRNA synthesis, using AzCyd labeling. These new data appear in Figure 3—figure supplement 3. Interestingly, these new data show that there is a progressive decline in rRNA synthesis, and that by 96 hours of treatment levels of both 18S and 28S rRNAs are reduced— again by about a factor of two. Our interpretation of this finding is that in response to the progressive decline in RPG transcription there is a secondary decrease in rRNA synthesis. This result is perhaps not surprising, but it does again add an important missing piece to our characterization of WIN site inhibitors and is further support for the concept that inhibition of ribosome production is a dominant part of the response to these agents.</p><disp-quote content-type="editor-comment"><p>(3) The WINi elicited DNA damage is incompletely characterized, rather it is inferred from H2AX activation. Comet assays would help to confirm such damage.</p></disp-quote><p>As noted in our response to Reviewer #2, our original inference of DNA damage, prompted by gamma-H2AX activation, is erroneous, and due instead to the ability of WIN site inhibitors to induce apoptosis. We thus did not pursue comet assays, etc., and removed discussion of potential DNA damage from the manuscript.</p><disp-quote content-type="editor-comment"><p>(4) Staining and microscopic observation of H2AX would be very useful. Is the WINi provoked DNA damage nucleolar-localized? Does the deficiency of ribosomal proteins lead to localized genotoxic nucleolar stress - or alternatively does the paucity of ribosomes and decreased translation lead to imbalances in other cellular pathways, perhaps including some involved in overall genome maintenance which would provoke more global DNA damage and H2AX staining, not limited to the nucleolus.</p></disp-quote><p>Again, please see our response to the Public Comment from Reviewer #2.</p><disp-quote content-type="editor-comment"><p>(5) It would be important to assess the influence and effects of WINi on some p53 mutant, p53-/- and p53 wild-type cell lines. Given their prevalence, p53 status may be expected to alter WINi efficacy.</p></disp-quote><p>The issue of how p53 status impacts the response to WINi is interesting and important, but we feel this is beyond the scope of the current manuscript. It is likely that many factors contribute to the response of cancer cells to these agents, and thus simply surveying some cancer lines for their response and linking this to their p53 status is unlikely to be very informative. Making definitive statements about the contribution of p53, and the differences between wild-type, lossof-function mutants, gain of function mutants, and null mutants will require more extensive analyses and is fertile territory for future studies, in our opinion.</p></body></sub-article></article>